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Chapter 1 : Introduction and outline of the thesis
General introduction
Since its advent 51 years ago [1], liver transplantation (LT) has progressed from an ex-
perimental treatment to an accepted therapeutic modality that has reversed the gloomy 
prognosis of end stage liver disease. The great success of LT is for the major part due 
to calcineurin inhibitors (CNI) like Cyclopsorin A and Tacrolimus. These are powerful 
immunosuppressants (IS), which prevent graft rejection and are the cornerstone of post-
transplant patient management. The introduction of Cyclosporine in March 1980 marked 
great clinical advance for graft and patient survival [2]. Following the introduction of 
cyclosporine in LT, one-year patient survival more than doubled (from approximately 33 
to 68%).[2,3], with an increment to above 80% nowadays. (www.eltr.org) [4,5].
Although immunosuppressive regimens are indispensible therapeutics for LT re-
cipients, the downside is their major adverse effects on the long-term. The obligatory 
lifelong use of these drugs increases patients’ morbidity by increasing their susceptibil-
ity for infections [6,7], cancer[8], cardiovascular diseases [9-11], kidney failure [12,13] 
and de-novo diabetes [14], which impair long-term survival and quality of life after 
transplantation. These adverse effects are largely caused by the non-specificity of the 
immunosuppressive medications. In addition CNI also exert undesirable side effects on 
vasoactive compounds resulting in vasculopathy [15-17], and on LDL receptor bile acid 
synthesis from cholesterol [18] and lipoprotein lipase activity [19], resulting in dyslipid-
emia.
Because of genetic and immunologic differences between patients, the effectiveness 
of immunosuppressive drug treatment as well as the adverse effects of these drugs show 
large inter-individual variations [20-23]. Not every patient responds similarly to the same 
dose of the same medication. Moreover, clinical experience shows that minimization or 
even complete withdrawal of immunosuppressive medication is possible in some liver 
transplant patients without graft rejection or impairment of graft and patient survival 
[22,24,25]. Minimization of IS improves long-term metabolic parameters, cardiovascu-
lar risk factors and renal function [26]. Unfortunately, no tools are currently available 
that accurately predict the risk of liver graft rejection, or which patients will develop 
immunosuppression-related complications and which patients not. Therefore, clinicians 
are compelled to maintain long-term treatment with CNI and other IS at recommended 
doses. Prognostic markers that predict the risk of graft rejection and/or the risk of ad-
verse effects of IS after transplantation will enable to individualize IS therapy, which will 
be beneficial for patient morbidity and mortality.
For this purpose, it is important to have a clear understanding of the immunological 
responses of patients to foreign liver grafts after transplantation, since these are main 
determinants of graft-survival. In addition, it is important to acquire a good knowledge 
of the genetic variations that influence the immunological responses to allogeneic 
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grafts, as well as genetic differences that affect processes regulating the metabolism of 
IS. Better understanding of these subjects may lead to new therapeutical and diagnosti-
cal developments which may subsequently contribute to individualisation of patient 
management after LT.
The immune system and its major components
By detecting and eliminating invading pathogens and foreign cells, the immune system 
is the protection mechanism of the human body against diseases . It detects a wide 
variety of agents, including bacteria, parasites, viruses and altered dangerous self-cells 
and can discriminate these from healthy self-cells in order to function properly.
The cells of the immune system originate from the bone marrow, and differentiate in 
the central lymphoid organs, which are bone marrow and thymus. They circulate via the 
blood and lymphatic vessels through the body and migrate via those vessels into the 
peripheral or secondary lymphoid organs, like the spleen and lymph nodes. The periph-
eral lymphoid organs provide the environment for cooperative interactions between 
antigen presenting cells (APC), T cells and B cells resulting in lymphocyte activation 
[27-29]. Lymphocytes recirculate between those organs and blood until they encounter 
an antigen.
The two major types of lymphocytes are B cells, which mature in the bone marrow; 
and T cells which migrate to the thymus and mature in this organ. B cells are mainly 
involved in the humoral immune response; after differentiation to plasma cells they 
produce specific antibodies that provide defence against pathogens [30,31]. Addition-
ally, they have the capacity to produce cytokines, including interferon-gamma (IFN-y), 
interleukin-6 (IL-6) and lymphotoxin α [31,32], express MHC class I and II molecules as 
well as costimulatory molecules and therefore can behave as APC, priming and reacti-
vating antigen-specific T cells [31,33-36].
T cells can be divided into CD4+ or T-helper cells and CD8+ or cytotoxic T cells. CD4+ 
T cells have the ability to “help” via production of stimulatory cytokines, or via cell-cell 
interactions, macrophages and CD8+ T cells, which are the key components of the effec-
tor arm of the immune system, to become fully functional.
CD4+ T cells comprise of helper 1 (Th1), Th2, Th17, and regulatory T cells (Tregs), all 
with different cytokine production profiles [37]. Th1 cells produce mainly interleukin 2 
(IL-2), interferon-γ, and tumor necrosis factor-α, and play an important role in helping 
CD8+ T cells, macrophages, and other immune cells to acquire effector capacity and 
execute cell-mediated immune responses [37]. Th2 cells produce mainly IL-4, IL-5, and 
IL-13 and play an important role in humoral responses [37]. Th17 cells produce IL-17A 
and IL-17F and mediate inflammatory responses against bacteria and fungi. Tregs are 
identified by their phenotype CD4+CD25+Foxp3+, produce IL-10 and transforming 
growth factor β (TGF-β), and provide negative feedback to activated T cell responses, 
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which is required to limit potential collateral damage [37]. In transplantation, Th1 and 
Th17 have been shown to be detrimental, whereas Th2 may sometimes be beneficial 
for graft survival. Treg cells are critical in preventing graft rejection and contribute to 
induction and maintenance of immunological tolerance to allogeneic grafts [38].
Activated CD8+ T cells are capable of eliminating pathogens, infected, allogeneic, 
and altered self cells, either by releasing cytotoxins, including perforin, granzymes [39] 
and granulysin [40], or by cell-surface interactions that activate apoptotic pathways in 
the target cells [41,42], resulting in cell death . The cytotoxin pathway is dominant in 
CD8 cytotoxic T lymphocytes. It depends on the pore-forming molecule perforin, which 
enables delivery of granzymes A and B to target cells, where they trigger apoptosis 
through both caspase-dependent and caspase-independent pathways [39]. Cytotoxic 
cell surface interactions are mediated by Fas ligand (FasL) which is expressed on the 
CD8+ T cell surface upon activation. Engagement of FasL and Fas receptor on target cells 
can trigger their death [41-43].
Naïve T cells are a subset of T cells which have never encountered an antigen before. 
They are activated when they recognize a specific antigenic peptide presented by an 
HLA molecule and subsequently can differentiate into effector T cells or memory T cells. 
NaiveT cells express high levels of chemokine receptor CCR7 and CD62L which enables 
them to migrate via high endothelial venules into the secondary lymphoid organs, 
where they encounter antigens ([44,45]. Naïve T cells are further characterized by the 
cell surface expression of the CD45RA isoform. The relative contribution of naïve T cells 
to allo-responses against transplanted organ in humans requires further study.
Memory T cells are a subset of T cells that have encountered their cognate antigens, 
persist in the human body, and are able to quickly expand to large numbers of effector 
T cells upon re-encountering their cognate antigen [46], thus providing the immune 
system with “memory” against past antigens. Memory T cells themselves again comprise 
of two subtypes: central memory T cells (TCM cells) and effector memory T cells (TEM cells), 
which differ in their homing properties [47], cytotoxic and proliferative capacities [48]. 
TCM cells express high levels of chemokine receptor CCR7 and adhesion molecule CD62L 
[47,49,50] that enables them to migrate from the blood circulation via high-endothelial 
venules into secondary lymphoid organs, whereas TEM cells express CD62L at variable 
levels but lack CCR7 [47,50] and are therefore prohibited from migration into secondary 
lymphoid organs. However TEM cells have transendothelial migration capacity allowing 
them to directly enter peripheral tissues from the circulation and react rapidly against 
invading pathogens [45]. Memory T cells can be either CD4+ or CD8+, but typically ex-
press the cell surface protein CD45RO, an isoform of CD45. Memory T cells have been 
demonstrated to be the main players in the vigorous allo-response against organ grafts 
in experimental animal studies [51,52], but the relative contributions of naïve and 
memory T cells to graft rejection in humans has not been fully elucidated.
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Optimal T-cell activation requires two signals, an antigen specific signal via the inter-
action between the T-cell receptor (TCR) and peptide-major histocompatibility complex 
(MHC), and an antigen independent signal, called costimulation, via the interaction 
between the costimulatory molecule CD28 on the T-cell surface membrane and the mol-
ecules B7-1 (CD80) or B7-2 (CD86) on the APC [53,54]. CTLA-4, which is only presented 
on the surface membrane of activated T-cells, is a homologue of CD28. By interacting 
with the B7 ligands it delivers inhibitory signals to T cells, resulting in downregulation 
of T cell responses [53-55]. Genetic polymorphisms in the CTLA-4 gene can result in 
an altered function of the CTLA-4 protein, which can influence the strength of T cell 
responses [21,56,57].
The mechanism of allo-response
Organ grafts are recognized by the recipient’s immune system as foreign tissue, because 
the graft is derived from an allogeneic (=genetically different) individual. The recipient’s 
immune system recognizes an organ graft as allogeneic because of the expression of 
“transplantation antigens”, which are proteins encoded by genes of the Major Histocom-
patibility Complex (MHC). These proteins, called Human Leukocyte Antigens (HLA), are 
highly polymorphic, i.e. show large differences between individuals. The physiological 
function of HLA-molecules is to present antigenic peptides to T-cells. The MHC consists 
of two classes of genes: class I genes encode HLA-A, -B and –C molecules, which present 
antigenic peptides to CD8+ cytotoxic T-cells; class II genes encode HLA-DP, -DQ and –DR 
molecules, which present peptides to CD4+ T-helper cells.
There are two major pathways of allo-recognition [58]. In the direct pathway recipi-
ent T cells recognize intact allogeneic MHC molecules on non-self cells. In the indirect 
pathway recipient T cells recognize donor MHC-derived peptides presented by self-MHC 
molecules expressed by recipient cells, which is basically the mechanism of the conven-
tional way of antigenic recognition by T cells. Both types of allo-antigen presentation 
can occur during pregnancy, upon blood transfusion, or after allogeneic transplantation 
of cells, tissue or organs. The semi-direct pathway has recently been introduced as a 
third pathway of allo-recognition, in which intact donor MHC molecules are transferred 
to host APC activate recipient T-cells[59]. Figure 1 displays the three pathways of al-
lorecognition
The role of direct and indirect donor HLA-recognition in allo-response
Since every individual has large numbers of T-cells with direct allo-specificity, allogeneic 
transplantation without IS therapy will inevitably be followed by an extraordinary al-
logeneic immune response to the allogeneic graft. However, the direct pathway is prob-
ably not the cause of rejections late after transplantation. There is growing evidence that 
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the numbers of T cells directly recognizing donor HLA-molecules decrease in time after 
transplantation [60-63].
Therefore, it is generally assumed indirect allo-response plays a role long after trans-
plantation. There is strong evidence from animal experiments that the strength of the 
indirect T-cell response is sufficient to reject allografts [64,65]. However, current tests 
for T cells with indirect allo-specificity are insensitive, and do not detect these T-cells in 
50% – 70% of organ transplant recipients [60,61,66-69].Therefore the role of the indirect 
pathway in rejection of allogeneic grafts in humans remains unclear.
Figure  1: Direct, indirect and semi-direct pathways of allorecognition (a) Direct pathway. Recognition of 
intact foreign MHC on donor APC primes CD4+ and CD8+ recipient T cells. CD4+ cells then provide T cell help 
for the effector function of CD8+ cells. (b) Indirect pathway. Recipient APCs traffic through transplanted 
organs, phagocytose allogeneic MHC shed from foreign cells through cell necrosis and apoptosis and pres-
ent the processed peptides in the context of self-MHC class II to MHC class II-restricted CD4+ T cells. (c) 
Semi-direct pathway. Cell-to-cell contact between donor and recipient APC may transfer intact membrane 
components including intact allo-MHC (a). Likewise, donor APC can release small vesicles, known as ‘exo-
somes’ containing intact MHC (b), which fuse with the membrane of recipient APCs (c). Recipient APCs, 
now chimeric for MHC, stimulate direct pathway CD4 and CD8 responses through intact foreign MHC and 
indirect responses through processing and presentation of peptides of foreign MHC acquired from necrotic 
and apoptotic cell material. Given that the same APC stimulates both CD4 and CD8 cells, linked help can 
occur. APC, antigen-presenting cells; dAPC, donor APC; MHC, major histocompatibility complex; rAPC, re-
cipient APC.
Afzadi et al, Curr Opin Organ Transplant. Aug 2008; 13(4)
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The role of viral infections in transplantations
Viral infections, including CMV infection, prevent tolerance induction to allogeneic 
grafts in experimental animal models [51,70,71]. One of the mechanisms contributing to 
this phenomenon is heterologous immunity resulting from anti-viral T cells that recog-
nize allo-HLA antigens via the direct pathway and contribute to allograft rejection [72]. 
Indeed, cross-reactive viral-specific memory T cells are common in humans, and many 
CMV-specific T-cells are cross-reactive to at least one allogeneic HLA molecule [72,73]. 
However, whether and how CMV infection influences allogeneic T-cell responses and 
the risk of graft rejection in humans is unknown.
Immunosuppressive management
A cornerstone of successful post-transplantation patient management is the preven-
tion of graft rejection with IS therapy. IS regimens to prevent both acute and chronic 
rejection have been designed based on the understanding of the mechanism of graft 
rejection and how immune-mediated tissue injury can be prevented, while at the same 
time minimizing the risks associated with immunosuppression. Because it is believed 
that T cells are the main role-players in graft rejection, the development of immuno-
suppressive regimens has been based on the understanding of T-cell biology and has 
focused almost exclusively on suppression of T-cell functions, including T-cell survival, 
trafficking capacity, antigen-driven activation, proliferation, and effector functions. 
Although current IS target mainly T cells, they have also effects on other immune cells 
and non immune cells[15-18]. In addition, suppression of immunity by IS is non-specific, 
meaning that IS also inhibit immune responses to pathogens and altered self cells. 
Therefore, , all immunosuppressive regimens have undesired side effects, the spectra 
of which vary and in some cases overlap [6,8,9]. Compromised immunity caused by 
these regimens is also responsible for reactivation of latent viral infections in recipients, 
of which cytomegalovirus (CMV) is the leading cause of viral infections after organ 
transplantation [74,75]. Transplantation of an allograft from a CMV seropositive donor 
can cause primary infection in previously uninfected patients, while previously infected 
patients can develop reactivation or reinfection, which subsequently may lead to an 
impaired post transplantation outcome [7].
Generally, most liver transplant centers use mono- bi- or triple therapy to prevent al-
lograft rejection. This includes a CNI, either cyclosporine or tacrolimus, combined with 
mycophenolate mofetil or, less commonly, azathioprine, and a glucocorticoid such as 
prednisone. According to the liver function tests, when normal and stable, immunosup-
pression is tapered down to monotherapy, which is usually a CNI.
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Calcineurin inhibitors
Cyclosporin is the first calcineurin inhibitor used in the clinic, and it was introduced in 
LT on 9th of March 1980. The treated patient was a 28-years old female. In 1983 the use 
of cyclosporine after LT was approved [3]. Since then, other CNI have been developed, 
like tacrolimus. CNI bind to the cytosolic protein cyclophilin and this formed complex 
inhibits calcineurin, which is responsible for the dephosphorylation of NFAT, a transcrip-
tion factor that activates cytokine production in T cells. Subsequently, the production of 
cytokines like interleukin-2, -4, -7, -9 and -15, and interferon-y are inhibited, leading to 
reduced proliferation of T cells and thereby immunosuppression [76,77].
Adverse of CNI include high susceptibility for infections [6], malignancies [8], cardio-
vascular diseases [9-11] and diabetes [14]. Another obstacle to the use of CNIs is neph-
rotoxicity [12,13]. The longterm use of CNIs has been associated with irreversible renal 
failure in organ transplant recipients caused by afferent arteriole vasoconstriction of the 
renal arteries. This leads to deterioration of the glomerular filtration rate. Also vasoac-
tive compounds and pathways which are stimulated by CNI, like the renin-angiotensin 
system, prostaglandins, endothelin and nitric oxide, contribute to chronic vasculopathy 
[15,16] which may result in renal deterioration. Additionally it has been shown that CNI 
induce the production of TGF-beta, an immunoregulatory and pro-fibrotic cytokine, 
which stimulates cells to produce extracellular matrix and decreases the production of 
extracellular matrix-degrading proteases, leading to interstitial fibrosis [17]. TGF-beta 
interacts also with various growth factors, cytokines and other peptides, like endothelin 
and angiotensin-II. The latter is known for its role in the development of chronic renal 
disease.
The clinical use of the CNI is complicated by their highly variable pharmacokinetics 
between individuals [78,79]. Interindividual differences in exposure to these drugs are 
related to genetic polymorphisms in the drug-metabolizing enzyme cytochrome P450 
(CYP) CYP3A5, and the drug transporter ABCB1 (previously known as P-glycoprotein), 
which are responsible for the clearance of these drugs [80,81]. These genetic polymor-
phism are associated with an altered metabolism of CNI, resulting in the need of higher 
or lower doses of CNI in affected patients.
Aims of this thesis
The protocol of post transplantation liver transplant patient management provides 
general recommendations, and all patients are treated with standard IS regimens and 
doses, although we know that the responses of individual patients vary. Some of the pa-
tients suffer more from severe side effects of IS than others. Despite powerful IS therapy, 
some patients experience one or more acute rejection episodes. In addition, we know 
that part of patients with stable liver graft functions will not reject without taking any 
immunosuppressive drugs, and these are therefore over-immunosuppressed. Together, 
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these considerations suggest that clinical benefit can be achieved by individualisation 
of IS therapy. However, since there are currently no tools available to predict whether 
an individual patient has a high or low risk of graft rejection, or which patient will be 
at risk of suffering from IS-related complications, LT patients are treated according to 
general IS protocols. Therefore, identification of accurate predictive markers for the 
risk of undesirable effects, like rejection and nephrotoxicity of IS., would be helpfull to 
individualise the dose of immunosuppression To achieve this, a good understanding of 
the mechanism of liver graft rejection and IS metabolism is required.
The aims of this thesis were to identify genetic factors that determine inter-individual 
differences in the risk of graft rejection or IS-related complications (chapters 2 & 3), to 
develop accurate and sensitive assays for quantification of allo-reactive T cells in trans-
plant recipients (chapter 4 & 5), and to study the effects of viral infection on allogeneic 
T cell responses and acute rejection (chapter 6). Such knowledge may be useful for de-
velopment of predictive diagnostic parameters and tools that identify LT patients at risk 
for these complications, in order to facilitate tailoring of IS for each individual patient 
to prevent on the one hand under-immunosuppression which may lead to graft rejec-
tion and on the other hand decrease IS-related morbidity, thereby optimizing patient 
survival. In Chapter 2 we studied whether genetic polymorphisms in the CTLA-4 gene 
are associated with the incidence of acute rejection after LT. We determined two single 
nucleotide polymorphisms (SNPs) in the CTLA4-gene in 485 LT-patients from three 
centers, and analysed retrospectively their association with the risk of acute rejection. 
Chapter 3 discusses whether genetic polymorphisms in the ABCB1 and CYP3A5 genes 
are associated with the incidence of chronic kidney disease after LT. It has been described 
that polymorphisms in these genes are associated with CNI-induced nephrotoxicity 
after renal transplantation. However, renal dysfunction after kidney transplantation has 
many causes other than the use of CNI, and even kidney biopsy (still considered the gold 
standard) may not be able to differentiate between CNI-induced kidney damage and 
other causes of renal dysfunction. Therefore, the genetic basis of chronic kidney disease 
(CKD) may be better studied in LT recipients. In this chapter we investigated whether 
SNPs in these genes in LT donors or recipients are related to Tacrolimus-induced post- 
transplantation chronic kidney dysfunction in a single center cohort of 125 Caucasian 
LT patients.
Chapter 4 starts with the immunological part of the thesis. We studied the longitudi-
nal course of circulating CD4+ and CD8+ T cells with direct allospecificity, utilizing an 
optimized assay, in 18 LT recipients. This study showed new insights into the kinetics of 
the direct donor-specific T cell response during the first year after LT.
In chapter 5, we determined the influence of CMV infection on T cell differentiation and 
alloreactivity, as well as on the risk of graft rejection after LT. Circulating T cell subsets 
(TCM, TEM, TN and TEMRA) and CD4+ and CD8+ with direct donor-specificity were quantified 
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in LT patients with different CMV serostatus. Additionally, the association between CMV 
serostatus and graft rejection was analysed.
Chapter 6 is a methodological description of the construction of a novel technique for 
quantification of human T cells with indirect allospecificity, which has several theoretical 
advantages compared to existing techniques.
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Abstract
Background: The cytotoxic T lymphocyte antigen 4 (CTLA‐4) gene encodes for a mem-
brane bound (mCTLA‐4) and a soluble (sCTLA‐4) isoform, which are both involved in 
regulation of T cell function. The CTLA‐4 +49A/G single nucleotide polymorphism (SNP) 
influences expression of mCTLA‐4; +6230G/A SNP affects the production of sCTLA‐4.
Aim:To examine whether these functional SNPs influence the rate of rejection after liver 
transplantation.
Patients and methods: Liver graft recipients (n = 483) were genotyped for both SNPs, 
and haplotypes were reconstructed. Association with rejection was tested by the log 
rank test using the Kaplan‐Meier method with time to the first acute rejection episode as 
outcome. Multiple analysis of SNPs together with demographic factors was performed 
by Cox regression.
Results: Three haplotypes were observed in the cohort: +49A/+6230A, +49A/+6230G, 
and +49G/+6230G. The +49A/+6230G haplotype was significantly and dose depend-
ently associated with acute rejection (p = 0.01). Of the demographic factors tested, only 
underlying liver disease was significantly associated with rejection. Adjusted for under-
lying liver disease, each additional +49A/+6230G haplotype allele resulted in a signifi-
cantly higher risk of acute rejection (risk ratio 1.34 (95% confidence interval 1.04–1.72); 
p = 0.02). Patients who lacked this haplotype had the lowest, carriers an intermediate, 
and homozygotes the highest risk of acute rejection.
Conclusion: The CTLA‐4 +49A/+6230G haplotype, which encodes for normal mCTLA‐4 
expression but reduced sCTLA‐4 production, is a co‐dominant risk allele for acute rejec-
tion after clinical liver transplantation. This implies that even under immunosuppres-
sion, CTLA‐4 is critically involved in the regulation of the human immune response to 
allogeneic grafts.
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Introduction
Cytotoxic T lymphocyte antigen 4 (CTLA‐4; CD152) is a homologue of CD28, which is 
expressed on the cell surface of activated memory T cells and on CD4+CD25+ regulatory 
T cells, and is critically involved in downregulation of T cell responses. Several mecha-
nisms may account for its inhibitory effects. Firstly, CTLA‐4 has a higher affinity for the 
B7 molecules CD80 and CD86 compared with CD28, and thereby serves as a competitive 
antagonist of CD28 for B7 binding [1]. Secondly, on binding to B7 molecules, CTLA‐4 
actively suppresses interleukin (IL)‐2 production and cell cycle progression of T cells [2]. 
Thirdly, CTLA‐4 is one of the inhibitory molecules by which CD4+CD25+ regulatory T cells 
exert their suppressive function on effector T cell activation [3]. Finally, an alternative 
splice form of CTLA‐4, which is secreted by resting T cells [4], can suppress allogeneic T 
cell activation [5]. This soluble CTLA‐4 (sCTLA‐4) isoform is present in human serum [4] 
and its levels are enhanced in the serum of patients with autoimmune thyroid disease.
[6]
Several autoimmune diseases have been found to be associated with allelic variations 
in the CTLA‐4 gene. The strongest associations have been observed with the single 
nucleotide polymorphisms (SNPs) CTLA‐4 +49A/G and +6230G/A. The +49 A/G SNP 
results in substitution of threonine by alanine in the leader peptide of the newly formed 
CTLA‐4 molecule. It was found to be associated with, for example, Graves’ disease [7], 
diabetes mellitus type 1 [8], primary biliary cirrhosis [9], and autoimmune hepatitis [10]. 
The +6230G/A SNP is situated in the 3′ untranslated region of the CTLA‐4 gene, and 
was recently found to be more strongly associated with Graves’ disease compared with 
the +49A/G SNP [11]. In addition, associations between the +6230G/A SNP and type 1 
diabetes [12], and clearance of hepatitis B virus (HBV) infection [13] were found.
In view of the important role of CTLA‐4 in regulating rejection activity against alloge-
neic organ grafts in experimental animals,[14,15] we examined whether genetic varia-
tions in the CTLA‐4 gene influenced the rate of acute rejection after liver transplanta-
tion. In a previous single centre study aiming to explore whether SNPs in costimulatory 
molecules influenced the risk of acute rejection after liver transplantation, we found 
evidence for an association of the +49A/G SNP with rejection [16]. Here we present data 
from a multicentre study with a larger cohort of patients which aimed to determine 
to what extent the functional CTLA‐4 +49A/G and +6230G/A SNPs influence the prob-
ability of rejection after liver transplantation.
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Patients and methods
Patients
In this retrospective study, 483 liver transplant recipients, derived from three centres 
(126 from Rotterdam, 204 from Birmingham, and 153 from Newcastle), who received an 
orthotopic liver transplant between 1987 and 2001, were included. Patients with a follow 
up period of less than 90 days and patients treated with anti‐IL‐2 receptor monoclonal 
antibodies as part of their immunosuppressive induction treatment were excluded from 
the study. All included patients received standard immunosuppressive therapy consist-
ing of ciclosporin or tacrolimus and prednisone, with or without azathioprine. Mean 
follow up was five years. Written consent was obtained from all participating patients, 
and the Medical Ethics Committee of the Erasmus MC in Rotterdam approved the study. 
Patient characteristics and data on acute rejection were derived from computerised da-
tabases or extracted from patient files. To correct for a possible influence of underlying 
liver disease on the risk of rejection, patients were classified according to their diagnosis 
for liver transplantation into the following categories: viral liver infection (acute or 
chronic HBV or hepatitis C virus (HCV) infection), autoimmune related liver diseases (pri-
mary biliary cirrhosis, primary sclerosing cholangitis, or autoimmune hepatitis), alcoholic 
liver cirrhosis, fulminant hepatic failure, or other (which contained all other diagnoses). 
Acute rejection was defined as an episode with increasing liver enzymes with no other 
identifiable cause, together with moderate or severe rejection activity in a liver biopsy, 
which was responsive to high dose corticosteroid or antilymphocyte immunoglobulin 
treatment.
Determination of SNPs
DNA was isolated from blood by the classic salting out method, involving proteinase 
K digestion and ethanol precipitation. Samples from Rotterdam and Birmingham were 
analysed in Manchester by allele specific polymerase chain reaction (PCR) by one of the 
investigators (ÖT) who was blinded to the clinical data. Allele specific forward primers 
and generic reverse primers were designed using the sequence of the CTLA‐4 gene 
published in the Nucleotide Data bank (http://www.ncbi.nlm.nih.gov). The sequences of 
the primers are depicted in table 1. Each of the allele specific primers was mixed with the 
associated generic primer in a 1:1 ratio and separate reactions were performed for deter-
mination of each allele. An internal control amplification of the human growth hormone 
(HGH) gene was used as a positive control for the PCR reaction. DNA was amplified in 
Mastermix (Abgene, Epsom, UK) supplemented with 5 μM CTLA‐4 and HGH primers. PCR 
was run in a PTC‐100 PCR machine (MJ Research, Massachusetts, USA) according to the 
following programme: 95°C 60 seconds, 10 cycles of 95°C 15 seconds, T1°C 50 seconds, 
72°C 40 seconds, and thereafter 20 cycles of 95°C 20 seconds, T2°C 50 seconds, and 72°C 
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50 seconds. The primer specific annealing temperatures T1 and T2 are depicted in table 
1. PCR products were monitored after electrophoresis on a 2% agarose gel containing 
ethidium bromide.
Samples from Newcastle were genotyped by a PCR‐restriction fragment length 
polymorphism method [10]. The sequences of the primers used to amplify the SNP 
flanking regions are shown in table 1. Bbvl was used to digest the G allele of +49 SNP 
and HpyCH4IV to digest the G allele of the +6230 SNP. Alleles were identified after elec-
trophoresis in an agarose gel.
Haplotype‐genotype estimation
The linkage disequilibrium coefficient (D′) between the two SNPs was calculated using 
Phase software version 2 [17] (http://archimedes.well.ox.ac.uk/pise/PHASE.html). This 
program was also used to estimate the most possible haplotype pair for each individual.
Statistical analysis
The Kaplan‐Meier method was used to determine the cumulative probability of the first 
episode of acute rejection in patient groups with different genotypes or haplotypes, 
and the log rank test was applied to compare rejection curves. Cox regression analysis 
was used to assess the influence of patient characteristics (age, sex, ethnicity, year of 
transplantation, and underlying disease) and the numbers of haplotypes on the risk of 
acute rejection, using the time to the first episode of acute rejection as outcome. To ad-
just the contributions of genetic CTLA‐4 haplotypes for those of patient characteristics 
Table 1 Polymerase chain reaction (PCR) primers used in the study
SNP PCR primer sequences Annealing temp (°C)
Primers used for allele specific PCR
CTLA-4 +49A/G 5’CAAGCCAGATTGGAGTTA 3’ T1 = 64 
5’CTCAGCTGAACCTGGCTA/G 3’ T2 = 58 
CTLA-4 +6230G/A 5’AGGAAGGCAGATCAAAATGC 3’ T1 = 65
5’CACCACTATTTGGGATATAACA/G 3’ T2 = 59 
HGH 5’GCCTTCCCAACCATTCCCTTA 3’
 5`TCACGGATTTCTGTTGTGTTTC 3’  
Primers used for PCR-RFLP
CTLA-4 +49A/G 5’CCACGGCTTCCTTTCTCGTA 3’ 56 
5’AGTCTCACTCACCTTTGCAG 3’ 
CTLA-4 +6230G/A 5’CATCCTTGCATTTGAATATTGTG 3’ 59
5’AAGAATCACAGAGGGCCCAGTG 3’ 
CTLA-4, cytotoxic T lymphocyte antigen 4; SNP, single nucleotide polymorphism; HGH, human growth hor-
mone; RFLP, restriction fragment length polymorphism
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to the risk of acute rejection, multiple Cox regression analysis was performed. In all Cox 
regression analyses patients were stratified on centre to correct for the influence of the 
different centres on outcome. A p value of <0.05 was considered statistically significant.
Results
Patient characteristics and acute rejection
The incidence of acute rejection in the investigated cohort was 39% (189 out of 483 
patients). Table 2 shows the influence of demographic patient characteristics on the 
rate of acute rejection. Risk ratios of acute rejection were calculated by Cox regression 
using the time to the first acute rejection episode as outcome and stratifying patients 
on centre. Female recipients had a higher incidence of rejection compared with male 
recipients. Patients with a viral liver infection (either HCV or HBV) as the indication for 
liver transplantation had about a twofold decreased risk of acute rejection compared 
with patients with other underlying liver diseases, except alcoholic cirrhosis. Recipient 
age and year of transplantation were not significantly related to risk of acute rejection. 
The latter indicates that changes in immunosuppressive treatment over the years did 
not significantly influence the rate of acute rejection.
Table 2 Association between patient characteristics and time to first acute rejection, as analysed by Cox 
regression and stratified on centre.
Patient Characteristics HR (95% CI) p Value
Sex 0.04
Male (N=259) 1 
Female (n=224) 1.35 (1.01-1.79) 
Age ( per year) 0.99 (0.98-1.01) 0.29
Year of transplantation 0.96 (091-1.03) 0.25
Ethinicity 0.10
Caucasian (n=449) 1 
Black African (n=19) 0.43 (0.13-1.36) 
Asian (n=15) 0.41 (0.10-1.65) 
Diagnosis 0.01
Chronic viral hepatitis (n=94) 1 
Autoimmune related (n=172) 2.06 (1.25-3.39) 
Alcoholic cirrhosis (n=80) 1.37 (0.77-2.44) 
FHF (n=44) 2.37 (1.29-4.34) 
Other (n=93) 1.79 (1.04-3.09) 
Groups with a hazard ratio (HR) of 1 were chosen as the reference categories. 95% CI, 95% confidence inter-
val. P values were derived from the log likelihood test. FHF, fulminant hepatic failure
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Single nucleotide polymorphisms and acute rejection
Figure 1 shows the cumulative probabilities of acute rejection in patient groups with 
different genotypes of the +49A/G and +6230G/A SNPs. Overall, neither SNP was sig-
nificantly associated with acute rejection but pairwise comparisons of the genotypes 
showed a significantly lower risk of rejection in patients with the +6230AA genotype 
compared with those with the AG genotype.
Haplotypes and acute rejection
The +49A/G and +6230G/A SNPs were in complete linkage disequilibrium (D′ = 1). 
Haplotype reconstruction from the SNP by Phase software showed that only three 
of the four possible haplotype combinations were present in the cohort—namely, 
+49A/+6230A, +49A/+6230G, and +49G/+6230G. To establish the associations between 
these haplotypes and acute rejection, we grouped patients by haplotype copy numbers 
Figure 1: Cumulative percentages of acute rejection (Kaplan‐Meier curves) in liver transplant recipients 
classified according to their cytotoxic T lymphocyte antigen 4 (CTLA‐4) +49A/G (A) or CTLA‐4 +6230G/A 
(B) genotype. The outcome used was the time to the first episode of acute rejection. Percentages indicate 
cumulative incidences of acute rejection in each group, eight years after transplantation. For better visuali-
sation of the kinetics of rejection, the x axis of the first half year was spread out and curves were cut off at six 
years. No acute rejections occurred after that time. p values were derived from the log rank test.
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(non‐carriers, heterozygous carriers, and homozygous carriers) for each haplotype 
allele. Kaplan‐Meier curves of the cumulative incidences of acute rejection in the 
different groups are depicted in fig 2 . As the +6230A allele was completely linked to 
the +49A allele, the curves of the +49A/+6230A haplotype (fig 2A ) were exactly the 
same compared with the curves of the +6230G/A SNP (fig 1B ), and the rate of rejec-
tion was significantly lower in patients homozygous for the +49A/+6230A haplotype 
compared with heterozygous carriers. However, the opposite haplotype +49G/+6230G 
Figure 2: Cumulative percentages of acute rejection in liver transplant recipients classified according to the 
numbers of CTLA‐4 +49/+6230 haplotype copies they carried. This is shown for haplotypes +49A/+6230A 
(A), +49A/+6230G (B), and +49G/+6230G (C). Patients who lacked the haplotype are termed group 0, het-
erozygous carriers group 1, and homozygous carriers group 2. The outcome used was the time to first 
episode of acute rejection. Percentages indicate cumulative incidences of acute rejection six years after 
transplantation. p values were derived from the log rank test
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was not a risk allele for acute rejection (fig 2C). Log rank analysis showed that overall 
only the +49A/+6230G haplotype (fig 2B ) was significantly associated with the rate of 
acute rejection. To investigate whether the influence of this haplotype on the risk of 
rejection was dose dependent, a univariate Cox regression model was used in which 
the +49A/+6230G haplotype was introduced as a continuous variable. In this model, 
the +49A/+6230G haplotype demonstrated a significant dose‐allele effect with a haz-
ard rate of 1.39 (95% confidence interval 1.08–1.79; p = 0.01). Collectively, these data 
indicate that the CTLA‐4 +49A/+6230G haplotype is a co‐dominant risk allele for acute 
rejection after liver transplantation. When patients were classified according to their 
CTLA‐4 +49/+6230 haplotype genotypes, Kaplan‐Meier plots confirmed that homozy-
gous and heterozygous carriers of the +49A/+6230G haplotype allele had the highest 
rates of acute rejection (fig 3), and homozygous carriers of both of the other haplotypes 
(49A/+6230A and +49G/+6230G) the lowest.
Multivariate analysis of the association of CTLA‐4 haplotypes and patient 
characteristics with the rate of acute rejection
To determine whether the CTLA‐4 haplotypes contributed to the risk of acute rejection 
independently of patients characteristics, a Cox regression model which included all 
haplotypes and patients characteristics was used. Non‐significant parameters were 
removed stepwise. Table 3 shows that only the +49A/+6230G haplotype and underly-
ing liver disease were significantly associated with rejection. Although in the univariate 
analysis a significant association between recipient sex and acute rejection was found, 
Figure 3: Cumulative percentages of acute rejection in liver transplant recipients classified according to 
their haplotype genotypes. Each curve represents a group of patients with one genotype, which is depict-
ed above or underneath the curve with the +49/+6230 genotypes, separated by a comma. The outcome 
tested was the time to first episode of acute rejection. Percentages indicate cumulative incidences of acute 
rejection six years after transplantation. The p value is derived from the log rank test
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this was not the case in multivariate analysis. Adjusted for the effect of underlying 
diseases, the +49A/+6230G haplotype was dose dependently associated with acute 
rejection, with a risk ratio of 1.34 for each additional +49A/+6230G haplotype allele. 
This means that heterozygous carriers had a 1.34 higher relative risk of acute rejection 
compared with patients who lacked this haplotype, and that homozygous carriers had a 
1.34 higher relative risk compared with heterozygous carriers.
Discussion
In the present study, we analysed the influence of two functional SNPs in the CTLA‐4 
gene on the rate of acute rejection after liver transplantation. The +49A/G SNP is located 
in the signal peptide of the molecule and influences expression of the full length iso-
form on the T cell membrane. Full length CTLA‐4 molecules encoded by the G allele are 
incompletely glycosylated, leading to retrograde transport of a portion of the molecules 
to the cytoplasm for degradation. This results in reduced expression on the T cell surface 
[18] and impaired inhibitory function of CTLA‐4 on T cell activation in individuals homo-
zygous for +49G [7]. The +6230G/A SNP is located in the 3′ untranslated region of the 
CTLA‐4 gene and was reported to influence the production rate of the soluble alterna-
tive splice form of CTLA‐4. sCTLA‐4 mRNA encoded by the +6230G‐allele is produced at 
a reduced rate compared with mRNA encoded by the +6230 A allele [11]. As the soluble 
isoform is a suppressor of allogeneic T cell activation [5], it is conceivable that carriers of 
the +6230G allele may be more susceptible to rejection after organ transplantation. This 
was indeed what we found on analysis of the association between the +6230 SNP and 
Table 3 Multiple Cox regression analysis of the influence of cytotoxic T lymphocyte antigen 4 (CTLA-4) 
+49/+6230 haplotypes and patient characteristics stratified on centre on the rate of acute rejection
Risk ratio 95% CI p Value
Haplotype +49A/+6230G (per allele number) 1.34 1.04-1.72 0.02
Diagnosis
Chronic viral hepatitis 1 0.01
Automimmune related 2.05 1.24-3.35 <0.01
Alcoholic cirrhosis 1.34 0.75-2.39 0.33
FHF 2.25 1.23-4.14 0.01
Others 1.76 1.02-3.04 0.04
In the Cox regression model each of the three different CTLA-4 +49/+6230 haplotypes were included as a 
continues variable, together with underlying liver disease, year of transplantation, and recipient ethnicity, 
seks and age. The diagnosis group with a hazard ratio of 1 was chosen as a reference category. Only those 
parameters which were significantly associated with acute rejection are shown. The overall p value was 
0.003 (log likelihood test). FHF, fulminant hepatic failure, 95% CI, 95% confidence interval.
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rejection: homozygous CTLA‐4 +6230A liver transplant recipients which lacked the G 
allele showed a reduced rate of rejection compared with carriers of the G allele.
However, haplotype analysis showed that the single +6230G allele was not the risk 
allele for acute rejection. The +6230G allele was not associated with an increased 
risk of rejection when it was combined in a haplotype with the +49G allele, but only 
when it was combined with the +49A allele. Thus the risk allele for acute rejection after 
liver transplantation (+49A/+6230G) combines the genetic predisposition for reduced 
capability to produce sCTLA‐4 (+6230G) with a normal capacity to express the full 
length CTLA‐4 isoform on the T cell membrane (+49A). The effect of this haplotype on 
rejection was dose dependent, meaning that each additional allele results in a higher 
risk of rejection. The conclusion that this specific combination of single alleles confers 
risk to acute rejection is further substantiated by the observation that carriers of one 
+49A/+6230A allele and one +49G/+6230G allele had a rate of rejection intermediate 
between carriers of the +49A/+6230G risk haplotype and homozygous carriers of the 
protecting +49A/+6230A and +49G/+6230G haplotypes (fig 3). Conceivably, the single 
risk alleles +49A and +6230G can also exert their combined effect on rejection when 
they are located on different chromosomes.
The finding that only the +49A/+6230G haplotype is the risk allele for acute rejection is 
remarkable. The +49A/+6230G and +49G/+6230G haplotypes were observed to be asso-
ciated to a similar extent with Graves’ disease [11]. For type I diabetes, the +49G/+6230G 
is a risk allele but the association of the +49A/+6230G haplotype with disease is either 
positive or negative, depending on the allele of the −319C/T SNP which is cotransmitted 
[12]. It is difficult to imagine how increased expression of the inhibitory mCTLA‐4, as 
encoded for by the +49A allele, contributes to an enhanced rate of rejection. A major 
difference between acute rejection of clinical organ grafts and autoimmune diseases is 
that rejection develops under the cover of continuous immunosuppression. Calcineu-
rin inhibitors such as ciclosporin and tacrolimus inhibit the upregulation of mCTLA‐4 
expression on the cell surface after T cell activation [19]. As sCLTA‐4 is produced by rest-
ing, but not by activated T cells, production of this isoform is probably not suppressed 
by calcineurin inhibitors. Therefore, the ratio between levels of mCTLA‐4 and sCLTA‐4 
expression in organ transplant recipients may be quite different from that in patients 
with developing autoimmune diseases. As a consequence, the effects of high or low 
mCTLA‐4 expression on acute rejection may differ from those on development of auto-
immune diseases. Furthermore, an additional unknown single allele which influences 
CTLA‐4 expression of function may be linked to the +49A+6230G haplotype, but not 
the +49G+6230G allele. The effect of this allele may only penetrate into a clinical effect 
under conditions of immunosuppression.
In a previous explorative single centre study, we found that liver transplant recipients 
who were homozygous for the CTLA‐4 +49 G allele had a lower incidence of acute rejec-
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tion after liver transplantation compared with homozygous or heterozygous carriers of 
the A allele [16]. A trend towards a similar association was found in the present study, 
but this was not statistically significant. Our previous finding seemed to contradict 
observations that the CTLA‐4 +49G allele is a disease predisposing allele for several 
autoimmune diseases.[7,8,9,10] In addition, Slavcheva and colleagues [20] found no as-
sociation between the +49 A/G polymorphism and acute rejection in a combined cohort 
of liver and kidney transplant recipients. The results of the present study may explain 
why differences in associations between the +49A/G polymorphism and acute rejection 
can be obtained in different study cohorts. Individuals with genotype +49G/G lack the 
risk haplotype allele +49A/+6230G, which makes them less susceptible to rejection, but 
carriers of +49A alleles can either carry the risk haplotype +49A/+6230G or the protective 
haplotype +49A/+6230A in conjunction with the +49A allele. Therefore, the association 
of the +49A/G genotype with rejection is dependent on the proportion of +49A alleles 
that are linked to the +6230G allele in the study cohort. In the present study, more than 
half (93/181) of the patients with the +49A/A genotype were homozygous carriers of the 
+49A/+6230A haplotype allele, and therefore had a low rate of acute rejection (fig 3). 
Consequently, in the cohort investigated in the present study, no significant association 
between the +49A/G polymorphism and rejection was found. The same may have been 
the case in the cohort studied by Slavcheva and colleagues [20].
The results of the present study do not contradict the association between liver graft 
survival and recipient CTLA‐4 +49 genotype observed by Marder and colleagues [21]. 
These authors reported that liver transplant recipients with the +49G/G genotype have 
a decreased graft survival in comparison with patients with +49A/A or A/G. The short-
ened graft survival was, however, not due to a higher incidence of acute rejection in this 
group but mainly related to recurrence of viral hepatitis. Therefore, the decreased graft 
survival in the +49G/G group was probably due to an increased immune response of the 
recipient to reinfection of the liver graft with hepatitis virus. Indeed, the CTLA‐4 +49G 
allele has been associated with an enhanced immune response against HBV [13].
The only patient characteristic that was significantly associated with acute rejection 
on multiple analysis was underlying liver disease. Liver transplant recipients with viral 
hepatitis or alcoholic cirrhosis as indication for liver transplantation had a twofold re-
duced risk of acute rejection. The first group included patients with HBV and HCV infec-
tion, transplanted for either acute liver failure or cirrhosis due to chronic infection. The 
reduced incidence of rejection is this patient category was probably due to prophylactic 
treatment of HBV positive patients with high dose anti‐hepatitis B immunoglobulins 
to prevent reinfection of the graft. Recently, we confirmed the original observation of 
Farges and colleagues [22] that treatment with intravenous anti‐hepatitis B immuno-
globulins protects against rejection, and we demonstrated that these immunoglobulins 
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inhibit both T cell and dendritic cell function.23 The relatively low incidence of rejection 
in patients with alcoholic cirrhosis has also been observed in other studies.24
In conclusion, the CTLA‐4 +49A/+6230G haplotype is a co‐dominant risk allele for 
acute rejection after clinical liver transplantation. This implies that, even under immuno-
suppression, CTLA‐4, in common with experimental animals, is critically involved in the 
regulation of the human immune response against allogeneic grafts.
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Abstract
Introduction: Chronic kidney disease (CKD) after liver transplantation (LT) is a major 
clinical problem that appears to be associated with non-genetic, as well as genetic 
determinants. Calcineurin inhibitor (CNI) use is considered to play a major role in the 
development of CKD after LT. We studied the influence of single-nucleotide polymor-
phisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 
and the CNI-transporting ABCB1, on the development of chronic kidney disease (CKD) 
after liver transplantation (LT).
Methods: Tacrolimus (Tac) predose concentrations at different time-points after trans-
plantation and the CYP3A5 6986A>G and ABCB1 3435C>T SNPs were determined in 125 
LT recipients and their respective donors to study the influence of Tac predose levels and 
genetics on CKD development.
Results: After a median follow up of 5.7 ± 2.9 years, CKD developed in 47 patients (36%). 
The Tac predose levels were not correlated with the development of CKD. Neither did we 
find a correlation between the investigated SNPs in either donor or recipient ABCB1 and 
CYP3A5 genes (or combinations thereof ) and the development of CKD. These genetic 
variatiants did not relate to Tac predose blood concentrations in our study.
Conclusion: An individual’s risk to develop CKD after LT is not associated with genetic 
variation in either recipient or donor CYP3A5 or ABCB1 genotype status.
43
Chapter 3 : ABCB1/CYP3A5 polymorphisms and chronic kidney disease 
Introduction
Tacrolimus (Tac) is currently the most commonly used calcineurin inhibitor (CNI) after 
liver transplantation (LT) to prevent allograft rejection. The clinical use of Tac is challeng-
ing because of variable pharmacokinetics between individuals [1-3]. In most transplant 
centers, the dosage of Tac is based on predose (whole-) blood concentrations to find 
a balance between under- and over-immunosuppression and its associated risks of 
rejection, nephrotoxicity, or infection. Nonetheless, undesired effects of Tac treatment 
cannot be totally prevented by performing therapeutic drug monitoring [4].
One of the mechanisms of inter-individual differences in Tac exposure is the activity 
of the polymorphically-expressed CNI-metabolizing enzyme cytochrome P450 (CYP) 
CYP3A5, and the drug transporter ABCB1 (previously known as P-glycoprotein).[5,6,7] 
CYP3A5 and ABCB1 are both expressed in the intestine, the liver and the kidney.[5,6,8-
11] ABCB1 is responsible for decreasing the systemic exposure to Tac, by increasing its 
efflux into the intestinal, canalicular and tubular lumina. CYP3A5 is responsible for the 
clearance of Tac and is co-expressed with ABCB1 in liver and kidney. Through the action 
of ABCB1 local Tac concentrations are kept low, ensuring efficient CYP3A5-mediated Tac 
metabolism.
Several single-nucleotide polymorphisms (SNPs) have been identified in the CYP3A5 
and ABCB1 genes. The best-studied SNP in CYP3A5 is that in intron 3, genomic 6986A>G.
[12,13] The variant allele, referred to as CYP3A5*3 (corresponding with the G allele), leads 
to the absence of functional CYP3A5 protein and occurs homozygously in 80% of the 
Caucasian and in 30% of the black population. Several investigators have demonstrated 
that patients carrying the CYP3A5*1 (wild-type) allele and who therefore express func-
tional CYP3A5, need a Tac dose which is on average 50% higher compared to patients 
with the CYP3A5*3/*3 genotype (non-expressers) [14]. In addition, an individual’s CYP3A5 
genotype may determine one’s risk of developing Tac-related nephrotoxicity [15].
More than 25 SNPs have been identified in ABCB1. The best-studied SNP is 3435C>T in 
exon 26, which may lead to the formation of an ABCB1 protein with an altered conforma-
tion and activity, and possibly intracellular accumulation of Tac.[15,16] There is ample 
evidence that intra-renally expressed ABCB1 is implicated in the pathogenesis of CNI-
induced renal dysfunction [17]. Additionally, several studies have provided evidence 
that genetic variation in ABCB1 may predispose patients to the nephrotoxic effects of 
CNIs after kidney transplantation.[18,19], .
Most studies on the role of genetic variation in CYP3A5 and ABCB1 in CNI-related 
nephrotoxicity were performed in renal transplant recipients.[15,19,21-23] However, 
renal dysfunction after kidney transplantation has many causes other than the use of 
CNIs, and even kidney biopsy (still considered the gold standard) may not be able to dif-
ferentiate between CNI-induced kidney damage and other causes of renal dysfunction. 
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Therefore, the genetic basis of chronic kidney disease (CKD) may be better studied in LT 
recipients. So far, three studies have investigated the role of ABCB1 and CYP3A5 in the 
development of CKD after LT [24-26]. However, these studies were performed in Asian 
(rather than Caucasian) or pediatric populations and included relatively small numbers 
of patients. In the present study, we investigated if genetic variation in CYP3A5 and 
ABCB1 is associated with CKD in a Caucasian, adult LT population.
Materials & Methods
Patients
This retrospective study included clinical data of patients who underwent a liver trans-
plantation between September 1997 and November 2009 and were followed at the out-
patient clinic of the Erasmus MC, University Medical Center Rotterdam, the Netherlands. 
Three months post-LT was considered as time-point 0, meaning the starting point of 
kidney function measurement. We chose this time point to minimize kidney dysfunction 
associated with liver failure and surgical related complications.
Starting in 1996 there has been a gradual transition from cyclosporine to the use of 
Tac, with Tac becoming the main immunosuppressant after the year 2000. The main 
immunosuppressant at 3-months post-LT was considered as the immunosuppressive 
regimen that the patient received. Patients received a CNI from day one post-LT, unless 
there was a medical reason to postpone the first gift. The doses of Tac were adjusted to 
achieve and maintain whole-blood predose concentrations of 10 to 15 ng/mL in the first 
month post-LT, and between 5 to 10 ng/mL from 1 month onwards. Doses were adapted 
for presumed CNI-related toxicity or allograft rejection.
For this study we used the following inclusion criteria: 1) Use of Tac at 3 months 
after LT, 2) Caucasian ethnicity, 3) availability of DNA of both donor and recipient 4) a 
follow-up time of at least one year after LT. Exclusion criteria were 1) a combined kidney-
liver transplantation, 2) a previous kidney transplantation, 3) recipient age <18 years, 4) 
death within the first year after LT, 5) a follow-up period of less than one year after LT 
(for reasons other than death), 6) a re-LT within one year after the first LT, 7) receiving 
immunosuppression other than Tac in the first three months and 8) an ethnicity other 
than Caucasian. Patients in need of a re-transplantation were censored at the time of 
their second transplantation.
The institutional medical-ethical review board of our hospital approved the current 
study and informed consent was obtained from all patients.
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Renal function
The estimated glomerular filtration rate (eGFR) was calculated by use of the Modification 
of Diet in Renal Disease study equation (MDRD) [25]. Serum creatinine values (µmol/L) 
were collected at 3, 6 and 12 months after LT and yearly thereafter. The same creatinine 
assay was used during the whole study period. Patients were categorized according to 
the Kidney Disease Outcomes Quality Initiative (KDOQI) groups: patients were consid-
ered to have mild renal insufficiency when their eGFR was between 30 and 60 mL/min 
per1.73 m2 (CKD stage 3). Moderate renal failure was categorized as CKD stage 4 (eGFR 
between 15 and 30 mL/min per 1.73 m2), and end-stage kidney disease or CKD stage 5 
(eGFR < 15 mL/min per 1.73 m2 or the need for renal replacement therapy).
Tacrolimus assay
Tacrolimus predose concentrations were determined throughout the study period in 
whole blood by use of immunoassays [the Emit 2000 assay (Syva Company, Dade Behring 
Inc., Cupertino Calif.) and the ACMIA-Flex assay (Siemens HealthCare Diagnostics, Inc., 
Newark, DE)] on several analyzers [the IMX (Abbott), the Cobas Mira Plus analyzer (Roche 
Diagnostic Systems, Basel, Switzerland), the V-twin and Dimension XPand (both Siemens 
HealthCare Diagnostics, Inc, Newark, DE)]. The upper limit of detection was 30 ng/mL 
and the lower limit of detection 1.5 ng/mL. Details on the sensitivity, reproducibility, and 
sensitivity of the Emit assay in our laboratory were published previously [26]. Proficiency 
samples were obtained from the United Kingdom Quality Assessment Scheme (Dr Holt, 
St George’s Hospital Medical School, London, United Kingdom).
DNA isolation and genotype determination
Deoxyribonucleic acid (DNA) was extracted from venous blood from recipients and 
splenocytes of deceased donors, by using a DNA Purification kit (Promega, Madison 
USA) according to the manufacturer’s guide. The subjects were genotyped for the 
CYP3A5 (6989A>G) and ABCB1 (3435C>T) SNPs as previously described [27]. In brief, 50 
ng of DNA was used in a total PCR volume of 50 µL containing 1x buffer (10-mmol/L 
Tris-hydrochloric acid, pH 8.3; 1.5 mmol/L magnesium chloride; 50-mmol/L potassium 
chloride; and 0.001% [wt/vol] gelatin [PerkinElmer, Inc, Wellesley, Mass]), 0.2-mmol/L of 
each deoxyribonucleoside triphosphate (Roche), 1.25 U of AmpliTaq Gold (Perkin-Elmer) 
and 40 pmol of each forward and reverse primer. For ABCB1, the forward primer 5’-CAT-
GCTCCCAGGCTGTTTAT-3’ and the reverse primer 5’-GTAACTTGGCAGTTTCAGTG-3’ were 
used. PCR conditions were as follows: 7 minutes at 94°C; 35 cycles of 1 minute at 94°C; 1 
minute at 55°C, 1 minute at 72°C and finally 7 minutes at 72°C. The PCR products were 
digested with SspI (CYP3A5) or DpnII (ABCB1) in a total volume of 15 µL for 2 hours at 37 
°C and subsequently analyzed on agarose/Tris-borate-ethyl-enediaminetetraacetic acid 
gel with ethidium bromide staining.
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Statistical analysis
SPSS 17.1 was used for data analysis. Differences in parametric en nonparametric values 
between groups were tested with the unpaired t-test and Pearson’s Chi Square, respec-
tively, for categorized variables and one-way ANOVA for continuous variables. Linear re-
gression was used for differences between Tac predose concentrations between groups. 
Survival curves according to Kaplan Meier log rank comparison were calculated for the 
univariate analysis of multiple covariates (tested separately) in correlation with CKD. 
Deviations from the Hardy-Weinberg equilibrium were studied using appropriate Chi 
Square testing, using a calculator on http://www.oege.org/software/hwe-mr-calc.shtml. 
P values < 0.05 were considered significant.
Results
Baseline characteristics
In the study period, a total of 328 patients underwent a liver transplantation of which 
52 subjects used cyclosporin as main immunosuppressive therapy. Within the first year 
after LT, 15 patients died and 43 underwent a re-LT. Of the remaining 218 patients, 2 were 
excluded because of kidney transplantation prior to LT and 2 patients were excluded 
because of combined kidney-liver transplantation. Of 52 subjects there was no DNA 
available and 25 were not Caucasian. Of 5 patients we did not have sufficient (clinical) 
data to calculate the eGFR. Seven patients were lost to follow-up, leaving a total of 125 
patients for the final analysis (Figure 1A).
The baseline characteristics of the 125 studied patients are depicted in Table 1, cat-
egorized in patients with and without renal dysfunction. The overall mean follow up 
time was 5.7 ± 2.9 years with a total follow up of 11.2 years. Patients developing kidney 
dysfunction were more often of female gender, older and had pre-transplant diabetes 
mellitus. Besides, there was a difference in primary indication for liver transplantation 
between the two groups. There were no differences between the pre-existent hepatitis 
C infection (HCV) and genetic distribution of the SNPs between the two groups.
In this study population, renal function remained normal in 62% (n = 78), 36% of 
patients (n = 45) developed mild renal dysfunction, and only 2% (n = 2) developed 
moderate renal failure (CKD 4). None of the patients developed end-stage renal disease 
[eGFR < 15 mL/min/1.73 m2] (Figure 1B). Figure 1C displays the dynamics of the mean 
renal function between patients with a normal eGFR and patients with renal impair-
ment. Patients with an impaired renal function started with a significantly lower eGFR at 
3 months after liver transplantation.
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Renal clearance and Tac predose levels
Tac predose blood concentrations were collected at several time-points for each patient, 
starting at month 1 after LT. The mean exposure to Tac in the early phase after transplan-
tation was 10.4 ± 4.8 mg/L (with a range of <1.5 mg/L and 26.4 mg/L) with a decrease 
thereafter and with a mean at month 48 of 5.8 ± 3.2 mg/L (range between <1,5 and 14.4 
mg/L). When analysis was performed of exposure of patients with an eGFR >60 mL/min 
and those with a eGFR <60 mL/min, there was no significant difference (Figure 2A) and 
both groups had Tac predose concentrations within the target range. Analysis of expo-
sure to Tac predose levels in patient groups with different genotypes was performed and 
shown in figure 2B to 2D, and no significant differences were observed. The Tac predose 
levels of the two patients with CKD 4 were on average lower than those of patients with 
normal renal function or those with CKD stage 3. After month 6, the predose levels of 
this group was below the target range of 5 mg/L (data not shown).
n = 328 
n = 276 
n = 218 
n = 214 
n = 137 
n = 125 
15 died within the first year 
2 combined kidney- and liver transplantation 
2 kidney transplantation prior to liver transplantation 
52 no DNA available 
25 other ethnicity than Caucasian 
7 lost to follow up 
5 insufficient data to calculate MDRD 
43 Re-LT within the first year 
A 
B 
C 
p < 0.01 
52 therapy with cyclosporine A 
Analysis 
eGFR 
eGFR 
eG
FR
 
Figure 1: A) Flow chart of study cohort, between September 1997 and December 2009, displaying how 
many subjects were excluded, leaving 125 LT recipients for final analysis B) Pie chart of distribution of 
chronic kidney failure classification; majority does not develop kidney failure (62%), 36% develops mild 
kidney failure (CKD 3) and only 2 % develops a eGFR between 15- and 30 mL/min (CKD 4); C) Mean eGFR 
levels through time between patients with a eGFR > 60 mL/min en eGFR < 60 mL/min. Patients develop-
ing CKD start with lower eGFR than patients with a normal kidney function, which is significant (p < 0.01)
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Table 1: Baseline characteristics of recipients of liver transplantation with and without chronic kidney fail-
ure (CKD)
EGFR>60 mL/min
Total N=78(%of N)
EGFR<60 mL/min
Total N=47(%of N)
p-value
Gender Male 59 (76) 21 (45) 0,01
female 19 (24) 26 (55)  
BMI (kg/m2) mean ± SE 25,7 ± 4,3 24,7 ± 2,9 0,15
Age mean ± SE 44,3 ± 12,6 50,6 ± 8,7 0,03
Primary disease acute hepatic failure 4 (5) 9 (19) 0,01
cholestatic disease 23 (30) 5 (11) 
alcoholic disease 9 (12) 11 (23,4) 
viral hepatitis 9 (12) 8 (16) 
HCC 7 (10) 3 (6) 
metabolic disease 3 (4) 1 (2) 
polycystic disease 1 (1,3) 5 (11) 
other 22 (28) 5 (11) 
Diabetes mellitus No DM 63 (81) 28 (60) 0,34
Post LT 6 (8) 7 (15) 
Pre-existent 9 (11) 12 (25) 
Hepatitis C negative 71 (91) 41 (87) 0,53
positive 7 (9) 6 (13)  
R_ABCB1 C>T CC 23 (30) 13 (28) 0,32
CT 31 (41) 22 (47) 
TT 22 (29) 12 (25) 
R_CYP3A5 A>G AA 0 0 0,42
AG 10 (13) 4 (8) 
GG 65 (87) 43 (92) 
D_ABCB1 C>T CC 17 (22) 9 (20) 0,91
CT 40 (60) 20 (56) 
TT 20 (26) 11 (23) 
D_CYP3A5 A>G AA 2 (3) 0 (0) 0,28
AG 6 (7) 7 (16) 
GG 70 (90) 38 (84) 
Baseline characteristics of LT recipients of Caucasian race, who received Tac as main immunosuppressant, 
genotyped for the CYP3A5 6986A>G and ABCB1 3435C>T SNPs (BMI = Body mass index). Gender, age en 
primary indication for transplantation and pre-existent diabetes mellitus are significantly different in be-
tween these groups.
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Influence of SNPs in CYP3A5 and ABCB1 on CKD development
All liver donors were Caucasians. Table 2 shows the allele frequencies and the genotype 
distributions of the SNPs in recipients and donors of our cohort, which were all in the 
Hardy-Weinberg equilibrium. The incidence of CKD was not associated with ABCB1 or 
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Figure 2: Tac predose levels A) No difference of Tac predose levels between patients with a normal renal 
function (> 60 mL/min) and an impaired renal function post-LT (< 60 mL/min) B) CYP3A5 non-expressers in 
the kidney (R_CYP3A5 GG) do not have higher Tac predose level than CYP3A5 expressers (R_CYP3A5 AG) C) 
Patients who received a donor liver which is not expressing the CYP3A5 protein have equal Tac predose lev-
els compared to patients who received an organ expressing CYP3A5 (D_CYP3A5 GG) D) Tac predose levels 
of LT recipients with expression of different forms of intra-renal ABCB1 protein, which do not significantly 
differ in between.
Table 2: Allele distribution in Caucasian
SNP
Allele frequency
(of variant allele) wt/wt wt/m m/m
R_CYP3A5 6986 A>G 0,94 0/122 14/122 108/122
D_CYP3A5 6986 A>G 0,93 2/123 13/123 108/123
R_ABCB1 3435 C>T 0,49 36/123 53/123 34/123
D_ABCB1 3435 C>T 0,52 26/123 66/123 31/123
Allele frequencies of CYP3A5 6986A>G and ABCB1 3435C>T SNPs do not significantly vary between donor 
and recipients (both Caucasian). Wt= wild type allele (allele A for CYP3A5 6986 and allele C for ABCB1 3435), 
m = mutant allele. Allele frequencies are displayed for the mutant allele.
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CYP3A5 genotype, either when considering donor or recipient genotype, as depicted 
in Figure 3. With univariate analysis, CYP3A5 expressers (CYP3A5*1 carriers) and non-
expressers (CYP3A5*3/*3 genotype) were compared with regard to the incidence of CKD. 
The same was done for ABCB1 genotype (ABCB1 3435 C allele or wildtype carriers vs. 
ABCB1 TT homozygotes). No relation between CYP3A5 and/or ABCB1 genotype and the 
incidence of CKD was observed.
Subsequently, we analyzed if the combined ABCB1 and CYP3A5 genotype was associ-
ated with the incidence of CKD. Patients with ABCB1TT who received an allograft from 
a CYP3A5AA donor did not have significant incidence of CKD (figure 4). However, in our 
study population only 4 of such combinations were present. The possibility of perform-
ing a multivariate analysis to establish risk factors for CKD was considered. However, in 
the univariate analysis, the p-value of the genetic factors was higher than 0.2, indicating 
that these risk factors would not be significant in a multivariate analysis.
Recipient CYP3A5 6986 A>G  
Number at risk  
       A-alllele carriers   14                9             4                1                 0 
       GG                           108             52            39             28               20             3   
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Donor CYP3A5 6986 A>G  
Number at risk  
      A-alllele carriers    15                4             1                                 
      GG                          108             58            42             30               20             2   
GG 
A-allele carriers 
C-allele carriers 
TT 
Recipient ABCB 3435 C>T  
Number at risk  
       CC-alllele carriers  88             42            31             20              13             2 
       TT                             35             19            12               9                7             1   
p = 0,82 
p = 0,20 p = 0,51 
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Donor ABCB 3435 C>T  
TT 
C-allele carriers 
Number at risk  
       CC-alllele carriers  92             45            32             23              16             3 
       TT                             31             18            13               8                4             1   
Time in years 
p = 0,90 
Figure 3: Association of CYP3A5 6986A>G and ABCB1 3435C>T SNPs with the development of CKD
No differences in the cumulative incidence of CKD were observed between CYP3A5 6986 A allele carriers 
(CYP3A5 expressers) and non-expressers (A and B). Likewise, there were no significant differences in the risk 
of developing CKD between ABCB1 3435 TT homozygotes and variant C allele carriers (C and D).
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Discussion
In this study, we analyzed the incidence of CKD after LT in a single-centre cohort consist-
ing of 125 adult, Caucasian patients and in relation to ABCB1 and CYP3A5 genotype of 
both donor and recipient. CKD developed in 38% of the LT patients, which is in line with 
the CKD incidence reported in other studies (between 20 and 70%).[30,31] The allele 
frequencies of the investigated SNPs in our population were also comparable to those 
of other studies.[19,32,33]
Our data show that neither the CYP3A5 6989A>G nor the ABCB1 3435C>T genotype of 
either donor or recipient were associated with CKD risk after LT. Even our sub-analysis 
with combining recipient ABCB1 TT genotype with the donor CYP3A5 genotype did not 
show a significant difference in the incidence of CKD. However, we cannot rule that the 
low numbers could have masked an effect.
Other studies, which previously did identify an association between CYP3A5 and/or 
ABCB1 genotype and renal dysfunction differed from ours in terms of the study popula-
tion, ethnicity, type of CNI prescribed, and primary endpoint.[24-26,34] For example, in 
one study, nephrotoxicity was defined as a 30% reduction in eGFR [25]. Other studies in-
vestigated the effect of genotype on Tac C/D ratios rather than renal endpoints.[25,26,34] 
Finally, the activity of CYP3A depends on a subject’s age (older patients require a lower 
CNI dose than younger ones) and therefore, the outcome of genetic association studies 
in young patients may not be extrapolated to the adult and elderly [35].
Recipient ABCB1 TT 
Donor CYP3A5 
A-allele cariers 
GG 
p = 0,052 
Number at risk  
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Figure 4: Sub-analysis of native ABCB1 mutants combined with graft CYP3A5 expressers
A trend of higher incidence of CKD development is observed in patients with native ABCB1 expression who 
received a graft with CYP3A5 expression, which is not significant.
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Most investigations into the association of post-transplant renal failure and CYP3A5 
and/or ABCB1 genotype performed up until now, were conducted in cohorts of kidney 
transplant recipients.[4,15,19,21,23,36,37,47] Although several authors have identified 
genetic risk factors for renal insufficiency after kidney transplantation, the findings of 
these studies are also conflicting.[13,18] In addition, in the kidney transplant setting, 
many factors other than the use of CNIs may influence renal function and these include 
recurrence of original kidney disease, ischemia-reperfusion injury, allograft rejection 
and quality of the kidney transplant. It should be taken into account that a kidney biopsy 
as the “gold” standard to diagnose CNI-induced renal insufficiency was not performed 
in several studies. Therefore, some of the reported findings may have been spurious 
associations or misdiagnoses. Nonetheless, even a renal biopsy may not always reliably 
establish a diagnosis of CNI-induced nephrotoxicity [39].
For the present analysis we chose eGFR as a measure of renal function. eGFR measure-
ments are routinely used in everyday clinical practice and we do not take renal biopsies 
in all patients with a decreased renal function. This is a limitation of the study but we 
feel that the proportion of patients that was misdiagnosed as having CKD resulting from 
prolonged Tac use, will be limited. First, certain causes of renal insufficiency such as 
rejection or recurrence of primary kidney disease do not apply to the LT setting. Second, 
although CKD after LT may occur for reasons other than the use of CNIs[30,31,40], pa-
tients underwent extensive clinical investigations which often included a renal biopsy, 
whenever a glomerulonephritis or tubulo-interstitial nephritis was suspected.
Although CYP3A and ABCB1 play an important role in the pharmacokinetics of Tac, 
there is at present no proof that intra-renal concentrations of Tac (or its metabolites) are 
related to the development of Tac-induced nephrotoxicity. Until recently, because of 
analytical difficulties, it was not possible to measure intra-renal Tac concentrations [41]. 
However, even if tissue Tac concentrations turn out to be an important determinant of 
its toxic effects, it remains to be demonstrated that intra-renal Tac concentrations are al-
tered to a significant degree by the studied genetic variants. A recent study by Zheng et 
al. provided some evidence that CYP3A5 genotype may be a determinant for intra-renal 
Tac concentrations. However, the influence of ABCB1 3435C>T on the pharmacokinetics 
of Tac is questionable and probably limited.[46,48]
In the present study there was no association between Tac predose concentrations 
and the development of CKD, which is supported by previous studies [40]. Although this 
may seem counter-intuitive at first view, this finding may be explained by the fact that 
LT recipients suffering from renal insufficiency underwent Tac dose reductions at some 
point during their posttransplant course in an attempt to limit the nephrotoxic effects 
of this agent.
In this cohort, patients developing CKD had a lower “baseline” eGFR at month 3. This 
could indicate that renal injury occurring before transplantation or in the early postop-
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erative phase, is critical for development of CKD. In our cohort, renal function remained 
stable after month 3 in most patients during the average follow up of 5.7 years. This 
relatively short follow up can`t exclude that tacrolimus is not a nephrotoxic drug. A lon-
ger observation may show deterioration of renal function in some patients treated with 
tacrolimus. Matas et al. questioned the chronic nephrotoxicity of CNI.[43,44]. However, 
a recent published prospective, randomized study in de novo liver transplant recipients 
comparing everolimus and reduced dose tacrolimus, standard dose tacrolimus and 
everolimus without tacrolimus from day 30 after transplantation clearly shows that early 
introduction of everolimus with reduced-exposure to tacrolimus provided a significantly 
better renal function at 2 years posttransplant [49]. This study confirms the potential 
nephrotoxic effect of tacrolimus in liver transplant recipients.
In summary, genetic variations in the CYP3A5 and ABCB1 genes were not significant 
risk factor for the development of CKD after LT. Tac whole-blood exposure was also not 
associated with the CKD risk. Genotyping LT recipients or their donors for SNPs in these 
genes is therefore unlikely to aid the clinician in preventing CKD.
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Abstract
Conventional assays for quantification of allo-reactive T-cell precursor frequencies (PF) 
are relatively insensitive. We present a robust assay for quantification of PF of T-cells with 
direct donor-specificity, and establish the kinetics of circulating donor-specific T cells 
after liver transplantation (LT).
B cells from donor splenocytes were differentiated into professional antigen-present-
ing cells by CD40-engagement (CD40-B cells). CFSE-labelled PBMC from 13 recipients 
obtained before and at several time points after LT, were stimulated with CD40-B cells. 
PF of donor-specific T cells were calculated.
Compared to splenocytes, stimulations with CD40-B cells resulted in 3 to 5-fold higher 
responding T-cell PF. Memory and naïve T-cell subsets responded equally to allogeneic 
CD40-B cell stimulation. Donor-specific CD4+ and CD8+ T-cell PF ranged from 0.5 to 19% 
(median: 5.2%). One week after LT, PF of circulating donor-specific CD4+ and CD8+ T cells 
increased significantly, while only a minor increase in numbers of T cells reacting to 3rd 
party allo-antigens was observed. One year after LT numbers of CD4+ and CD8+ T cells 
reacting to donor antigens, as well as those reacting to 3rd party allo-antigens, were 
slightly lower compared to pre-transplant values.
In conclusion, our alternative approach enables detection of allo-reactive human T 
cells at high frequencies, and after application we conclude that donor-specific T-cell 
PF increase immediately after LT. However, no evidence for donor-specific hypo-respon-
siveness of the direct pathway was obtained, underscoring the relative insensitiveness 
of previous assays.
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Introduction
After allogeneic transplantation, recognition of major allo-antigens by recipient T-cells 
occurs via two different pathways: 1) the direct pathway whereby intact donor MHC is 
presented by donor-derived Antigen-Presenting Cells (APC) to recipient T cells; 2) The 
indirect pathway, whereby processed donor MHC is presented to recipient T cells as 
peptides on self-MHC molecules expressed on self-APC [1-2].
Direct pathway T cells are activated by donor-derived APC that migrate from the graft 
into recipient secondary lymphoid tissues [3-6]. Animal studies have shown that donor 
APC migration is a transient phenomenon after transplantation [3, 5]. Recently, we 
observed that a similar transient migration of donor-derived APC into recipients occurs 
after liver transplantation (LT) in humans [7]. Therefore, the general presumption is that 
direct pathway responses dominate during the early post-transplant period, but subside 
thereafter [2]. However, due to their cross-sectional approach [8-13] not any study has 
described the kinetics of recipient T-cell alloreactivity after organ transplantation in 
humans in detail.
A common assumption is that frequencies of allogeneic T cells stimulated by the 
direct pathway are 100- to 1000-fold higher than responses to pathogens [2, 14]. Animal 
studies showed that frequencies of T cells with direct allo-specificity range between 0.01 
and 21% [15-21]. However, the reported alloreactive T cell frequencies in humans are 
generally lower, ranging from 0.001 to 0.1% [8, 12-13, 22-23]. This raises the question 
if this difference in reported frequencies is due to an underestimation of alloreactive T 
cells in humans caused by suboptimal sensitivity of conventional assays.
Traditionally, allo-reactive T cells have been quantified by limiting dilution analysis 
(LDA). It is now known that LDA detect frequencies of pathogen-specific T cells that are 
one to two logs lower than those detected by MHC tetramer staining [24-25]. Hence, a 
more robust assay for quantification of alloreactive human T cells is required. Because 
the restricted availability of MHC-tetramers (especially of MHC class II tetramers) is insuf-
ficient to cover the enormous heterogeneity of HLA, and the knowledge of peptides 
involved in direct pathway allo-recognition is limited[26], we chose an alternative ap-
proach.
The first aim of the present study is to set up a sensitive assay for quantification of fre-
quencies of direct pathway alloreactive T cells. For this purpose, we used CD40-activated 
donor-derived B cells instead of donor leukocytes from spleen or blood, as stimulator 
cells, and calculated frequencies of responding recipient T-cells from division patterns 
measured by flow cytometric analysis of carboxyfluorescein succinimidyl ester (CFSE) 
fluorescent dye dilution. CFSE-dilution has a sensitivity similar to MHC-tetramer stain-
ing [27] [28-30], and CD40-B cells are a uniform source of professional APC [31-34]. The 
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second aim was to determine the kinetics of the direct pathway allo-response after liver 
transplantation by applying this assay.
Materials and Methods
Ethics Statement:
“The Ethics committee of the Erasmus Medical Center has approved the collection of 
blood in patients after liver transplantation for immunologic monitoring. A written 
consent from patients was obtained prior to the study.”
Patients
This study included 13 patients who underwent an orthotopic liver transplantation 
between 1997 and 2000 at Erasmus University Medical Centre. All patients received a 
graft from a deceased donor. Indication for LT was: post-alcoholic liver cirrhosis (n=4), 
primary sclerosing cholangitis (n=4), chronic hepatitis C (n=1), chronic hepatitis B (n=1), 
auto-immune hepatitis (n=1), Morbus Wilson (n=1), and heamangio-endothelioma 
(n=1). Initial immunosuppressive therapy consisted of cyclosporine A (CsA) or tacroli-
mus together with prednisone, and with or without azathioprine. Patient follow up was 
at least one year.
Patient and donor cells
Splenic tissue from donors was obtained during multi-organ donation procedure, and 
single cell suspensions were made. Venous blood from patients was collected before 
transplantation and at several time points after transplantation. For optimization of the 
assay conditions, blood from healthy individuals was obtained from the blood bank. 
Peripheral Blood Mononuclear Cells (PBMC) and splenocytes were isolated by Ficoll-
Hypaque density gradient centrifugation and stored frozen in 10% DMSO solution.
CD40-B cell generation
B cells were expanded from donor splenocytes or recipient PBMC using a mouse fibro-
blast cell line stably transfected with human CD40L (L-CD40L) that was kindly provided 
by prof. Cees van Kooten (LUMC, Leiden, The Netherlands)[35]. L-CD40L cells were ir-
radiated (52 Gy) and plated on 6-well plates (Costar, Cambridge, USA) at a concentration 
of 0.2x106 cells per well in medium containing RPMI 1640 (Lonza, Basel, Switzerland), 
10% heat inactivated FCS (Sigma-Aldrich, St Louis, US) and 1% penicillin/streptomycin 
(Gibco, California, USA). After overnight culture, L-CD40L cells were rinsed with RPMI. 
PBMC were seeded at 1x106 cells/ml IMDM (Lonza) with 10% heat inactivated human 
male AB serum (Lonza), 1% penicillin/streptomycin and 1% insulin-transferrin-selenium 
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solution (Gibco) (B-cell medium) on L-CD40L cells. Recombinant human interleukin-4 
(rhIL-4) (40 IU/ml) (Strathmann Bioscience, Germany) and CsA (1 ug/ml) (Novartis, Basel, 
Switzerland) to prevent T-cell expansion were added. Every 3-4 days the cultured cells 
were transferred to freshly irradiated L-CD40L cells in a ratio of 1 CD40L cell: 4 CD19+ 
cells. Proportions of B- and T cells were checked at regular intervals. When the percent-
age CD19+ cells was > 85%, CsA was discontinued for at least 3 days before their use in 
T-cell stimulators. When the purity of CD19+ cells was > 95%, CD40-B cells were used in 
assays.
CFSE-MLR
Before labeling with CFSE (Invitrogen, Paisley, UK), PBMC were thawed and recovered 
during overnight culture at 37°C with 5% CO2. Labeling was performed with 0.5 µM CFSE. 
CFSE-labeled PBMC (1x105) were stimulated with 2x105 irradiated (30 Gy) donor CD40-B 
cells, third party CD40-B cells, or autologous PBMC-derived CD40-B cells in 96-wells 
U-bottom plates in a final volume of 200 μl B-cell medium. Each assay was performed 
in triplicate. PHA-stimulated recipient PBMC were included as positive controls to test 
viability of thawed PBMC. Results were only included if PBMC showed responsiveness 
to PHA. Unless otherwise stated in the results section, flow cytometric analysis was 
performed after 6 days of culture at 37˚C and 5% CO2.
Data Analysis with ModFit® Software
Precursor frequencies were calculated using ModFit LT® software (Verity Software House, 
USA). The basic principles of the calculation model of the program are that the cell num-
ber duplicates at each division and that CFSE is equally distributed over the daughter 
cells, resulting in a two-fold reduction of the CFSE intensity after each division cycle [36] 
as explained in Figure 1. The software calculates backwards the precursor frequency (PF), 
which is the proportion of the total cells calculated to have been present at the start of 
the experiment that responded to the allo-stimulus by dividing. Because the width of the 
intensity histogram of T cells in the parent generation spreads slowly during culture, it is 
difficult to differentiate cells that have divided once from non-divided cells. Supported 
by other studies [28, 37], we considered cells that had undergone at least two divisions 
as responders in our data analysis. Only ModFit® plots with a reduced chi-square (which 
is a measurement for the association of the calculated model and the real CFSE-dilution 
histogram: or in other words, a measurement for the fit of the model into the dilution 
histogram) smaller than 5 were included in the analysis. Mean PF were calculated from 
triplicate cultures. To assess the accuracy of the technique, we calculated the coefficient 
of variation of triplicates in 6 patients using the following formula: SDtriplicate/mean triplicate.
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FACS data acquisition
Cultured cells were stained for 15 minutes at room temperature in 96-wells U-bottom 
plates with appropriate concentrations of CD3-PE (Biolegend, San Diego, USA), CD4-
APC (eBioscience, San Diego, US) and CD8-Pacific Blue (BD Biosciences, San Jose, CA, 
USA) antibodies in a final volume of 50 µl PBS. In individual experiments indicated in 
the Results section, cultured cells were stained with CD8-Pacific Blue mAb, after which 
cells were fixed and permeabilized with Fix & Perm® reagent (ADG Bio Research GmbH, 
Vienna, Austria) and incubated with PE-labeled anti-granzyme B (Sanquin, Amsterdam, 
The Netherlands) and anti-perforin (BD Pharmingen) mAb to analyze intracellular ex-
pression of cytotoxic molecules. 7AAD (BD Biosciences, San Jose, CA, USA) was added 
just before measurement started to exclude dead cells. Data acquisition was performed 
with a Canto II Flowcytometer from BD Biosciences (San Jose, CA, US).
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Figure 1: Analysis of CFSE-dilution patterns by ModFit® software
ModFit-derived CFSE-pattern of CD3+ T cells after 6 days of stimulation with allogeneic CD40-B cells. The 
software draws peaks within the CFSE-histogram centered on halving intensity values from the parental 
peak CFSE-intensity. Non-divided T cells are CFSEhigh and are depicted blue, while the peaks left from it cor-
respond to divided cells. Based on the enumerated proportions of T cells detected in each generation (=% 
under each peak) and the total number of CD3+ T cells analyzed by the flowcytometer, the program calcu-
lates the absolute numbers of daughter T cells in each generation. The numbers of precursors which gave 
rise to the daughter cells are extrapolated by dividing the absolute numbers of T cells in each generation by 
2n, in which n stands for the division cycle (=absolute # of precursors). The PF is calculated by dividing the 
numbers of precursors from generation 2 onwards (=B) by the total number of precursors in all generations 
including the parent peak and generation 1 (=A). In this example the calculated PF= (362,302 – (337,620 + 
8925) / 362,302) x 100 = 4.3%. The fit of the derived Gaussian peaks in the CFSE-dilution pattern is indicated 
by the reduced chi-square value. Values below 5 were considered as a good fit according to the manufac-
turer’s instructions, and were included in the analysis.
65
Chapter 4 : Direct pathway kinetic
FACS sorting
PBMC from healthy subjects (200x106) were labeled in PBS with sterile CD14-PE (BD Bio-
sciences, San Jose, US), anti-BDCA1-PE (Miltenyi, Bergisch Gladbach, Germany), CD19-PE, 
CD123-PE, CD56-PE , CD45RA-FITC and CD45RO-APC (all from Beckman Coulter, Miami, 
US) in a final volume of 500 µl for 30 minutes at 4˚C, followed by a double wash step 
with 3 ml PBS (Lonza) . The cell pellet was resuspended to a concentration of 50x106 
PBMC/ml PBS. Naïve and memory T-cell populations were sorted with a FACS Aria (BD 
Biosciences, San Jose, CA, USA) by exclusion of PE-positive cells and gating on the CD45-
RAhigh and CD45-ROhigh cells. CD3+ purity was checked after sorting with CD3-PerCP-Cy5 
(Biolegend, San Diego, US).
Statistics
Differences between groups were analyzed using the Wilcoxon test and were considered 
statistically significant if the p-value was ≤ 0.05.
Results
CD40-B cells expand and differentiate from splenocytes and PBMC into 
professional antigen presenting cells
Within 21 days, co-culture of human splenocytes or PBMC with L-CD40L cells in the pres-
ence of IL-4 and CsA resulted in a 104-fold increase of total B-cell numbers, followed by a 
decrease after 27 days (Figure 2A). The decrease was due to loss of CD40 expression on 
CD40-B cells (data not shown). B-cell purity > 95% was reached between day 9 and 12. 
CD40-B cells did not only expand, but also differentiated to professional APC, expressing 
CD38 (activation marker), HLA-DR and co-stimulatory molecules (Figure 2B). Contrary, 
human splenocytes contained 47 ± 5% HLA-DR+ APC, of which only a small fraction 
expressed co-stimulatory molecules (CD80+: 0.9±0.9%, CD86+: 7.1±5.2%; n=6) (Figure 
2C), indicating that CD40-B cells are a more uniform preparation of APC. CD40-B cells did 
not differentiate to plasma cells, as all cells lacked CD138.
Optimization and validation of CFSE-MLR
To determine the optimal culture period for quantification of T cells reacting to alloge-
neic stimulation with CD40-B cells, CFSE-dilution patterns of CD3+, CD4+ and CD8+ cells 
were analyzed daily till day 7 of culture using ModFit® software. Proliferation of T cells 
started at day 4, and new T cells were recruited to proliferate until day 5, thereafter PF 
reached a plateau value (Figure 3A). After day 6 PF increased again, which is probably 
due to non-specific bystander activation [27]. Therefore, we decided to determine PF 
at day 6 of culture. CD8+ T cells acquired cytolytic molecules from day 4 onward, and at 
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day 7 about 50% of CD8+ T-cells that proliferated in response to allogeneic CD40-B cells 
(=CFSElow CD8+ T cells) expressed granzyme B and/or perforin, indicating that they had 
acquired cytolytic effector function (Figure 3B).
In calculating PF, ModFit® assesses the total number of T cells at the start of the allo-
geneic stimulation using backward calculation from the cells analyzed at the end of the 
culture. In contrast, LDA and ELISPOT calculate PF based on the numbers of T cells that 
are put into culture. To assess whether this difference would influence the outcomes of 
the different approaches of calculating PF, we counted daily the numbers of vital PBMC 
and calculated the proportions of CD3+, CD4+ and CD8+ T cells in CD40-B cell-stimulated 
CFSE-MLR. Figure 3C shows that numbers of all T-cell subsets decreased during the first 
2 days of cultures by 36% for the CD3+, 34% for the CD4+ and 38% for the CD8+ T cells, 
a phenomenon called preparation-induced cell death [38]. Thereafter, numbers of T 
cells increased. Most likely, T cells alive at day 2 are the real starting population from 
which allo-reactive T cells are recruited to proliferate, suggesting that LDA and ELISPOT 
underestimate PF, while CFSE-based assays may yield more accurate PF.
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Figure 2: Expansion and differentiation of B cells using L-CD40L cells
A. Human splenocytes or PBMC were co-cultured with L-CD40L cells, IL-4 and CsA. Within 3 weeks, a 104 
fold increase of the numbers of B cells was obtained with a purity of > 95%. T cells did not expand due to 
the presence of CsA. The current graph represents expansion from PBMC, splenocytes gave similar results.
B. Cell surface marker expression on CD40-B cells harvested at day 12 of culture. CD40L-expanded B cells 
were activated (CD38+) and expressed the co-stimulatory molecules CD80 and CD86, and MHC class-II, in-
dicating that they became professional APC. However, they did not become plasma cells, since they lacked 
CD138. Solid lines represent the expression of surface markers at day 0; dotted lines represent the expres-
sion at day 12 after culture.
C. Donor splenocytes contained about 50% of HLA-DR+ APC, however these lacked CD80 and showed low 
expression of CD86.
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Comparison of CD40-B cells with conventional splenocytes as stimulators in CFSE-MLR
To compare the efficacy of CD40-B-cells with conventional splenocyte stimulation, CFSE la-
beled PBMC from patients were cocultured with donor splenocyte-derived CD40-B cells or 
with non-manipulated splenocytes from the same donor. Figure 4A displays that at day 6 T 
cells responded abundantly to stimulation with CD40-B cells, while splenocyte stimulation 
resulted in a much lower response. The results of paired comparisons between stimulations 
of LT recipient PBMC with CD40-B cells or splenocytes are summarized in Figure 4B and 
C. Although stimulation with autologous CD40-B cells also resulted in T-cell proliferation, 
responses to allogeneic CD40-B cells were significantly higher (4B). The PF of T cells spe-
cifically responding to donor-derived CD40-B calculated in this ways were 6.8 fold, 5.9-fold 
and 8.6-fold higher PF for CD3+, CD4+ and CD8+ T cells, respectively, compared to specific 
responses to donor-derived splenocytes. Specific allogeneic responses to donor-derived 
CD40-B cells were calculated by subtraction of PF reacting to autologous CD40-B cells, and 
specific allogeneic responses to donor splenocytes by subtraction of PF of unstimulated 
T cells (4C). These data also reveal that comparable proportions of alloreactive precursors 
are detected within CD4+ and CD8+ subsets upon CD40-B cell stimulation (median PF: 
6.4% ± 4.0 for the CD4+ and 8.45% ± 5.4 for the CD8+ subpopulation). Finally, CD40-B cell 
stimulation resulted in less variation between triplicate PF measurements than splenocyte 
stimulation; the coefficient of variation of measured triplicates was 3-fold lower (Figure 4D).
0 1 2 3 4 5 6
0.0
0.2
0.4
0.6
0.8
1.0
CD3+
CD4+
CD8+
days
ab
so
lu
te
 n
um
be
r o
f c
ell
s 
(x
 1
0E
6)
1 2 3 4 5 6 7
0
20
40
60
CD3+
CD4+
CD8+
unstimulated
days
pr
ec
ur
so
r f
re
qu
en
cy
 (%
)A 
B 
C 
1 2 4 5 6 7
0
10
20
30
40
50
CD8+
days
G
ra
nz
ym
e 
B
/P
er
fo
rin
e 
(%
) 1 2 3 4 5 6 7
0
20
40
60
CD3+
CD4+
CD8+
unstimulated
days
pr
ec
ur
so
r f
re
qu
en
cy
 (%
)
Figure 3: Kinetics of allogeneic T-cell re-
sponses to CD40-B cell stimulation
CFSE-labeled PBMC from a healthy individ-
ual were cultured for 7 days with allogeneic 
splenocyte-derived CD40-B cells. A. CFSE-
dilution patterns of CD3+, CD4+, CD8+ T cells 
were analyzed daily, and PF were calculated 
with ModFit® software. B. Intracellular gran-
zyme B and perforin expression were ana-
lyzed daily in CD8+ T cells. Depicted are the 
percentages of CD8+CFSElow T cells that ex-
pressed granzyme B and/or perforin.
C. Absolute numbers CD3+, CD4+ and CD8+ 
T cells during co-culture of CFSE-labelled 
PBMC with allogeneic CD40-B cells. Vital 
PBMC were counted daily using trypan 
blue, and proportions of CD3+, CD4+ and 
CD8+ T cells were analyzed by flowcytom-
etry. Absolute numbers of T-cell subsets 
were calculated by multiplying the number 
of vital PBMC with the proportions of T cells 
obtained from flowcytometric analysis.
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Figure 4: Comparison of CD40-B cell and splenocyte stimulation
A. CFSE-labeled PBMC from an LT-recipient were stimulated for 6 days with allogeneic splenocyte-derived 
CD40-B cells or with splenocytes from the same donor. Dot-plots and CFSE-dilution graphs of CD3+ T cells 
show increased T-cell proliferation upon stimulation with CD40-B cells compared to splenocytes. Percent-
ages in dot plots depict % dividing (CFSElow) T cells. Percentages in histograms are calculated PF.
B: Paired comparisons of PF of LT-recipient CD3+, CD4+ and CD8+ T cells upon stimulation with donor-de-
rived CD40-B cells, autologous patient CD40-B cells, splenocytes or without stimulus. Sixty CFSE-labelled 
PBMC-samples of 6 LT-recipients, obtained either before, or at different time points after transplantation, 
were stimulated with donor-derived or autologous CD40-B cells or with splenocytes from the same donor 
for 6 days. Bars represent median values.
C: Donor-specific T-cell responses obtained by subtraction of PF reacting to autologous CD40-B cells from 
PF responding to donor-derived CD40-B cells, or subtraction of PF in the absence of allo-antigen (negative 
controls) from PF responding to donor splenocytes. Bars represent median values.
D: Paired comparisons of the coefficients of variation of triplicate measurements of LT-recipient CD3+ PF in 
108 PBMC-samples of 6 LT-recipients upon stimulation with donor-derived CD40-B cells or donor-derived 
splenocytes. Bars represent median values.
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Relative contributions of naïve and memory T cells to the alloresponse measured 
by CFSE-dilution
To dissect the contributions of naïve (CD45RA+) or memory (CD45RO+) T cells to the allo-
geneic responses measured by CSFE-MLR upon stimulation with CD40-B cells, we sorted 
CD3+CD45RA+ and CD3+CD45RO+ cells (Figure 5A) and stimulated them separately with 
CD40-B cells. Figure 5B shows that after 6 days of culture memory and naïve subsets 
contributed equally to the alloresponse, with median CD3+ T-cell PF of 6.7% and 7.7%, 
respectively.
Kinetics of the direct pathway donor-specific T-cell response after LT
To determine the kinetics of donor-specific T cell reactivity after LT, we quantified PF of 
donor-specific T cells in PBMC of 13 LT-recipients using donor-spleen derived CD40-B 
cells as stimulators. PBMC were collected before transplantation, and 1 week, 1 month, 
3 months and 1 year after transplantation. To evaluate the specificity of variations in 
responses to donor allo-antigens, we stimulated CFSE-labeled patient PBMC also with 
3rd party spleen-derived CD40-B cells or with CD40-B cells derived from autologous 
PBMC. Recipients and donors differed on the average in 1.5 HLA-AB alleles and in 1.7 
HLA-DR alleles. Third-party stimulators were mismatched with recipients in 1.7 HLA-AB 
alleles and 1.8 HLA-DR alleles. Donor-derived and 3rd party-derived stimulator cells dif-
fered on the average at 1.8 HLA-AB loci and 1.5 HLA-DR loci. In all samples measured, 
PF of T cells reacting to autologous CD40-B cells were low compared to PF of T cells 
reacting to donor or 3rd party CD40-B cells. In addition, autologous responses did not 
change over time after transplantation. On the contrary, the numbers of circulating 
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Figure 5: Relative contributions of naïve and memory T cells to the allo-response in CFSE-MLR upon stimu-
lation with CD40-B cells
CFSE-labelled naïve CD3+CD45RA+and CD3+CD45RO+ memory T cells were isolated from PBMC of healthy 
individuals by flowcytometric sorting, and stimulated with allogeneic CD40-B cells for 6 days.
A. Purity of CD3+CD45RO+ and CD3+CD45RA+ T cells after sorting.
B. PF of CD3+CD45RO+ and CD3+CD45RA+ T cells proliferating upon stimulation with allogeneic CD40-B 
cells. Depicted are means ± SD of data from two independent experiments, each with 3 replicates.
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Figure 6: Longitudinal course of circulating donor-specific T-cell precursor frequencies in LT-recipients
CFSE-labeled PBMC of 13 LT-recipients obtained before transplantation (Pre), or at 1 week (W1), 1 month 
(M1), 3 months (M3) or 1 year (Y1) after transplantation, were co-cultured for 6 days with donor-derived 
splenic CD40-B cells, 3rd party splenic CD40-B cells or autologous PBMC-derived CD40-B cells. PF of CD3+, 
CD4+ and CD8+ T cells responding to these stimulators were determined.
A. Numbers of T-cell precursors responding to donor-derived CD40-B cells increased significantly 1 week 
after transplantation in all T-cell subsets, followed by a decrease to values below pre-transplant levels.
B. Non-specific variations in allo-responses were determined by stimulating patient PBMC with third-party 
spleen-derived CD40-B cells. Changes in PF of CD4+ and CD8+ T cells responding to 3rd party CD40-B cells 
between subsequent time points were generally smaller compared to those in donor-specific PF.
C. Donor-specific responses were calculated by dividing PF responding to donor-alloantigen by third-party 
PF to obtain the relative responses (RR). RR increased significantly 1 week after transplantation in all T-cell 
subsets, followed by a significant decrease at 1 year after LT.
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T cells reacting to donor-derived CD40-B cells increased significantly at 1 week after 
LT in all T-cell subsets, followed by a decrease to values below pre-transplant levels 1 
year after LT (Fig 6A). Variations in T-cell PF reacting to 3rd party allo-antigens showed 
the same trend, although the differences in PF between subsequent time points were 
generally smaller, and the increases in the first week after LT were not significant in the 
separate CD4+ and CD8+ T-cell subsets (Figure 6B). To correct variations in the response 
to donor allo-antigens for nonspecific changes in numbers of circulating allo-reactive T 
cells, we calculated the donor-specific responses (relative response; RR) by dividing PF to 
donor antigens by PF to third parties. Figure 6C shows that the RR significantly increased 
in all T-cell subsets during the first week after LT compared to the pre-transplant levels 
(CD3+: 1.4-fold, CD4+: 1.3-fold and CD8+: 1.1-fold), followed by a gradual decrease after 
week 1. However, after correction for responses to 3rd party allo-antigens, none of the 
donor-specific responses declined below pre-transplant values. Together these data 
show a donor-specific increase in direct pathway T cell PF immediately after LT, followed 
by a non-specific decline of allo-reactive T cells numbers to values slightly below pre-
transplant levels within the first year after LT.
Discussion
Combining CFSE- dilution as a read out with CD40-B cells as stimulator cells, we devel-
oped a robust assay that detects human T cells with direct allospecificity at frequencies 
comparable to those predicted by animal experiments and 1- to 3-logs higher than PF 
detected with conventional LDA or ELISPOT [19-21, 39-40]. This CFSE-MLR assay is able 
to discriminate between CD4 and CD8 PF and detects both naïve and memory T-cell re-
sponses to allo-antigens in the same culture. By application of this assay we found that, 
even with immunosuppressive therapy, numbers of circulating CD4+ and CD8+ T cells 
with direct donor-specificity increase immediately after LT, indicating that both subsets 
are primed by the graft, followed by a gradual decrease within the first year. Importantly, 
after correction of changes in responses to 3rd party allo-antigens, no decrease below 
pre-transplant values was observed, showing that CD4+ and CD8+ T cells with direct 
donor-specificity persist in the circulation up to at least 1 year after LT. However, a non-
specific decrease in frequencies of circulating allo-reactive CD4+ and CD8+ T cells to 
values slightly below pre-transplant values was observed 1 year after LT.
The first improvement contributing to the robustness of the described assay is utilizing 
CD40-B cells as stimulators, resulting in 3- to 5-fold higher PF compared to stimulations 
with splenocytes. CD40-engagement induces B-cell differentiation into professional 
APC with uniform expression of co-stimulatory molecules, that are able to prime both 
memory and naïve T-cell reponses [31, 34, 41-43] [44]. Contrary, splenocytes contain 
only about 50% APC, of which a minority express co-stimulatory molecules. CD40-B 
cells can be expanded from thawed splenocytes or PBMC, even when these have a low 
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viability, and their expansion enables repeated measurements of donor-specific T-cell 
reactivity in cases of limited supply of donor cells. Importantly, the absence of T cells 
within CD40-B cell preparations precludes that donor-derived T cells are included in 
CFSE-profiles of responder T cells, which would lead to wrong PF calculations.
The second improvement is the use of CFSE-dilution in combination with software that 
calculates PF as a read-out technique. Detection of responding cells by this technique is 
not dependent on the number of progeny cells in each individual culture, which in LDA 
may lead to underestimation of PF when small clones of progeny cells remain undetected 
[17, 24-25, 45]. Moreover, estimated PF are not negatively influenced by “preparation-
induced cell death” of responder T cells at the beginning of the cultures, because PF are 
calculated from the sum of precursors present at the end of the cultures instead from 
cell input at the start of the culture. We showed that allogeneic stimulations are prone 
to significant loss of responder T cells during the first 2 days of culture. Since dying cells 
do not respond, techniques calculating PF from numbers of cells present at the start of 
the culture, like LDA and ELISPOT, underestimate actual PF [38]. Conversely, the CFSE-
MLR may overestimate PF if more non-proliferating cells compared to proliferating cells 
die during culture. It is difficult to analyze whether non-proliferating cells die, but the 
appearance of a plateau phase of PF between day 5 and 6 of culture indicates that at 
least during this last phase of the cultures no preferential death of non-proliferating T 
cells occurs.
ELISPOT may also underestimate PF by ignoring allo-reactive T cells that do not se-
crete the particular cytokine detected. In contrast to short-term ELISPOT assays which 
detect only the rapidly reacting allo-reactive memory T cells [23], the CFSE-MLR detects 
allo-reactive precursors in memory and naïve T cells simultaneously. Because the allo-
reactive repertoire contains both naive and memory T cells [10, 46-47], we judge that 
simultaneous quantification of both subsets is an advantage of the current technique 
compared to ELISPOT. Together, these differences may explain why published PF of 
donor-specific T cells in human organ transplant recipients detected by LDA [8-10, 13, 
48-49] or ELISPOT [22-23, 50-52] are significantly lower compared to those observed in 
this study with the CFSE-MLR.
Importantly, use of CD40-B cells as stimulators to detect allogeneic T-cell responses 
[53], and CFSE-dilution as a technique to measure the proliferative response of T cells 
to allo-antigens [45][46] have both been described, but to our best knowledge these 
techniques have never been combined. A limitation of the CFSE-MLR in its current form 
is that it detects T-cell proliferation only and not effector functions. However, we ob-
served that about 50% of CD8+ T cells that proliferated in response to allogeneic CD40-B 
cells also acquired cytolytic molecules. We have not investigated cytokine production, 
but Zand et al [53] have shown that CD40-B cells are much more efficient in stimulating 
cytokine production by allogeneic T cells compared to PBMC. Therefore, we believe that 
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the majority of T cells that proliferate in response to allogeneic CD40-B cells also acquire 
effector function. In a future application, simultaneous measurement of T-cell prolifera-
tion and effector functions may allow discrimination between proliferating T cells that 
acquire effector functions and those that do not.
It is generally assumed that recipient T-cell responses against directly presented 
donor allo-antigen peak shortly after transplantation [2], but this has never been 
formally proven in humans. So far, the only other study that quantified donor-specific 
T-cell responses longitudinally after human organ transplantation [50] actually found 
a nadir in frequencies of donor-specific T cells at 1 week after kidney transplantation 
using IFN-γ ELISPOT. We observed, after correction for changes in responses to 3rd 
party allo-antigens, a significant, but modest, increase of circulating donor-specific 
CD4+ and CD8+ T-cell numbers immediately after LT, followed by a decrease to levels 
equal to numbers of T cells responding to 3rd party allo-antigens within the first year. 
This increase was not due to variations in immunosuppression, because it was corrected 
for variations in 3rd party responses. The observed increase in T-cell PF reacting to 3rd 
party allo-antigens, which was smaller compared to the increase in donor-specific T-cell 
PF, may be explained by partial overlap in HLA between donor and 3rd party stimulator 
cells spleen CD40-B cells. Due to limited availability of banked splenocytes, complete 
HLA mismatching between donor and 3rd party stimulators was not always possible. Our 
results are congruent with recent observations in mice showing a significant increase in 
direct pathway donor-specific T-cells shortly after transplantation [54].
With LDA, it has repeatedly been shown that after organ transplantation in humans, 
numbers of circulating donor-specific T cells decrease below pre-transplant values 
and below numbers of T cells responding to 3rd party allo-antigens [8-11, 13, 22, 55]. 
Donor-specific hypo-responsiveness was already observed at 1 month after LT [13]. This 
phenomenon was attributed to induction of anergy in donor-specific T cells [56] or to 
suppression exerted by CD4+Foxp3+ regulatory T cells [11]. Of notice, donor-specific 
hypo-responsiveness in cytotoxic T-cell PF detected by LDA after lung transplantation, 
could not be confirmed using flow-cytometric detection of CD8+ T-cell activation and 
IFN-γ production [57]. Therefore, the lack of donor-specific T-cell hypo-responsiveness 
observed in the present study is probably due the higher sensitivity of the CFSE-MLR 
compared to LDA. Our data are consistent with those of Kusaka et al [58], who showed 
high levels of donor HLA-specific T-cell clonotype mRNAs in PBMC late after renal 
transplantation. Both studies imply that T cells which recognize donor allo-antigens 
via the direct pathway remain present in the recipient circulation for at least one year 
after transplantation. If donor-specific hypo-responsiveness might develop later after 
transplantation will be subject of a future study.
In conclusion, by using a novel technical approach, we showed for the first time an 
increase of donor-specific T-cell frequencies shortly after LT in humans. In addition, we 
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observed that T cells reacting to donor allo-antigens presented via the direct pathway 
remain present in the recipient circulation for at least 1 year after transplantation. To 
determine the role of the direct pathway in liver graft damage late after transplantation, 
quantification of donor-specific T-cell PF during acute or chronic rejection late after LT 
should be performed.
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Abstract
Background & Aims: Cytomegalovirus (CMV) is a leading viral infection after liver 
transplantation (LT) with immune-modulatory effects. Viral infections, including CMV, 
abrogate transplantation tolerance in animal models. Whether this occurs in humans 
as well remains elusive. We investigated how CMV infection affects T cells and rejection 
episodes after LT.
Methods: Phenotype and alloreactivity of peripheral and liver allograft-infiltrating 
T cells of LT patients with different CMV status were analyzed by flow cytometry. The 
association of CMV status with early and late acute rejection (EAR and LAR) was retro-
spectively analyzed in a cohort of 639 LT patients.
Results: CMV infection was associated with rapid expansion of circulating CD4+ and 
CD8+ effector memory (TEM) and CD8+ terminally differentiated effector memory T cells 
(TEMRA) after LT. CMV primary infection (CMV-PI) patients showed donor-specific hypore-
sponsiveness in CD8+ T cells and CD4+ TEM. Moreover, while TEMRA comprised the majority 
of circulating donor-specific CD8+ T cells in CMV-PI patients, they were hardly present 
in liver allografts. In the retrospective analysis, CMV-PI was significantly associated with 
lower incidence of LAR. Multivariate Cox regression analysis showed that CMV-PI was an 
independent protective factor for LAR (hazard ratio=0.17, 95%CI=0.04-0.83, P=0.01). In 
addition, CMV-PI patients showed the highest Vδ1/Vδ2 T-cell ratio, which is associated 
with operational tolerance after LT.
Conclusions: CMV-PI patients develop donor-specific T-cell hyporesponsiveness after 
LT, and they are protected from LAR and show signs of operational tolerance. CMV infec-
tion may promote immunological tolerance to liver allografts, and CMV status should be 
taken into account when tapering immunosuppression.
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Introduction
Cytomegalovirus (CMV) is a prevalent β-herpesvirus causing lifelong latency in humans, 
and a leading viral infection after solid organ transplantation [1]. Immune responses 
to viruses, including CMV, have been proposed as one of the main barriers to the 
achievement of transplantation tolerance [2], as they prevent tolerance induction in 
experimental animal models [3-5]. However, associations between CMV infection and 
graft rejection in humans vary between different types of organ transplants and show 
conflicting results [6]. Therefore, no consensus has been made on the effect of CMV 
infection on graft rejection or tolerance after LT.
Acute rejection (AR) is primarily initiated by recipient T lymphocytes (T cells) that 
recognize non-self antigens derived from donor [7]. T cells can be classified into differ-
ent subsets based on their differentiation status, reflecting distinct migration patterns 
and effector functions upon antigenic stimulation. While naive (TNaive) and central 
memory (TCM) T cells proliferate robustly in response to antigen, effector memory (TEM) 
and terminally differentiated effector memory (TEMRA) T cells produce high amounts 
of pro-inflammatory cytokines and cytolytic mediators[8, 9]. In addition, TNaive and TCM 
recirculate between secondary lymphoid organs, while TEM home to inflamed peripheral 
tissues [10]. On one hand, accumulation of CD8+ TEMRA is a typical characteristic of CMV-
driven immune senescence [11], which is associated with increased susceptibility of the 
elderly to infections, and poor responses to vaccinations[12, 13]. On the other hand, 
CMV-specific memory T cells are hypothesized to be detrimental to allografts as they can 
be cross-reactive to allogeneic HLA[14, 15]. However, no literature is available on how 
CMV infection alters T-cell alloreactivity after LT.
To address these issues, using ex vivo isolated cells from peripheral blood and from 
liver allografts explanted during re-LT, we investigated the effect of CMV infection on 
T-cell differentiation and alloreactivity, as well as on γδ T-cell subset distribution, which 
has been shown to be associated with operational tolerance after LT[16, 17]. In addi-
tion, we performed a retrospective study in a cohort of 639 LT patients, to analyze the 
associations of CMV infection with both early (< 6 months) and late (> 6 months) acute 
rejection (EAR and LAR).
Patients and methods
Study subjects
Peripheral blood samples were collected from 75 patients that underwent primary 
orthotopic LT at Erasmus MC, the Netherlands (summarized in Supplementary Table 1). 
84
Liver allograft biopsies were obtained from explants from 8 patients that underwent 
re-LT (summarized in Supplementary Table 2).
In the retrospective analysis to study the impact of CMV on graft rejection, 639 pa-
tients that underwent LT at Erasmus MC from 1992-2010 were included. Demographic 
Table 1: Demographic and baseline clinical characteristics of patients included in the retrospective analysis
Variable Total: 639 patients
Recipient age (median, range), years 50 (16-71)
Recipient, female 264 (41.3%)
Recipient BMI (mean±SD), kg/m2 25±4
Primary liver disease
AHF 119 (18.6%)
HCC 64 (10.0%)
PBC/PSC/AIH 149 (23.3%)
HBV/HCV 84 (13.1%)
Alcoholic cirrhosis 71 (11.1%)
Cryptogenic cirrhosis 41 (6.4%)
Others 111 (17.4%)
Donor age (median, range), years 46 (8-78)
Donor, female 333 (52.1%)
DCD donor 49 (7.7%)
Cold ischemia time (mean±SD), minutes 493±166
Warm ischemia time (mean±SD), minutes 45±24
Re-LT 75 (11.7%)
Basiliximab as induction immunosuppression 375 (58.7%)
Calcineurin inhibitor
Cyclosporin A 249 (39.0%)
Tacrolimus 367 (57.4%)
CMV serostatus
R-/D- 127 (19.9%)
R-/D+ 122 (19.1%)
R+ 390 (61%)
CMV viremia 152 (23.8%)
Timing of CMV viremia detection after LT (median, range), days 35 (2-2502)
Timing of first CMV viremia after LT < 180 days 140 (92.1%)
Early acute rejection 144 (22.5%)
Timing of early acute rejection (median, range), days 9 (2-166)
Late acute rejection 41 (6.4%)
Timing of late acute rejection (median, range), days 487 (186-6368)
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details of donors and recipients are summarized in Table 1. Patients were followed up 
until graft loss, death, or the end of the study period on 31 December 2011.
Written informed consent was obtained from all patients before collection of samples. 
The medical ethics committee of the Erasmus MC approved this study.
Cell isolation and flow cytometry
Protocols for cell isolation, list of antibodies, and flow cytometry details are in Supple-
mentary Materials and Methods.
Quantification of alloreactive T-cell frequencies
Alloreactive T cells were analyzed by determination of the activation-induced CD137 
expression on CD4+ and CD8+ T cells after allogeneic stimulation for 24 hours by ei-
ther donor or third-party (mismatched at HLA-A, B and DR loci with both donor and 
recipient) splenocytes. This assay has been used in the identification and isolation of 
viral, tumor, and importantly allospecific T cells regardless of their differentiation stage 
or cytokine production profile[18, 19]. Details are described in Supplementary Materials 
and Methods.
Immunosuppression
The standard immunosuppressive therapy in our center consisted of prednisone, 
cyclosporine or tacrolimus, with or without azathioprine or mycophenolate mofetil 
(MMF). Since 1998, basiliximab was introduced as induction immunosuppression and 
was used in 58.7% of all patients in the retrospective cohort (Table 1), and meanwhile 
the use of cyclosporine was gradually replaced by tacrolimus. Immunosuppressive 
regimens were similar in patients from whom blood samples were collected, consisting 
of corticosteroids, MMF, tacrolimus, and induction with basiliximab in 85% of patients 
(Supplementary Table 1).
Viral diagnostic, treatment, and CMV status definition
CMV serostatus of patients was defined as: CMV negative (neg: R-/D-), primary infection 
(PI: R-/D+), and non-primary infection (NPI: R+). Viral diagnostic and treatment details are 
in Supplementary Materials and Methods.
Definition of early and late acute rejection
AR was defined as: graft dysfunction accompanied by moderate or severe rejection 
activity (RAI≥5) detected in the liver biopsy according to Banff criteria, and responsive-
ness to additional immunosuppressive treatment. While early acute rejection (EAR) was 
defined as rejection occurring within 180 days after LT, late acute rejection (LAR) was 
defined as those occurring after 180 days after LT. Associations of CMV with EAR or LAR 
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were analyzed separately, as EAR is most common during the first few weeks after LT, 
generally preceding CMV infection.
Statistical analysis
For data obtained from ex vivo analysis, differences between groups were analyzed us-
ing the nonparametric Mann-Whitney U test for unpaired data or the Wilcoxon matched 
pairs test for paired data. P-values < 0.05 were considered significant.
In the retrospective analysis, data were summarized using mean with standard de-
viation or median with range for continuous variables and percentage for discrete vari-
ables. The cumulative incidences of EAR and LAR were estimated using the Kaplan-Meier 
method and differences between curves were analyzed using a log-rank test. Analysis 
of risk factors for EAR and LAR was performed using the Cox proportional-hazards re-
gression model with a likelihood ratio test. For multivariate analysis, we first performed 
univariate analysis for each potential independent variable. Independent variables with 
P-values less than 0.2 were included in the multivariate analysis together with CMV se-
rostatus and viremia. Linearity of continuous variables and clinical relevant interactions 
were tested. Where
multiple pairwise comparisons were made, a Bonferroni correction on the alpha 
level was applied. SPSS v. 21 was used for statistical analysis, and P-values < 0.05 were 
considered significant.
Results
CMV infection is associated with the expansion of effector memory T-cell subsets 
in peripheral blood after liver transplantation
We prospectively collected PBMC samples from 34 patients before, at 1 month and at 
6 months after LT. Peripheral T-cell subsets were analyzed by flow cytometry on basis 
of CCR7 and CD45RO expression [10], as shown in representative plots (Fig.1A). The 
proportion of CD8+ TNaive decreased continuously within the first 6 months after LT (pre-
LT: 48%; 1 month: 42%; 6 months: 22%). In contrast, the percentages of CD8+ TEM and 
especially TEMRA increased (Fig.1B), and TEMRA became the predominant CD8+ T-cell subset 
6 months after LT (pre-LT: 23%; 1 month: 28%; 6 months: 43%). No significant changes 
were observed in CD4+ T-cell subsets within the first month after LT (Fig.1C). However the 
fraction of CD4+ TNaive decreased significantly 6 months after LT (pre-LT: 51%; 1 month: 
52%; 6 months: 39%), which was mainly compensated by an increased percentage of TEM 
(pre-LT: 16%; 1 month: 16%; 6 months: 23%).
To determine whether the observed changes in CD4+ and CD8+ T-cell subsets were 
attributed to CMV, we divided patients into three groups based on CMV status: CMV 
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Figure 1: Changes of circulating CD4+ and CD8+ T-cell subsets after LT in relation to patient CMV status. (A) 
T-cell subsets were defined as TNaive (CCR7+CD45RO-), TCM (CCR7+CD45RO+), TEM (CCR7-CD45RO+), and TEMRA 
(CCR7-CD45RO-), shown as representative FACS plots from one patient. Distribution of (B) CD8+ and (C) 
CD4+ T-cell subsets before (white), at 1 month (blue) and at 6 months (red) after LT were compared (n=34). 
Then patients were grouped based on CMV status, and changes of each (D) CD8+ and (E) CD4+ T-cell subset 
were compared between CMV negative (neg, n=7), CMV primary infection (PI, n=10), and CMV non-primary 
infection (NPI, n=17) patients. Horizontal lines indicate mean values. *P<0.05, **P<0.01, ***P<0.001.
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negative (neg: R-/D-), primary infection (PI: R-/D+), and non-primary infection patients 
(NPI: R+). With the exception of a small increase of CD4+ TEMRA in CMV negative patients, 
all the changes in the subset distribution of CD8+ (Fig.1D) and CD4+ (Fig.1E) T cells after 
LT were observed only in CMV positive patients (both PI and NPI). Particularly CD8+ T-cell 
subsets from PI patients underwent the most dramatic changes (TNaive: pre-LT 69%, 6 
months 18%; TEMRA: pre-LT 14%, 6 months 57%). Together, these data show that CMV in-
fection is associated with the expansion of effector memory T-cell subsets in peripheral 
blood after LT.
CD8+ T cells from CMV primary infection patients develop donor-specific 
hyporesponsiveness
We hypothesized that the expansion of effector memory T-cell subsets driven by CMV 
might increase the frequencies of alloreactive T cells, as cross-reactive viral-specific 
memory T cells are common [15]. Thus we quantified the frequencies of donor-specific 
and third party-reactive T cells in 51 patients at minimum 6 months after LT by measur-
ing the allogeneic activation-induced CD137 expression (Supplementary Fig.1A, B).
Overall CD8+ T cells showed donor-specific hyporesponsiveness (Fig.2A, left panel). 
We did not observe higher frequencies of alloreactive T cells in CMV positive patients 
than CMV negative patients. Unexpectedly, CMV-PI patients showed prominent donor-
specific hyporesponsiveness in CD8+ T cells (Fig.2B, left panel), which was evident in 
TNaive, TCM and TEM (Fig.2C). In contrast, no donor-specific hyporesponsiveness was ob-
served in CMV negative patients, while in CMV-NPI patients significant donor-specific 
hyporesponsiveness was only observed in TEM.
Next, we assessed the subset composition of alloreactive CD8+ T cells (CD8+CD137+ T 
cells) (Supplementary Fig.1B). Compared to CMV negative and CMV-NPI patients, donor-
specific T cells from CMV-PI patients were predominantly TEMRA (Fig.2E, F), suggesting 
an important role of TEMRA in the anti-donor CD8+ T-cell response in these patients. Alto-
gether, our data show that CMV-PI is associated with the development of donor-specific 
hyporesponsiveness in CD8+ T cells after LT.
CD4+ effector memory T cells from CMV positive patients are less alloreactive than 
those of CMV negative patients
Overall CD4+ T cells did not develop significant donor-specific hyporesponsiveness 
(Fig.2A, right panel). Alloreactive T-cell frequencies were also similar in patients with dis-
tinct CMV status (Fig.2B, right panel). However when we zoomed into each CD4+ T-cell 
subset, we found that both CD4+ TEM and TEMRA subsets in CMV-PI and NPI patients were 
less reactive to donor as well as to third-party stimulation than those of CMV negative 
patients (Fig.2D). In addition, CD4+ TEM of CMV-PI and NPI patients showed donor-specific 
hyporesponsiveness.
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Figure 2: CMV primary infection is associated with the development of donor-specific T-cell hyporespon-
siveness after LT. The frequencies of peripheral alloreactive CD8+ and CD4+ T cells were analyzed by flow cy-
tometric determination of CD137 expression on T cells after allogeneic stimulation. (A) Overall frequencies 
of donor-specific and third party-reactive CD8+ (left panel) and CD4+ (right panel) T cells were compared 
(n=51). Alloreactive T-cell frequencies of (B) total CD8+ (left panel) and CD4+ (right panel) T cells, and of each 
(C) CD8+ and (D) CD4+ T-cell subset were compared between patients with different CMV status (CMV neg 
n=18, PI n=15, NPI n=18). Horizontal lines indicate mean values. Subset composition of alloreactive CD8+ T 
cells was assessed by measuring CD45RO and CCR7 expression on CD137+CD8+ T cells, and was compared 
between patients with different CMV status. (E) Proportions of each T-cell subset within donor-specific and 
third party-reactive CD8+ T cells are shown as median values and interquartile ranges, (F) also summarized 
as pie charts presenting mean proportions. *P<0.05, **P<0.01, ***P<0.001.
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TEM are the major T-cell population infiltrating liver allograft and are enriched for 
donor-specific CD8+ T cells
As TEMRA were the major CD8+ T-cell subset present in peripheral blood after LT, and com-
prised the majority of residual donor-specific CD8+ T cells in CMV-PI patients, we asked 
whether CD8+ TEMRA can infiltrate liver allograft and thereby contribute to allograft rejec-
tion. To investigate which T-cell subsets infiltrate liver allograft, we isolated intrahepatic 
lymphocytes (IHLs) from liver allografts which were explanted during re-LT (n=8). IHLs 
contained mainly CD4+ and CD8+ TEM and hardly any TNaive and TCM (Fig.3A, B). CD8+ TEMRA 
were present in the liver allografts but accounted for a significantly smaller proportion 
than in paired PBMC samples. The ratio between CD8+ TEM and TEMRA was on average 
5-fold higher in liver allografts than in peripheral blood (Fig.3C).
Sufficient amounts of IHLs were isolated from two of the liver explants to measure their 
reactivity to donor and third-party stimulation. In the absence of allogeneic stimulation 
ex vivo, considerable percentages of CD4+ and CD8+ T cells expressed CD137, indicating 
that they were activated in the liver allografts in vivo (Fig.3D). CD8+ TEM were enriched for 
donor-specific T cells, as 20% and 33.9% of CD8+ TEM from two IHLs samples respectively 
were reactive to donor splenocytes, while 8.8% and 7.5% of them responded to third-
party stimulation (CD137 expression in conditions without allogeneic stimulation were 
subtracted). CD8+ TEMRA contained less alloreactive cells than TEM. CD4+ TEM, but not TEMRA, 
contained high numbers of alloreactive T cells, but the percentages were similar for 
donor and third-party stimulation. Altogether, these data indicate that TEM preferentially 
infiltrate liver allografts, and that infiltrating CD8+ TEM are enriched for donor-specific 
T cells which may contribute to intragraft alloreactivity. In contrast, CD8+ TEMRA largely 
remain in the circulation, even though they contain the majority of donor-specific CD8+ 
T cells in the peripheral blood of CMV-PI patients.
CMV primary infection protects patients against the occurrence of late acute 
rejection
To study whether the donor-specific T-cell hyporesponsiveness that we observed in 
CMV-PI patients has any clinical relevance, we performed a retrospective study on 639 
patients that underwent LT in our center between 1992 and 2010 to investigate the 
impact of CMV infection on EAR and LAR. One, 3, or 6 months after LT have been vari-
ably used in literature as the cut-off to define EAR and LAR [20]. In our center, the first 
episodes of CMV viremia were detected at median 35 days after LT, 92.1% of which were 
within the first 6 months (Table 1). Thus we choose 6 months as the cut-off to define LAR 
in order to focus on the effect of CMV infection on graft rejection and not the other way 
around. Of the 639 patients, 144 (22.5%) developed EAR (median 9 days after LT; range 
2-166 days), and 41 (6.4%) developed LAR (median 487 days after LT; range 186-6368 
days) (Table 1).
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Figure 3: TEM are the major T-cell population infiltrating liver allograft and are enriched for donor-specific 
CD8+ T cells. Intrahepatic lymphocytes (IHLs) were isolated from explant liver allografts to study the subset 
composition and alloreactivity of graft infiltrating T cells. CD8+ and CD4+ T-cell subsets between paired 
PBMCs and IHLs were compared, shown (A) as representative FACS plots from one patient and (B) as sum-
marized (n=8). (C) Ratios CD8+ TEM and TEMRA were also compared between paired PBMCs and IHLs. Large 
amounts of IHLs were isolated from two explant allografts and were co-cultured with donor and third-party 
splenocytes. Donor-specific and third party-reactive T cells were identified by CD137 upregulation. (D) Re-
sults are shown by FACS plots and percentages of CD137+ T cells for each subset are depicted in the plots 
for two experiments. *P<0.05, **P<0.01.
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EAR and LAR were set as the endpoints for risk factor analysis, and CMV serostatus 
and viremia were analyzed. CMV serostatus was not associated with the cumulative 
incidence of EAR (P=0.77) (Fig.4A), while the incidence of LAR in CMV-PI (R-/D+) patients 
was significantly lower than in CMV negative (R-/D-) patients (P=0.014) and CMV-NPI (R+) 
patients (P=0.017) (Fig.4B). In univariate Cox regression analysis, recipient age (P=0.007), 
recipient BMI (P=0.026), donor gender (P=0.034), warm ischemia time (P<0.001), basilix-
imab induction (P<0.001), tacrolimus as CNI (P<0.001), and CMV viremia (P=0.003) were 
significantly associated with EAR (Supplementary Table 3). Meanwhile, CMV serostatus 
(P=0.015) was the only factor associated with LAR (Table 2).
In the multivariate Cox regression analysis, recipient age (P=0.048, hazard ratio 
[HR]=0.99), donor gender (P=0.019, HR=0.66), basiliximab induction (P=0.014, HR=0.59), 
tacrolimus as CNI (P<0.001, HR=0.48), and CMV viremia (P=0.008, HR=1.70) were consid-
ered as independent factors associated with EAR (Supplementary Table 3). In contrast, 
CMV serostatus was the only independent factor associated with LAR (P=0.014; HR for 
R-/D+=0.17; HR for R+=0.97)(Table 2). Altogether, these data show that CMV-PI after LT 
protects patients against the occurrence of LAR, corroborating the ex vivo donor-specific 
T-cell hyporesponsiveness that we observed in CMV-PI patients.
Figure 4: CMV primary infection protects patients against the occurrence of late acute rejection. Patients 
were grouped based on CMV serostatus before LT as follows: Group 1: R-/D-; Group 2: R-/D+; Group 3: R+. The 
cumulative incidences of (A) early acute rejection (EAR) and (B) late acute rejection (LAR) were estimated 
using the Kaplan-Meier method and differences between curves were analyzed using a log-rank test. The 
number of patients at risk are depicted below the graphs.
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CMV primary infection patients shows the highest Vδ1/Vδ2 γδ T-cell ratio after LT
To further investigate whether CMV-PI patients show signs of tolerance, we measured 
peripheral Vδ1 and Vδ2 γδ T-cell subsets, and calculated the Vδ1/Vδ2 γδ T-cell ratio, 
which is associated with operational tolerance after LT[16, 17]. CMV-PI patients con-
tained the highest percentage of Vδ1 γδ T cells within peripheral CD3+ cells, while CMV 
negative patients contained the lowest (CMV-neg: 0.65%, PI: 4.69%, NPI: 2.29%; median 
values) (Fig.5A). Meanwhile the percentages of Vδ2 γδ T cells were similar (CMV-neg: 
0.56%, PI: 0.37%, NPI: 0.42%; median values) (Fig.5B). Moreover, CMV-PI patients showed 
higher Vδ1/Vδ2 γδ T-cell ratio than CMV-neg and NPI patients (CMV-neg: 1.76, PI: 11.1, 
NPI: 4.62; median values) (Fig.5C).
Table 2. Risk factor analysis for late acute rejection following liver transplantation
 
Variable
Univariate analysis Multivariate analysis
HR 95% CI P Value HR 95% CI P Value
Recipient age, year 0.99 (0.97-1.02) 0.455      
Recipient, female 1.29 (0.70-2.39) 0.416      
Recipient BMI, kg/m2 1.04 (0.97-1.12) 0.309      
Primary liver disease     0.189     0.225
HBV/HCV (Ref ) 1.00     1.00    
AHF 1.45 (0.49-4.34)   1.72 (0.56-5.33)  
HCC 0.29 (0.03-2.50)   0.35 (0.04-2.98)  
PBC/PSC/AIH 1.54 (0.56-4.29)   1.88 (0.66-5.36)  
Alcoholic cirrhosis 0.49 (0.10-2.54)   0.60 (0.12-3.14)  
Cryptogenic cirrhosis 2.04 (0.59-7.07)   2.19 (0.62-7.77)  
Others 0.81 (0.24-2.81)   1.03 (0.29-3.67)  
Donor age, year 0.99 (0.97-1.01) 0.239      
Donor, female 1.35 (0.72-2.51) 0.342      
DCD donor 1.43 (0.44-4.65) 0.575      
Cold ischemia time, 10 min 0.99 (0.97-1.01) 0.344      
Warm ischemia time, 10 min 1.01 (0.89-1.15) 0.877      
Re-LT 0.94 (0.33-2.63) 0.900      
Basiliximab induction 0.97 (0.51-1.85) 0.920      
Calcineurin inhibitor, Tacrolimus 0.63 (0.34-1.19) 0.154 0.70 (0.37-1.32) 0.268
Early acute rejection 0.90 (0.44-1.86) 0.781      
CMV serostatus     0.015     0.014
R-/D- (Ref ) 1.00     1.00    
R-/D+ 0.18 (0.04-0.81)   0.17 (0.04-0.83)  
R+ 0.87 (0.43-1.76)   0.97 (0.47-2.02)  
CMV viremia 0.93 (0.45-1.89) 0.832 1.18 (0.55-2.54) 0.670
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Discussion
Heterologous immunity induced by anti-viral T cells to allo-HLA antigens is proposed to 
promote allograft rejection and prevent the establishment of tolerance [14]. Cross-re-
active viral-specific memory T cells are common in humans. About 45% of viral-specific, 
including CMV-specific, T-cell clones are cross-reactive to at least one allogeneic HLA 
molecule [15]. Unexpectedly, and contrary to our initial hypothesis, we did not find high-
er frequencies of alloreactive T cells in CMV positive LT patients. In contrast, the frequen-
cies of alloreative T cells were generally lower in CD4+ effector memory T-cell subsets of 
CMV positive patients and, most conspicuously, we found a robust donor-specific CD8+ 
T-cell hyporesponsiveness in CMV-PI patients. In accordance with the observed donor-
specific hyporesponsiveness, CMV-PI patients had a significantly lower risk to develop 
LAR in our retrospective analysis, and showed the highest ratio of peripheral Vδ1/Vδ2 γδ 
T cells, which is associated with operational tolerance after LT. To our knowledge this is 
the first study showing that CMV-PI remarkably reduces donor-specific T-cell reactivity 
and is a protective factor against the occurrence of LAR after LT, suggesting a role of CMV 
in achieving transplant tolerance to liver allografts in humans.
We first found that CMV infection, and particularly CMV-PI, is associated with the 
expansion of CD4+ and CD8+ effector memory T-cell subsets in peripheral blood after 
LT. Since TEM and TEMRA subsets can mount rapid effector responses upon allostimulation 
[8], they are hypothesized to be detrimental to allografts [21]. However our data do not 
support a detrimental role of CD8+ TEMRA after LT, as we found that CMV-PI patients, in 
which CD8+ TEMRA are the major circulating CD8+ T cell subset and contain the majority 
of the remaining donor-specific CD8+ T cells, have a reduced incidence of LAR. Similarly, 
Figure 5: CMV primary infection patients show the highest peripheral Vδ1/ Vδ2 γδ T cell ratio after LT. 
Peripheral blood Vδ1 and Vδ2 γδ T-cell subsets were analyzed by flow cytometry in LT patients. The percent-
ages of (A) Vδ1 and (B) Vδ2 γδ T cells within total CD3+ T cells, and (C) the subsequent Vδ1/ Vδ2 γδ T-cell ratio 
were compared between patients with different CMV status (CMV neg n=21, PI n=26, NPI n=27). Horizontal 
lines indicate median values. *P<0.05, ***P<0.001.
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a recent report shows that increased numbers of circulating CD8+ TEMRA before kidney 
transplantation are associated with a reduced incidence of acute rejection [22]. These 
results may be explained by our finding that CD8+ TEMRA largely remain in circulation and 
scarcely migrate into liver allografts. Similarly, few CD8+ TEMRA were found in rejecting 
kidney allografts [23]. However we cannot rule out the possibility that TEMRA may change 
their phenotype into TEM upon infiltration.
An intriguing question is: how does CMV infection induce donor-specific T-cell hy-
poresponsiveness? CMV infection is known to drive immunosenescence, manifested 
by inflation of CMV-specific effector memory T cells. It has been postulated that the 
massively expanded CMV-specific effector memory T-cell pool competes with newly 
generated T cells for niches and survival factors, and as a consequence T-cell diversity 
and responses to other pathogens are restricted[24, 25]. Indeed both in humans and 
mice CMV infection causes impaired T-cell immunity to other pathogens[26, 27], and 
CMV infection after organ transplantation is associated with a higher incidence of op-
portunistic infections [28]. The global immunosenescence driven by CMV may explain 
the lower numbers of alloreactive CD4+ TEM and TEMRA that we observed in CMV positive 
patients. This is supported by previous findings showing that high numbers of CMV-IE-
1-specific memory T cells are associated with lower numbers of alloreactive T cells and 
improved renal allograft function [29], and that high CMV-specific CD4+ T-cell responses 
correlate with protection from cardiac allograft rejection [30]. We hypothesize that the 
donor-specific T-cell hyporesponsiveness observed in CMV-PI patients could be related 
to the multifaceted immune evasion capacity used by CMV to establish latency, in par-
ticular its capacity to modulate antigen presentation [31]. Alexander et al. reported the 
development of hematopoietic chimerism and donor-specific hyporesponsiveness in a 
patient with severe CMV disease early after LT [32]. We also reported 3 cases of long-term 
hematopoietic chimerism within liver allografts [33], interestingly all 3 patients were R+/
D+ with detection of viremia in two of them (unpublished data). The immune-modifying 
effects of CMV may have contributed to the engraftment of donor cells, leading to sub-
sequent donor-specific hyporesponsiveness. Moreover, dendritic cells present in liver 
grafts are the main instigators of T-cell immunity against the graft [34], but CMV infected 
dendritic cells are impaired in their ability to stimulate allogeneic lymphocytes [35]. The 
exact mechanisms attributing to this phenomenon remain to be investigated.
In the retrospective analysis, we found that CMV viremia was positively associated 
with EAR. However, EAR occurred on median 9 days after LT, preceding the detection 
of CMV viremia in general. This finding is in line with the hypothesis that alloimmune 
stimulation triggers CMV replication from the latency stage. In contrast, we found that 
CMV-PI was an independent protective factor against LAR, while CMV negative patients 
had the highest incidence of LAR. As there is no indication that in CMV negative and NPI 
patients immunosuppression was prescribed differently causing more LAR, the lower in-
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cidence of LAR is probably a reflection of the pro-tolerogeneic status of CMV-PI patients. 
This finding indicates that CMV during active replication or in a quiescent state may 
have differential effects on graft rejection, which may also contribute to the discrepancy 
of EAR and LAR in relation to CMV infection. Careful distinguishing between CMV-PI and 
CMV-NPI, and between EAR and LAR in our analysis, may be a possible reason why this 
association has never been reported before.
Immunosuppression can be completely discontinued in more than 40% of adult, 
stable LT patients[36, 37]. Whether CMV infection plays a role in achieving operational 
tolerance after LT has yet not been investigated. However, studies sought to identify 
biomarkers for operational tolerance have found expansion of peripheral Vδ1 γδ T cells, 
and an increased Vδ1/Vδ2 ratio in tolerant LT patients. Vδ1/Vδ2 ratio has also been used 
as a surrogate marker to predict operational tolerance[16, 17]. Interestingly, expansion 
of Vδ1 γδ T cells is also a feature that is shared by CMV infection[38, 39], arguing in 
favour of a potential association between CMV infection and liver graft tolerance. In 
addition to previous findings, we found CMV-PI patients showed the highest Vδ1/Vδ2 
ratio. This finding corroborates the lower incidence of LAR in our retrospective analysis 
and suggests that CMV-PI patients may have the highest chance to achieve operational 
tolerance after immunosuppression discontinuance. However we do not minimize im-
munosuppression routinely in our center, thus we are not able to demonstrate the direct 
link between CMV infection and operational tolerance.
To conclude, the primary findings of this study are the development of donor-specific 
T-cell hyporesponsiveness in CMV-PI patients, and that CMV-PI patients are protected 
from the occurrence of LAR and show signs of operational tolerance. Further investiga-
tions into the role of CMV infection in the development of operational tolerance after LT 
are necessary. Since CMV status is easily measured without additional effects or costs, 
this parameter can be taken into account by physicians when tapering immunosuppres-
sive therapy in LT patients. Altogether, for the first time to our knowledge, we show evi-
dences that CMV infection may promote immunological tolerance towards allogeneic 
liver graft in humans.
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Abstract
Studies on indirect allorecognition in transplant patients are hampered by the lack of 
a reliable assay to detect T cells with indirect allospecificity. The aim of this study is to 
set up a novel technique based on messenger RNA (mRNA) electroporation to measure 
indirect T cell responses after organ transplantation. For this purpose, we synthesized 
mRNA encoding the human leukocyte antigen (HLA) A*0201 by in vitro transcription 
from a DNA template. To exclude the possibility of direct allorecognition, the transmem-
brane region of the HLA-A*0201 α-chain was deleted from the DNA construct, while the 
human DCLamp gene was included to obtain translocation of the translated protein to 
the MHC class II compartments. By stimulation with CD154-expressing fibroblasts in the 
presence of IL-4, peripheral blood B cells of HLA-A*0201-/HLA-DR*0101+ donors were 
expanded and differentiated into antigen presenting B cell blasts (CD40-B). These CD40-
B cells were electroporated with the HLA-A*0201-encoding mRNA and co-cultured with 
three different CD4+ T cell clones recognizing HLA-A*0201 derived peptides presented 
in HLA-DR*0101. After electroporation, HLA-A*0201 was not expressed on the surface of 
the CD40-B cells but was detected intracellularly as soon 2 hours later. The CD4+ T cell 
clones produced high amounts of IFN-y upon co-culture with electroporated CD40-B 
cells, and IFN-y production was completely abrogated by addition of anti-MHC class II 
antibody, demonstrating MHC class II restriction.
In conclusion, we set up a novel technique to measure human T cells with indirect 
allospecificity using mRNA electroporation. This technique may be promising to study 
indirect allorecognition in patients after organ transplantation.
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Introduction
Organ graft rejection is induced by activation of the recipient immune system by 
allo-antigens which are derived from graft tissue of a genetically disparate donor. 
MHC-molecules are the major allo-antigens to which the host immune system vigor-
ously reacts, due to their highly polymorphic nature. There are two major pathways 
of allo-recognition by T cells [1]: 1. The direct pathway in which the recipient T cells 
recognize intact allogeneic MHC molecules on non-self cells, which can occur during 
pregnancy, upon blood transfusion, or after allogeneic transplantation of cells, tissue 
or organs; 2. The indirect pathway in which the recipient T cells recognize donor MHC-
derived peptides presented by self-MHC molecules expressed on recipient cells, which 
is basically the same mechanism as used in recognition of pathogen-derived antigens. 
The semi-direct pathway has been discovered more recently as a third pathway of allo-
recognition in which membrane fragments containing intact donor MHC molecules that 
are transferred to recipient antigen presenting cells activate recipient T-cells [2]. Many 
studies have shown the importance of direct pathway donor-specific T cells in immune 
reactivity to allogeneic organ grafts in humans [3-5]. It is believed that the direct pathway 
is the major driving force of early acute rejection of allogeneic transplants, since it leads 
to exceptionally robust inflammatory T-cell responses. The direct pathway response is 
thought to extinguish after transplantation because of depletion of donor Antigen Pre-
senting Cells (APC). In contrast, when intact donor MHC-molecules have been taken up 
by host APC and are presented to recipient T cells, the indirect pathway T-cell response 
becomes active. [6,7] [8] [9]. Previously, it was believed that the evanescence of direct 
pathway allogeneic T-cells occurred within weeks after transplantation [3-5], however in 
our recent study in which we used a more robust technique to quantify T-cell responses 
to directly presented allo-antigens, we showed that direct pathway allogeneic T-cells 
remain detectable at least after one year after liver transplantation [10].
The indirect T cell alloresponse is thought to be weaker than the direct T cell allo-
response, but long-lived and tending to spread to formerly cryptic determinants on 
donor and self-tissue specific antigens [11]. This feature of indirect T-cell alloreactivity is 
presumably associated with the sustained presence of recipient APC that can maintain 
a chronic inflammatory response similar to that observed in autoimmune diseases [1] 
[11]. Therefore, it is generally assumed that the indirect pathway contributes to rejection 
episodes late after transplantation and to chronic rejection. However, current ex vivo 
assays for measuring T cells that recognize allo-antigens via this pathway are rather in-
sensitive, not enabling detection T cells with indirect allospecificity in 50%-70% of organ 
transplant recipients [3,12-14]. Because the indirect alloresponse is assumed to play a 
central role in late rejection episodes it is of clinical importance to develop a sensitive 
assay for monitoring this pathway.
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Different ex vivo techniques for measuring T cells that respond to indirectly presented 
allo-antigens have been described, but all have important limitations [15]. In one ap-
proach, recipient peripheral mononuclear cells (PBMCs) are loaded with donor tissue 
homogenates made by multiple freeze-thaw cycles to disrupt cell membranes [3,16-19]. 
Subsequently recipient PBMC internalize donor cell fragments and present donor anti-
gens as peptides on self-MHC molecules. A first technical limitation is that PBMC contain 
limited numbers of APC, which are moreover in an immature state, together resulting in 
a suboptimal presentation of antigens, which is crucial for detection of low frequency 
T-cells with indirect specificity. In addition, a recent study shows that tissue homog-
enates used as allo-antigen source poorly activate T cells via the indirect pathway, but 
instead activate direct pathway T-cells [20]. Apparently, intact donor HLA molecules are 
transferred to autologous APC in the cultures, resulting in activation of recipient T cells 
via semi-direct presentation.
Another method loads recipient APC with synthetic MHC-peptides corresponding to 
the donor or mismatched allotype [6,12,13,21].Since it is impossible to add sufficient 
peptides to cover the complete donor MHC repertoire which is mismatched with the 
recipient into the ex vivo cultures, a selection of putative peptides representing one or 
a few dominant donor HLA-alleles is made. Furthermore, because it is not known which 
peptides are generated during MHC processing in APC, synthetic peptides may present 
neo-epitopes that are not naturally occurring. Besides, the use of peptides is restricted 
by the HLA-typing of the recipient, because different HLA allotypes present different 
peptides, and prediction of HLA class II binding peptides is complex [22]. Recently, a 
third technique for allo-antigen loading of recipient APC was published which uses puls-
ing of recipient APC with HLA class-I monomers [20].
In the current study we constructed a technique which has the potential to overcome 
these problems. The first modification we introduced is the use of a pure source of 
recipient APC in the ex vivo assay to optimize antigen presentation. The second im-
provement is the development of a technique for transfection of recipient APC with 
mRNA encoding for mismatched donor MHC in order to achieve efficient presentation of 
naturally processed donor HLA peptides to recipient T cells. This technique is being used 
in tumor immunology to achieve presentation of a broad range of natural peptides of 
tumor antigens to both CD4+ and CD8+ T cells [23-28]. The transfected APC synthesize 
the antigen(s) encoded by the electroporated mRNA, degrade it by using their natural 
processing machinery into a natural repertoire of peptides, and present them on self-
MHC molecules to T cells, thereby preventing the generation of neo-epitopes. A further 
advantage of this technique is its independence of the patient’s HLA-repertoire. Despite 
its success in tumor immunology, this technique has not been applied yet in transplan-
tation immunology.
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Whereas most studies using mRNA electroporation to achieve antigen presentation to 
T cells have used monocyte-derived dendritic cells(moDCs) as APC, we decided to use 
B-cells expanded from PBMC by co-culture with CD40-ligand transfected fibroblasts and 
IL-4 (CD40-B cells), since B cells expanded by this technique have potent T-cell stimula-
tory capacity and can be generated in large numbers from a small volume of peripheral 
blood [10] . MessengerRNA-transfected CD40-B cells have been demonstrated as an 
alternative source of APC able to induce functional antigen-specific T cell responses 
ex vivo [23,24,29-32] . By electroporation of recipient-derived CD40-B cells with mRNA 
encoding for one or more genetically disparate MHC alleles, we aimed to simulate in vivo 
indirect allo-antigen presentation to T cells as strict as possible in an ex vivo environment.
Materials & Methods
Cell lines
The L-CD40L cell line, a mouse fibroblast cell line stably transfected with human CD40L 
(kindly provided by prof. C. van Kooten) was cultured in RPMI (Lonza, Breda, The Neth-
erlands) with 10% FCS (Sigma-Aldrich, Zwijndrecht, The Netherlands) and penicillin/
streptomycine (Gibco, Bleiswijk, The Netherlands) in T75 culture flasks. For splitting, the 
cells were detached from the culture plates with 0.5% Trypsin/0.2% EDTA (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and washed with serum free RPMI before transferring 
them at a concentration of 1x10E5 cells/mL into fresh culture medium.
K562 cells, a human immortalised myelogenous leukaemia line which lacks HLA class I 
surface expression, were cultured in the same medium in T 175 culture flasks.
B cell expansion
HLA-typed buffy coats were obtained for the Sanquin Blood Bank (Rotterdam, The 
Netherlands) , and PBMC were isolated by Ficoll gradient centrifugation. B cells were 
expanded from PBMC by co-culture with irradiated mouse fibroblast cells that were sta-
bly transfected with human CD40L in the presence of cyclosporin and IL-4 as described 
previously [10]. When the purity of CD19+ cells was > 95%, CD40-B cells were used in 
assays.
Construction of vectors for in vitro mRNA generation
A schematic overview of the constructed vectors is depicted in Figure 1, in which the 
cloning order of the functional parts is shown including the unique restriction sites. 
Transcription of all vectors is driven by a T7 bacteriophage promotor, which is followed 
by a signaling peptide which is either exon 1 of the inserted HLA molecule or a synthetic 
sequence, which is responsible for directing the transportation of the encoded protein 
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Figure 1: Overview of the DNA constructs used for in vitro transcription.
A] pGEM vectors driven by T7 bacteriophage promotor and encoding for: signaling peptide (sig) which 
is a synthetic sequence responsible for targeting the encoded protein to the endoplasmatic reticulum, 
Enhanced Green Fluorescence Protein (eGFP), DCLamp (DCL) which is a targeting signal to the endolyso-
somes, intact HLA-A*0201 molecule including the sequence for the complete HLA-A*0201 α1α2 and α3 
domain, 3`flanked Untranslated Restriction (3`UTR) and 64 bp long poly-A tail both responsible for a slower 
degradation of the synthesized protein. The positions of the restriction sites, HindII, BamH1 and SpeI are 
shown. B] pST1 vectors with different encoding parts resembling the pGEM vector, difference with the 
pGEM vectors are the 120 bp long poly-A tail and the unique restriction site with SapI at the end of the vec-
tor. The sequences encoding for the HLA-A*0201α1α2, HLA-B*3501α1α2 and HLA-A*0201α1α2α3 without 
the transmembrane part (HLA-A*0201α1α2α3delTm) are located directly after the T7 promotor. Different 
vectors with and without DCLamp (DCL) are shown including the positions of the restriction sites HindIII, 
BamH1 and SapI.
C] Schematic overview of HLA class II protein on the cell surface. The α1, α2, and α3 domain are shown 
together with the transmembrane cytoplasmic tail
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to the endoplasmatic reticulum. We used the backbone vector plasmid pST1, which was 
kindly provided by dr. U. Sahin, Mainz, Germany [33], to make constructs that encoded 
for parts of human HLA molecules. To prevent the expression of intact HLA-molecules 
resulting in direct pathway allorecognition, we did not include exons 5,6,7 and 8 which 
encode the transmembrane, cytoplasmic parts and the unspecified part of HLA-mole-
cules, respectively. The first constructs that we made comprised only exons 2 and 3 of 
HLA-A*0201 or HLA-B*3501, which encode for the for α1 and α2 domains which contain 
the peptide binding groove of the HLA-molecules. This part is the most polymorphic 
part, and encodes for the majority of allo-antigens. The gene fragment encoding for 
α1 and α2 domains of the human MHC alleles were amplified from pcDNA-HLA-A*0201 
or from DNA isolated from a HLA-B*3501 transfected Single Antigen expressing Line 
[34], (both kindly provided by Dr. I.I. Doxiadis, LUMC, Leiden) by PCR using the following 
primers:
HLA-A*0201 sense:  5`- AAA AAG CTT GCC ACC ATG GCC GTC ATG GCG CCC C-`3
 antisense: 5`-AAG GAT CCG TGC GCT GCA GCG TCT CC-`3
HLA-B*3501 sense 5`- AAA GCT TGC CAC CAT GCG GGT CAC GGC GCC CC-`3
 antisense: 5`- AAA GGA TCC GCG CGC TGC AGC GTC TCC-`3
Primers were designed with a linked restriction site for HindIII at the 5’ end and for 
BamH1 at the 3’ end to enable ligation of the amplified sequence into the backbone 
vector plasmid pST1, which has a HindIII restriction site after the T7 promotor region and 
BamH1 before the sequence encoding Enhanced Green Fluorescence Protein( eGFP). A 
Kozak sequence was added for the initiation of the translation, which starts after the 
restriction site. HLA exon-coding sequences in these constructs are directly followed by 
sequences encoding eGFP and/or the transmembrane and luminal region of Dendritic 
Cell Lysosome Associated Membrane Protein (DCLamp), which is a targeting signal for 
the endo-lysosome, resulting in peptide loading in MHC-II [35]. The 3’ UTR (untranslated 
region) and the 120 poly-A tail are responsible for a slower degradation of the elec-
troporated mRNA, leading to a longer time for translation and peptide-formation. The 
nonfunctional parts of the plasmid for mRNA synthesis are not shown. These constructs 
are called pST1-HLA*A0201-α1α2-eGFP-DCLamp and pST1-HLA-B*3501-α1α2-eGFP-
DCLamp, respectively. In addition, constructs containing the same HLA-inserts, but 
lacking the eGFP sequence were generated; called pST1-HLA-A*0201α1α2-DCLamp and 
pST1-HLA-B*3501α1α2-DCLamp.
The second type of construct that we made in backbone pST1 contains an insert that 
encodes the complete HLA-A*0201 protein including the α1α2 and α3 domain except 
the transmembrane part. This insert was synthesized by Geneart (Life Technologies 
Europe, Gent, Belgium) and is referred as HLA-A2 α1α2α3delTm, when cloned into pST1 
vector including eGFP and DClamp it is referred as pST1-HLA-A*0201 α1α2α3delTm-
eGFP-DCLamp. For comparison, we used a pGEM construct containing intact HLA-
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A*0201 sequence, including the transmembrane and cytoplasmic parts, referred 
as pGEM-HLA-A*0201. For development of an electroporation protocol suitable for 
transfections of CD40-B cells, we constructed: The pGEM-eGFP plasmid which encodes 
for eGFP flanked by the 5’ and 3’ UTRs of Xenopus Laevis β-globin and 64 bp poly A 
tail of which the backbone pGEM was kindly provided by Dr E Gilboa, Duke University 
Medical Center, Durham, NC, USA and eGFP was flanked as described by Meirvenne et al. 
and collegues [36][37]; 2. The pGEM-eGFP-DCLamp in which the MHC class II targeting 
transmembrane/luminal region sequence of DCLamp is inserted at the 3’ end of eGFP.
In vitro transcription of DNA constructs
Prior to in vitro transcription, the plasmids in backbone vector pST1 were linearized with 
SapI and plasmids in backbone vector pGEM were linearized with SpeI. In vitro transcrip-
tion was performed using the T7 RNA polymerase and ARCA (anti-cap analogue) kit 
(Ambion m MESSAGE mMachine T7ultra kit; Austin, TX, USA) according to the manufac-
turers guidelines. The concentration and quality of the in vitro transcribed mRNA were 
assessed by spectophotometry and agarose gel electrophoresis. The obtained mRNA of 
the constructs were stored at -80°C till utilization.
mRNA electroporation
Before electroporation, B cells were washed twice, first with serum-free IMDM (Lonza, 
Breda, The Netherlands) and subsequently with Opti-MEM (Invitrogen-Life technologies, 
Bleiswijk, The Netherlands). Cells were resuspended in Opti-MEM to a final concentra-
tion of 20x106 cells/mL. Thereafter, 200 µL of the cell suspension was mixed with 20 µg 
mRNA in a 0.4-cm gap sterile disposable electroporation cuvette and electroporated 
with a BioRad Gene pulser Xcell Electroporation system using a program generating 
square wave pulses of 800 V (or different voltages as indicated in the Figure legends) for 
0.5 ms. Immediately after electroporation cells were transferred into fresh cell culture 
medium, including IMDM (Lonza Breda, The Netherlands) with 10% heat-inactivated hu-
man male AB serum (Lonza, Breda, The Netherlands), 1% penicillin/streptomycin and 1% 
insulin-transferrin-selenium solution (Gibco, Bleiswijk, The Netherlands), and incubated 
at 37°C in a humidified atmosphere supplemented with 5 % CO2. Two to 5 hours after 
electroporation, cells were harvested and washed with PBS (Lonza, Breda, The Nether-
lands) and resuspended in fresh culture medium for further experiments.
Flowcytometric analysis
For analysis of HLA-A2 expression, mRNA electroporated CD40-B cells were incubated 
with anti-HLA-A2-Fitc mAb (BD Pharmingen, Breda, The Netherlands). For determina-
tion of transfection efficiency, eGFP expression was measured at indicated time points 
after transfection. Cells were measured using a BD Facs flow cytometer (BD Biosciences, 
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Breda, The Netherlands), and flow cytometric data were analysed using FacsDiva (BD 
biosciences, Breda, The Netherlands) or FLowJo software version 8.8.4 (Treestar, San 
Carlos, CA). To exclude non-viable cells, 7-AAD (BD Biosciences, Breda, The Netherlands) 
added just before flow cytometric measurement.
CD4+ T-cell clones
HLA-DR*0101 restricted HLA-A*0201 specific CD4+ clones 4.12, 4.43 and 4.44, gener-
ated from an HLA-A*0201 negative patient with severe GVHD after administration of 
HLA-A*0201 positive donor lymphocyte infusion [38] were used as responder cells for 
testing indirect presentation of HLA-A*0201. Cells were expanded by stimulation with 
allogeneic PBMC which were irradiated at 35 Gy and supplemented with PHA (2 ug/ml), 
in T-cell medium containing IMDM (Lonza, Breda, The Netherlands) supplemented with 
5% FCS (Hyclone, GE Healthcare Life Sciences, Eindhoven, The Netherlands), 5% human 
AB-serum (Lonza, Breda, The Netherlands), penicilline/streptomycine (Gibco, Bleiswijk, 
The Netherlands), L-glutamine (Lonza, Breda, The Netherlands) and IL-2 (2ug/mL) at a 
T-cell: feeder cells ratio of 1:5. Cells were cultured at 37 °C in a humidified atmosphere 
supplemented with 5% CO2. Every three days T-cell clones were further expanded by 
splitting of the cultures and replenishing of fresh culture medium without feeder cells. 
At day 9, cells were harvested and used for experiments.
Antigen presentation assay
In a 96-wells- U bottom microtiter plate, 1 x 10E4 cells of the T-cell clones were co-
cultured in T cell medium without IL-2 together with 1x10E5 HLA-A*0201 – DRB1*0101 
+ CD40-B cells either or not transfected with mRNA for 24 hours at 37°C in a humidified 
atmosphere supplemented with 5% CO2. After incubation, cell-free supernatant was 
collected and the concentrations of IFN-γ were determined by a standard enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturer’s instructions (eBioscience, 
San Diego, CA). For positive control experiments, synthetic 20-mer peptides correspond-
ing to residues 99-114 or 103-120 of the α1 and α2 domain of the HLA-A*0201 molecule 
were synthesized by EZbiolab (Carmel, USA). CD-40 B cells were diluted in culture 
medium including IMDM (Lonza, Breda, The Netherlands) with 10% heat inactivated 
human male AB serum (Lonza, Breda, The Netherlands), 1% penicillin/streptomycin and 
1% insulin-transferrin-selenium solution (Gibco, Bleiswijk, The Netherlands) at a concen-
tration of 1x10E6 cells/mL and the HLA-A*0201 synthetic 20-mer peptides were added 
at a concentration of 10 ug/ml and incubated between 3 and 12 hours before utilization 
for stimulation of T cells.
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Results
Establishment of optimal conditions for mRNA transfection of CD40-B cells
First we established the optimal conditions for mRNA transfection of CD40-B cells by 
electroporation at different voltages. Figure 2 shows the transfection efficiency and 
viability of CD40-Bcells after electroporation of pGEM-eGPF-derived mRNA at different 
voltages. Transfection efficiencies increased with increasing voltages. The highest trans-
fection efficiency was observed at the highest voltage (800 Volt), while no eGPF expres-
sion was observed at 300 Volt (Fig 2A). More than 80% of CD40-B cells expressed eGFP 
upon electroporation of pGEM-eGPF-derived RNA at 800V, and expression remained 
stable for 22 hours. After 42 hours still 40% of transfected CD40-B cells expressed eGFP. 
We observed more cell death at higher voltages (fig 2B). Nevertheless, upon electropora-
tion at 800V 80% of CD40-B cells remained viable up to 22 hours of culture, and after 42 
hours still 60% of CD40-B cells were viable. Therefore, in all subsequent experiments we 
used 800V for electroporation.
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Figure 2: Optimization of the electroporation protocol of CD40-B cells using pGEM-eGPF-derived RNA. A)
Transfection efficiency upon electroporation at different voltages. Depicted are % eGFP expressing CD40-
B cells after different periods of culture upon electroporation. B) Viability of CD40-B cells as measured by 
7-AAD exclusion upon electroporation at different voltages.
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To study the effect of DCLamp on protein expression, we compared the transfection 
efficiency of mRNA derived from pGEM-eGFP to mRNA derived from pGEM-eGFP-
DCLamp in CD40-Bcells. The transfection efficiency of pGEM-eGFP-DCLamp RNA was 
lower than that of RNA without a DCLamp encoding sequence, and also the decline of 
eGFP expression upon electroporation with RNA containing DCLamp was faster (Fig 3).
No indirect allo-antigen presentation by CD40-B cells electroporated with mRNA 
encoding for alpha 1 and 2 domains of MHC class I alleles
To study whether electroporation of CD40-B cells with mRNA encoding for a fusion 
protein of α1 and α2 domains of HLA*A0201 and DCLamp results in presentation of 
HLA*A0201-derived peptides to CD4+ T cells, HLA-A*0201-negative HLA-DR*0101-
positive (HLA* A0201-DR0101+) CD40-B cells were electroporated with mRNA derived 
from pST1-HLA*A0201α1α2-DCLamp, and thereafter co-cultured with HLA-DR*0101-
restricted HLA-A*0201 specific CD4+ Tcell clones 4.12 or 4.44. As a positive control, we 
co-cultured the T-cell clones with HLA*A0201-DR0101+ CD40-B cells loaded with the 
specific HLA*A0201 peptides that are recognized by these CD4+ T cell clones. Figure 4 
shows that both T-cell clones reacted in positive control conditions, but did not react to 
the electroporated HLA*A0201-DR0101+ CD40-B cells.
To investigate why electroporation with pST1-HLA*A0201α1α2-DCLamp mRNA did 
not result in activation of the T cell clones, we analysed whether electroporation with 
mRNA derived from pST1HLA*A0201-α1α2-eGFP-DCLamp resulted in eGFP expression. 
As is shown in Figure 5A, electroporation of K562 cells with mRNA derived from this 
construct cells resulted in eGFP expression in the majority of these cells, but electro-
poration of CD40-B cells did almost not, suggesting that the failure to achieve antigen 
presentation to HLA-DR*0101-restricted HLA-A*0201 specific CD4+ clones might be due 
to lack of translation of mRNA derived from pST1HLA*A0201α1α2-DCLamp into protein 
in CD40-B cells. However, when HLA-A*0201 negative CD40-B cells were electroporated 
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Figure 3: Transfection efficiencies upon electroporation of RNA transcribed from pGEM-eGFP constructs 
with and without DCLamp in CD40-B cells. DCLamp is responsible for a lower transfection efficiency and 
faster degradation of eGFP.
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with mRNA derived from a construct containing intact HLA*A0201 (pGEM-HLA*0201) 
including the transmembrane and cytoplasmic parts but lacking the DCLamp encoding 
sequence, we observed HLA-A*0201 expression on the cell surface, as detected with 
an anti-HLA-A2 specific antibody (Figure 5B). In addition, when HLA*A0201-DR0101+ 
CD40-B cells were electroprated with mRNA derived from the construct with intact 
HLA*A0201 lacking DCLamp (pGEM-HLA*A0201), both HLA-A2-specific CD4+ T cells 
clones were activated (Figure 6). These data demonstrate that, while mRNA derived from 
pST1-HLA*A0201 α1α2-DCLamp can be translated into protein in K562 cells, it is poorly 
translated in CD40-B cells and does not result in HLA*A0201 peptide presentation to 
CD4+ T cells. Conversely, electroporation of CD40-B cells with mRNA derived from a 
construct containing intact HLA*A0201 without DCLamp (pGEM-HLA*A0201), results 
translation into protein and presentation of HLA*A0201 peptides to CD4+ T cell clones.
Transfection of CD40-B cells with mRNA encoding for HLA-A2 without 
transmembrane part results in MHC class II-restricted antigen presentation to 
CD4+ T cells
Since electroporation of CD40-B cells with mRNA encoding intact HLA*A0201 also 
resulted in presentation of intact HLA*A0201 on the cell surface, enabling recognition 
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Figure 4: Electroporation of HLA-A*0201-HLA-DR*0101+ CD40-B cells with pST1-HLA-A*0201α1α2- 
DCLamp mRNA does not result in activation of HLA-DR*0101- restricted HLA-A*0201 specific CD4+ clones.
Cytokine production of HLA-DR*0101- restricted HLA-A*0201 specific CD4+ clones upon 24 hours stimula-
tion with the following conditions: negative: T-cell clones in culture medium only, peptide pulsed: T-cell 
clones stimulated with peptide pulsed HLA-A*0201-HLA-DR*0101 CD40-B cells (positive control), B-cell 
alone: HLA-A*0201-HLA-DR*0101+ CD40-cells in culture medium, mock: HLA-A*0201-HLA-DR*0101+ CD40-
B cells electroporated without mRNA, eGFP: T-cell clones stimulated with HLA-A*0201-HLA-DR*0101+ 
CD40-B cells electroporated with pGEM-eGFP-DCLamp mRNA, B3501: T-cell clones stimulated with HLA-
A*0201- HLA-DR*0101+ CD40-B cells electroporated with pST1-HLA B*3501α1α2-DCLamp mRNA, A0201: 
T-cell clones stimulated with HLA-A*0201 HLA-DR*0101+ CD40-B cells electroporated with pST1-HLA 
-A*0201α1α2-DCLamp mRNA. This figure shows only IFN-y production upon stimulation with peptide-
pulsed CD40-B cells.
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Figure 5: Electroporation of HLA-A*0201-HLA-DR*0101+ CD40-B cells with mRNA encoding intact
HLA-A*0201 results in surface expression of HLA-A*0201.
A] eGFP expression of pST1-HLA-A*0201-eGFP-DCLamp mRNA in K562 and CD40-B cells. There is eGFP pro-
tein synthesis in K562 but not in CD40-B cells. B] HLA-A2 surface expression on HLA-A2- CD40-B cells after 
electroporation with pGEM-HLA-A*0201 (containing intact HLA*A0201), which induces HLAA*0201 protein 
synthesis and presentation on the surface of CD40-B cells. The x-axis shows different timepoints (in hours) 
after electroporation at which HLA-A*0201 expression was determined.
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Figure 6: Electroporation of CD40 B cells with mRNA encoding intact HLA-A*0201 results in IFN-y produc-
tion by HLA-DR*0101 restricted HLA-A*0201 specific CD4+ T-cell clones. IFN-y production by CD4+ T cell 
clones 4.12 and 4.43 upon 24 hours stimulation in the following conditions:
- Medium: CD4+ clones in T-cell medium
- HLA-A2+: CD4+ clones stimulated with HLA-A*0201-HLA-DR*0101+ + CD40-B cells
- HLA*A2 RNA: CD4+ clones HLA-A*0201-HLA-DR*0101+ CD40-B cells electroporated with pGEM-HLA-
A*0201 mRNA
- Mock: CD4+ clones stimulated with HLA-A*0201-HLA-DR*0101+ CD40-B cells electroporated without 
mRNA
The y-axis shows the concentration of IFN-y in pg/mL and the x-axis the different Stimulation conditions. 
Open bars show cytokine production of T cells which were added to CD40-B cells 2 hours after electropora-
tion, while hatched bars show cytokine production of T cells added to CD40-B cells 5 hours after electro-
poration.
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by T cells via the direct pathway and electroporation of mRNA encoded by the pST1-
HLA*A0201α1α2-DCLamp vector did not result in T-cell activation, a new construct in the 
pST1 vector was designed in which only the transmembrane region of the HLA-A*0201 
α-chain was deleted to exclude the possibility of direct allorecognition, while the hu-
Surface and intracellular HLA-A*2 expression after electroporation 
A 
B 
Figure 7: Electroporation of CD40 B cells with mRNA encoding HLA-A*0201 without transmembrane re-
gion results in IFN-y production by HLA-DR*0101-restricted HLA-A*0201-specific CD4+ T-cell clones. A] Sur-
face and intracellular expression of HLA-A2 after electroporation of CD40-B cells with mRNA derived from 
pGEM-HLA-A*02010-DCLamp (intact HLA-A2) or pST1HLA*A0201α1α2α3delTM- eGFP-DCLamp (truncated 
HLA-A2). Surface expression of HLA-A*0201 is detected when electroporation with intact HLA-A2 mRNA is 
performed. Electroporation with truncated HLA-A2 prevents surface expression of HLA-A*0201, however 
intracellular expression is detected, ensuring that protein translation occurs. B] IFN-y production of HLA-
DR*0101restricted HLA-A*0201-specific CD4+ clones when stimulated with CD40-B cells electroporated 
with truncated HLA-A2. Since IFN-y production is abrogated by addition of MHC-II blocking antibody, it is 
ensured that CD4+ activation is restricted by MHC class II.
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man DCLamp gene was included to obtain translocation of the translated protein to 
the MHC class II compartments (pST-HLA*A0201α1α2α3 delTM -DCLamp). Electropora-
tion of HLA*A0201-DR0101+ CD40-B cells with mRNA derived from the latter construct 
did not result in surface expression of HLA-A2, but intracellular HLA-A2 was detected 
(Figure 7A). In addition, the HLA-A*0201-specific CD4+ T cell clones were activated by 
HLA*A0201-DR0101+ CD40-B cells electroporated with pST-HLA*A0201 α1α2α3delTM-
DCLamp mRNA. Importantly, CD4+ T cell responses could be completely abrogated by 
addition of an MHC class II blocking antibody, demonstrating that HLA-A*0201 peptides 
were recognized in an MHC class II-restricted manner (Figure 7B).
Conclusion/ Discussion
In this study we demonstrate that electroporation of CD40-expanded B cells with in vitro 
transcribed mRNA that encodes a genetically disparate HLA-A0201 molecule results in 
presentation of this molecule as a peptide in cognate MHC class II molecules on CD40-B 
cells, and that this is suitable technique to activate selectively CD4+ T cells with indirect 
specificity.
It has been shown that mRNA transfection is as potent in achieving antigen pre-
sentation to CD4+ and CD8+ T cells as lentiviral gene transduction [23]. Besides, it is 
a more time saving method and cleaner system without risk of pseudotransduction 
phenomenon when compared to lentiviral transduction. Additionally, it is applicable for 
different cell types, such as PBMCs, monocytes, moDCs and CD40-Bcells [23,24,26,28,30-
32,39-45]. When compared to other methods of RNA gene transfer like lipofection and 
passive pulsation, mRNA electroporation has been shown to be superior in terms of 
gene transfection efficiency and reduced cell toxicity [26].
Using mRNA encoding for eGFP we optimized the electroporation protocol, showing 
that CD40-B cells translate the electroporated mRNA into protein, which can be con-
cluded by the fact that eGFP is detectable by flow cytometric analysis (Figure 2). The 
highest transfection efficiency was obtained with an electroporation voltage of 800 volt. 
Despite the higher percentage of non-viable cells after electroporation at this voltage, 
still 80% of the electroporated CD40 B cells remained viable after 18 hours. Comparable 
results for transfection efficiency and viability of CD40-B cells were described by van den 
Bosch et al., although they applied a lower electroporation voltage of 300 V [32].
We used square wave pulses to transfect CD40-B cells with mRNA, because this has 
been described to be more efficient in gene transfer than exponential decay pulses [46] 
Our goal was to obtain presentation of peptides derived from the transfected mRNA-
encoding MHC molecules in MHC-class II. However, since peptides derived from cell-
intrinsic proteins are generally presented by MHC-class I and not by MHC class II, we 
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included as a targeting signal in the mRNA to the endolysosomes a sequence encoding 
for the luminal and transmembrane parts of DCLamp, which has been shown to en-
able efficient antigen presentation to CD4+ T cells [24,29,30,32,35,44,45]. After electro-
poration CD40-B cells with pGEM-eGFP-DCLamp mRNA, expression of eGFP diminished 
more rapidly than after electroporation with the control construct pGEM-eGFP without 
DCLamp in CD40-Bcells (Figure3), suggesting indirectly that there is targeting of the 
protein to the endo-lysosomes followed by degradation.
To prevent expression of intact allogeneic HLA molecules on the cell surface of recipi-
ent APC, we designed a plasmid construct containing only the sequences encoding the 
α1 and α2 regions of HLA-A*0201 molecule, without or with the eGFP gene to enable 
measurement of transfection efficiency. Similar constructs were generated for HLA-
B*3501.For detection of allo-antigen presentation via the indirect pathway, we stimu-
lated CD4+ T-cell clones which specifically recognize HLA-A*0201 peptides restricted by 
HLA-DRB*0101, with HLA-A*0201-negative HLA-DRB*0101-positive CD40-Bcells electro-
porated with HLA-A*0201 mRNA derived from the pST1-HLA-A*0201α1α2-DCLamp con-
struct. However, the T-cell clones showed no responses (figure 4). When we verified the 
protein production after electroporation of pST1-HLA-A*0201α1α2-eGFP-DCLamp mRNA 
in K562 and CD40-Bcells, we discovered that pST1-HLA-A*0201α1α2-eGFP-DCLamp pro-
tein was produced in K562 cells but barely in CD40-Bcells (Figure 5A). Currently we do 
not know why mRNA derived from the pST1-HLA-A*0201α1α2-eGFP-DCLamp construct 
is not efficiently translated into protein in CD40-B cells. It could be that synthesis of a 
fusion protein of the two α-chains of HLA-A*0201 and DC-Lamp is inefficient, or that 
the resulting protein is unstable and is rapidly degraded. In contrast, electroporation 
of HLA-A0201- HLA-DRB*0101+ CD40-B cells with mRNA coding for intact HLA*A0201 
(pGEM-HLA*A0201) resulted in rapid membrane expression of HLA-A*0201 (Figure 5B) 
and in presentation to CD4+ T cells (Figure 6). Since electroporation with mRNA encoding 
for intact HLA-A*0201 resulted in HLA-A*0201 surface expression, mRNA derived from 
this construct is not suited for enumeration of patient T cell responses with indirect allo-
specificity, since allo-recognition in a direct manner cannot be ruled out. Since mRNA of 
vector pST1-HLA-A*0201α1α2-eGFP-DCLamp did not result in protein synthesis in CD40-
B cells, we designed new DNA construct in which only the transmembrane region of 
the HLA-A*0201 α-chain was deleted to exclude the possibility of direct allorecognition, 
while the human DCLamp gene was included to obtain translocation of the translated 
protein to the MHC class II compartment; pST1-HLA-A*0201α1α2α3delTM-DCLamp. 
Electroporation of HLA-A*0201-HLA-DRB*0101+ CD40-Bcells with mRNA derived from 
the latter construct resulted in intracellular protein expression but not in surface protein 
expression (Figure 7A). Most importantly, HLA-A*0201-HLA-DRB*0101+ CD40-B cells 
electroporated with pST1-HLA-A*0201α1α2α3delTM-DCLamp derived mRNA were able 
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to induce activation of HLA-A*0201-specific HLA-DRB*0101-restricted CD4+ T cells. Anti-
gen presentation was restricted by MHC class II, as was shown by blocking MHC class II.
This new approach of ex vivo antigen loading of CD-40 Bcells to present HLA-peptides 
via the indirect pathway has several advantages; allorecognition via the direct or semi-
direct pathway is excluded, since the sequence encoding the transmembrane region 
of the HLA-molecule is lacking, which prevents any presentation on the cell surface. 
Recently Breman et al [20] used synthetic HLA class I monomers to achieve indirect 
presentation to CD4+ T cells. Although they demonstrated that this technique did not 
lead to semi-direct HLA antigen presentation to a CD8+ T cell clone, the design of their 
technique does not exclude the possibility of semi-direct antigen presentation to occur 
when using T cells from patients. Compared to peptides, the technique presented here 
does not require knowledge of the peptides presented by different MHC molecules and 
is not restricted by HLA-typing of the patient. CD40-B cells can be charged with the full 
antigenic spectrum of allo-peptides using mRNA encoding to whole HLA-antigens (only 
exluding the transmembrane part) without prior identification of HLA-peptides. Addi-
tionally, mRNA encoding for different HLA molecule can be co-electroporated together, 
in case of multiple HLA mismatches between donor and recipient [28]
Although dendritic cells (DC) are considered to be the most professional APC of the 
immune system, deriving them for ex vivo utilization suffers from serious drawbacks in 
practice: primary DC constitute only 0·1-0·5% of human peripheral blood mononuclear 
cells [47]. Ex vivo generation of dendritic cells from patients’ monocytes or CD34+ pre-
cursor cells is a more practical alternative [48], but requires multiple phlebotomies, 
leukapheresis or even bone marrow aspiration, especially from immunosuppressed 
transplant patients in whom circulating immune cells are already repressed due drugs. 
Instead, our technique uses CD40-expanded B cells as a source of antigen presenting 
cells, which can be rapidly expanded to large amounts from a limited volume of blood 
[10,32].
Altogether, we show a proof of principle of this new approach for detection of T cells 
with indirect allospecificity. However further development of the protocol for detection 
of CD4+ T cell responses to indirectly presented donor HLA in blood or graft-infiltrating 
cells is required before this assay can be applied for studying the role of T cell responses 
to indirectly presented donor HLA after organ transplantation in humans.
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Liver transplantation is a lifesaving treatment for end stage liver diseases, which has 
become a routine therapy nowadays. Despite growing experience in surgery and 
immunosuppression protocols, the long-term mortality after liver transplantation 
remains much higher than in the general population. Although this is partly due to 
chronic allograft injury or rejection, the main causes are comorbidities provoked by 
chronic immunosuppressive drug usage [1-5]. Minimization of these regimens would 
improve patients’ quality of life by decreasing the side effects and subsequently the 
comorbidities. Therefore research priorities in the transplantation field should be more 
focussed on minimization or even withdrawal of immunosuppression. Withdrawal of 
immunosuppression has been described in selected patients after liver transplantation, 
where approximately 20% of patients could safely discontinue all immunosuppressive 
drugs [6,7]. However, a recent prospective withdrawal study showed that immunosup-
pression could be completely discontinued in about 40% of adult LT patients [8]. These 
patients, maintained stable graft function without signs of rejection and are supposed 
to be operationally tolerant for their graft. These studies used transcriptional profiles to 
characterize tolerant (patients in which immunosuppression can be weaned off safely) 
and non-tolerant (patients in whom immunosuppression cannot be safely weaned off )
liver graft recipients. Tolerant recipients exhibited peripheral blood mRNA expression 
profiles which were significantly enriched in genes preferentially expressed by gamma-
delta T cells (γδT cells) and NK cells and in  genes encoding for proteins involved in 
cycle cell arrest.  In addition, tolerant patients were observed to differ from non-tolerant 
patients in the distribution of circulating γδT cells cell subsets (Vδ1:Vδ2 γδT cells) and in 
the frequency of potentially regulatory Tcells (Tregs) . Finally, tolerant and non-tolerant 
patients were found to differ in intragraft expression of genes involved in the regulation 
of iron hemostasis  [9-11, 49]. However, there is a difficulty of reproducibility of these 
results because of  the relatively small numbers of patients and variability between 
patients included in these studies. Therefore, the mechanisms of operational tolerance 
in LT patients remain obscure, and predicting which patient can be safely withdrawn of 
immunosuppression is still not possible.
It is therefore important to have a better apprehension of the immunological responses 
after liver transplantation, including the role of different genetic factors in determining 
immunological responses to the allogeneic liver graft. Such knowledge may lead to new 
therapeutic and diagnostic developments, which potentially could lead to individual-
ized immunosuppressive regimens, sufficient for preventing rejection and improving 
outcome and quality of life in individual patients. Besides, a financial benefit for the 
society could be achieved, not only because of reduced use of expensive immunosup-
pressive drugs, but also by reduction of their side effects which cause additional medical 
and societal costs.
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Examples of immunosuppression associated morbidities are renal failure [12-14], op-
portunistic infections [15], cancer [16], cardiovascular diseases [17,18] and de novo dia-
betes [19]. Prognostic markers can be investigated on molecular, cellular, immunologi-
cal, and genetic level. In this thesis we attempted to find a prognostic genetic marker for 
acute rejection, and investigated if we could predict calcineurin inhibitor-related renal 
dysfunction after liver transplantation using genetic markers. In addition, we elucidated 
the longitudinal course of circulating T cells that recognize donor allo-antigens via the 
direct pathway of allorecognition after liver transplantation, including the contribution 
of T-cell subsets Tcm, TN, Tem and d Temra. Moreover, we studied the influence of CMV infec-
tion on donor-specific T cell responses and acute rejection after liver transplantation, 
and started to develop a novel technique for monitoring T cells with indirect allospeci-
ficity, as an aid for tapering down immunosuppressive regimens.
Acute rejection occurs in 27% to 58% of the LT-recipients, depending on several 
factors such as the type of graft (living or post mortem donor) and the intensity of im-
munosuppression [20,21]. Prognostic factors for acute rejection could aid in dosing 
immunosuppressive drugs on an individual base. Chapter 2 describes the influence of 
two functional SNPs in the CTLA-4 gene on the rate of acute rejection post-LT. Full length 
CTLA-4 molecules encoded by the +49G allele are incompletely glycosylated, leading 
to retrograde transport of a portion of the molecules to the cytoplasm for degradation, 
resulting in reduced expression on the T cell surface and impaired inhibitory function 
of CTLA-4 on T cell activation in individuals homozygous for +49G. The +6230G/A SNP 
was reported to influence the production rate of the soluble alternative splice form 
of CTLA-4, in which the +6230G allele produces sCTLA-4 at a reduced rate compared 
with mRNA encoded by the +6230 A allele. As the soluble isoform inhibits allogeneic 
T cell activation, it is conceivable that carriers of the +6230G allele may be more sus-
ceptible to rejection after organ transplantation, as was supported with our  analysis 
of the association between the +6230 SNP and acute rejection: homozygous CTLA-4 
+6230A liver transplant recipients which lacked the G allele showed a reduced rate of 
rejection compared with carriers of the G allele. However, haplotype analysis showed 
that the single +6230G allele was not the risk allele for acute rejection. The +6230G al-
lele was only associated with an increased risk of rejection when it was combined in a 
haplotype with the +49A allele. Thus the risk allele for acute rejection after liver trans-
plantation (+49A/+6230G) combines the genetic predisposition for reduced capability 
to produce sCTLA-4 (+6230G) with a normal capacity to express the full length CTLA-4 
isoform on the T cell membrane (+49A). The effect of this haplotype on rejection was 
dose dependent, meaning that each additional allele results in a higher risk of rejec-
tion. The conclusion that this specific combination of single alleles confers risk to acute 
rejection is further substantiated by the observation that carriers of one +49A/+6230A 
allele and one +49G/+6230G allele had a rate of rejection intermediate between car-
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riers of the +49A/+6230G risk haplotype and homozygous carriers of the protecting 
+49A/+6230A and +49G/+6230G haplotypes. Unfortunately, even though the risk ratio 
of the +49A/+6230G was dose dependent and significant, the risk ratio of 1.34 for each 
additional risk haplotype is too low to be useful for guiding individualized immunosup-
pressive treatment. Moreover, only 2% of the patients were homozygous for the risk 
allele. Nevertheless, this study shows that even under conventional immunosuppres-
sive therapy, CTLA-4 is critically involved in the regulation of the anti-donor immune 
response after liver transplantation. Other SNPs in immune-regulatory genes should be 
determined too, and a full haplotype analysis with all the functional SNPs should be 
performed in order to obtain a more robust prognostic marker.
Another common problem in long-term survivors of liver transplantation is chronic 
kidney disease (CKD) of which the prevalence ranges between 20-70% [12,13] and 
complicates medical management because of its associated increased morbidity and 
mortality [14,22-26]. In chapter 3, we evaluated the association between SNP ABCB1 
3435C>T and CYP3A5 6986A>G and the incidence of CKD after LT in a single-center 
cohort of 125 adult Caucasian LT-patients with up to 23 years of follow-up. CKD devel-
oped in 38% of the LT patients, which is in line with the CKD incidence reported in other 
studies (between 20 and 70%). The allele frequencies of the investigated SNPs in our 
population were also comparable to those of other studies. Our data show that neither 
the CYP3A5 6989A>G nor the ABCB1 3435C>T genotype of either donor or recipient 
were associated with CKD risk after LT. Even our sub-analysis in which we combined re-
cipient ABCB1 TT genotype with the donor CYP3A5 genotype did not show a significant 
difference in the incidence of CKD. However, we cannot rule that we did not detect an 
association because of the low numbers of patients included in the study. Neverthe-
less, to date our study presents the largest Caucasian adult non-renal organ transplant 
cohort in which associations between CYP3A and/or ABCB1 SNP in both donors and re-
cipients with CKD have been studied, but did not confirm findings from previous studies 
in liver transplant recipients which did identify associations between CYP3A5 6989A>G 
and the ABCB1 3435C>T SNPs [27-29] Differences in study populations (ethnicity, age) 
type of CNI prescribed, and primary endpoints studied are possible explanations for our 
different finding. Moreover, most studies were conducted in renal transplant recipients 
[30-36] in which confounding factors as recurrence of original kidney disease, ischemia-
reperfusion injury, allograft rejection and quality of the kidney allograft could have 
influenced reported associations.
T cells that recognize donor alloantigens via the direct pathway are activated by 
donor-derived APC that migrate from the graft into recipient secondary lymphoid tis-
sues [37-40]. This is a transient process, which has been confirmed as well as in animal 
as in human studies. [37,39,41]. In experimental animals direct pathway T-cell responses 
dominate during the early post-transplant period and subside thereafter [42], but in the 
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human transplantation setting the only evidence available is from cross-sectional stud-
ies [43-48]. There were no studies describing the kinetics of recipient T-cell alloreactivity 
after organ transplantation in humans in detail. The kinetics of the direct pathway in 
LT-recipients was determined in chapter 4, by using a novel technical approach. Our data 
showed for the first time an increase of donor-specific T-cell frequencies shortly after 
LT and additionally, we observed that T cells reacting to donor allo-antigens presented 
via the direct pathway remain present at levels similar to pre-transplant levels in the 
recipient circulation for at least 1 year after transplantation. Previous studies have 
shown the rapid decrease of the direct pathway within one month to values below 
pre-LT levels [48]. Our study shows that the direct pathway remains longer active and 
could be responsible for rejection up till at least 1 year after transplantation. However, 
to confirm this proposition, blood samples taken during episodes of late acute rejec-
tion episodes should be investigated for T cells with direct allospecificity. The different 
findings between our study and previous studies may be explained by the stronger 
donor-derived stimulator cells that we have used, resulting in an increased sensitivity 
compared to conventional assays.  use of this assay as a diagnostic tool for for guidance 
of individualized immunosuppression first requires establishment of the relationship 
between numbers of circulating T cells that respond to donor allo-antigens presented 
via the direct pathway and acute rejection long after LT.
The exact mechanism and the cells contributing to immunological tolerance to al-
logeneic (liver) grafts is still unknown. Whether ignorance, anergy, deletion or regulation 
of immune cells are involved is still unclear. Studies have demonstrated that tolerant LT 
patients show expansion of Vδ1+ γδT cells, and related transcriptional profiles, in blood 
[9,10,49]. Expansion of Vδ1+ γδT cells is also seen after CMV infection [50-52] arguing in 
favour of a potential association between CMV infection and liver graft tolerance. More-
over, accumulation of CD8+ TEMRA, which also is a typical characteristic of CMV-driven 
immune senescence [53,54], is associated with increased sensitivity and susceptibility 
of the elderly to infections, and poor responses to vaccinations [55,56], suggesting com-
promised immunity. On the other hand, CMV-specific memory T cells are hypothesized 
to be detrimental to allografts as they can be cross-reactive to allogeneic HLA [57] and 
anti-viral memory T cells are regarded as one of the main barriers to the achievement of 
transplantation tolerance. Despite the vast amount of literature on the clinical impact 
of CMV infection after organ transplantation, it is poorly understood whether and how 
CMV infection influences T cell allo-reactivity. In chapter 5 we show that CMV infection 
after LT is associated with accumulation of differentiated effector memory (TEM) CD4+ 
and CD8+ T cells and CD8+ terminally differentiated effector memory T cells (TEMRA) 
in the peripheral blood within the first half year post-transplant. Most importantly, 6 
months after transplantation, hyporesponsiveness of circulating CD8+ T cells to directly 
presented donor allo-antigens was observed in CMV primary infection patients, sug-
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gesting that these patients might have developed a certain degree of immunological 
tolerance to their graft. This conclusion was supported by the observation that LT 
patients with primary CMV infection showed a higher ratio of circulating Vδ1:Vδ2 γδT 
cells compared to CMV naïve patients and patients which were already CMV IgG posi-
tive before LT. In addition, patient with primary CMV infection demonstrated a reduced 
incidence of late acute rejection episodes compared to other LT patients. Interestingly, 
direct pathway donor-specific responsiveness in patients with primary CMV infection 
was observed in all CD8+ T cell subsets except TEMRA. Apparently CD8+TEMRA are not very 
detrimental for liver allografts, which might be partially explained by our observation 
that these cells poorly infiltrate into liver allografts. Thus, our data show an unexpected 
role of primary CMV infection in the development of hypo-responsiveness of CD8+ T 
cells to directly presented donor allo-antigens. How primary CMV-infection attributes to 
this donor-specific hypo-responsiveness in the CD8+ T cell compartment is currently un-
known. CMV is known for utilizing multifaceted immune evasion strategies to establish 
latency, in particular the capacity to modulate antigen presentation [58]. While dendritic 
cells present in liver grafts are the main instigators of T cell immunity against the graft 
[40,59], CMV infected dendritic cells are impaired in their ability to stimulate allogeneic 
lymphocytes[60,61]. Moreover, the myelosuppression effect of ganciclovir treatment 
cannot be neglected. The exact mechanisms attributing to this phenomenon remains 
to be investigated.
Chapter 6 is a methodological chapter on the development of a robust assay for deter-
mination of T cells with indirect allospecificity. Indirect allorecognition is the recognition 
by recipient T cells of processed donor antigens presented as peptides in the context 
of self-MHC. Evidence for this pathway came from the observations that graft rejection 
still occurred in experimental animal transplant models in the absence of immunogenic 
donor derived passenger cells in the graft [62,63]. Alloantigens shed from the graft are 
internalized and processed in the same manner as exogenous antigens, and they are 
presented by recipient APCs as peptides in self-MHC class II molecules to T-helper cells. 
Recipient APCs migrate continuously to the donor graft where donor derived peptides 
are encountered, internalized, processed, and subsequently presented to recipient T 
cells in the peripheral lymph nodes and spleen. Experimental animal transplantation 
models have demonstrated that the frequency of T cells with indirect allospecificity is 
lower than that of T cells with direct allospecificity and the indirect T cell response peaks 
later [64], but its magnitude is sufficient to induce graft rejection [63]. Current assays for 
monitoring these T cells in humans are relatively insensitive, and in addition, their ac-
curacy is debated [65]. Because of the complexity of this pathway it is difficult to mimick 
it in vitro. Therefore, little is known about the contribution of T cells that recognize donor 
antigens via the indirect pathway to graft rejection, or their relevance in development 
of tolerance to allografts in humans. Different techniques have been described for 
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detection of T cells with indirect allospecificity. Some studies use donor cell fragments 
to pulse recipient APC. An advantage is that donor cell fragments theoretically cover 
the full HLA-repertoire of the donor. However the HLA-specificity of the responding T 
cells is unknown, and there is evidence that intact donor HLA-molecules present in the 
fragmented donor cell suspensions are also presented to T cells and thereby direct T cell 
alloresponses can be induced in this type of in vitro stimulations [66]. Other studies use 
synthetic donor HLA peptides to pulse recipient APC. Disadvantages of this approach 
are, firstly, that it is impossible to add sufficient peptides to cover all mismatched donor 
HLA-molecules to the in vitro cultures. Secondly, since we do not know which donor HLA 
peptides are presented in vivo, synthesized peptides may contain neo-epitopes that do 
not occur in vivo. Therefore, we studied a novel approach for detection of T cells with 
indirect allospecificity by gene transfection of recipient APC with mRNA encoding for 
donor HLA. For this purpose, we designed a DNA construct suited for in vitro transcrip-
tion, that contains the full HLA-A*0201 sequence, except the transmembrane region, 
thereby preventing the expressionof the intact HLA-A*0201 molecule on the surface 
after electroporation, which might result in recognition by T cells with direct allospeci-
ficity. This DNA-construct was used to synthesize HLA-A*0201-encoding mRNA by in 
vitro transcription. Electroporation was chosen as the technique for genetic transfection 
because of high efficiency compared to other transfection techniques. As recipient APC 
we chose CD40-activated B cells because, in contrast to monocyte-derived dendritic 
cells which are generally used as APC in this type of assays, they can be expanded from 
small numbers of PMBC. We showed that the proof of principle for this new approach 
was successful, when three different CD4+ T cell clones, each recognizing a HLA-A*0201 
peptide in the context of a HLA-DR*0101 molecule, responded to HLA-A*0201- HLA-
DR*0101+ CD40-B cells electroporated with HLA-A*0201 mRNA. Addition of a blocking 
anti-MHC class II antibody completely abrogated stimulation of the CD4+ T cell clones, 
demonstrating that their activation was MHC class II-restricted. In addition, after trans-
fection of HLA-A*0201- CD40-B cells with the HLA-A*0201-encoding mRNA, that lacked 
the transmembrane part of the α3 domain, we observed that HLA-A2 could be detected 
intracellularly but not on the cell surface, and therefore direct recognition is prevented. 
An accurate assay for monitoring indirect T cell alloresponses is essential to determine 
the kinetics and clinical relevance of these T cells in allograft rejection. If these cells 
critically contribute to allograft rejection, a robust assay for quantification indirect T cell 
responses may aid in identification of patients in which immune suppressive drugs can 
be safely tapered. Further studies will reveal whether the assay that we developed is 
able to accurately quantify CD4+ T cell responses to indirectly presented donor HLA-
molecules in transplant recipients.
The main findings from our research were:
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1. The CTLA‐4 +49A/+6230G haplotype is a co‐dominant risk allele for acute rejection 
after clinical liver transplantation. This implies that, even under immunosuppression, 
CTLA‐4, in common with experimental animals, is critically involved in the regulation 
of the human immune response against allogeneic grafts
2. Genetic variations in the CYP3A5 and ABCB1 genes were not significant risk factors 
for the development of CKD after LT. Genotyping LT recipients or their donors for 
SNPs in these genes is therefore unlikely to aid the clinician in preventing CKD
3. By using a novel technical approach, we showed for the first time an increase of 
donor-specific T-cell frequencies shortly after LT in humans. In addition, we observed 
that T cells reacting to donor allo-antigens presented via the direct pathway remain 
present in the recipient circulation for at least 1 year after transplantation.
4. The development of donor-specific T-cell hyporesponsiveness in CMV-PI patients, 
and that CMV-PI patients are protected from the occurrence of LAR and show signs 
of operational tolerance meaning that CMV infection may promote immunological 
tolerance towards allogeneic liver graft in humans.
5. We show a proof of principle of a new approach for detection of T cells with indirect 
allospecificity, in which CD40-Bcells are electroporated with mRNA of mismatched 
HLA-protein are able to induce response of T cells with indirect allospecificity
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Levertransplantatie is een levensreddende behandeling voor eindstadium leverfalen, 
welk tegenwoordig als routinematige behandeling wordt toegepast. Ondanks de 
groeiende ervaring in operatie en immunosuppressie protocollen, blijft de lange 
termijn morbiditeit hoger bij levertransplantatie patiënten dan bij de algemene po-
pulatie. Hoewel dit gedeeltelijk verklaard kan worden door chronische transplantaat 
beschadiging of afstoting, wordt het merendeel van de co-morbiditeit uitgelokt door 
het chronisch gebruik van immunosuppressiva [1-5]. Het gebruik van  immunosuppres-
siva na levertransplantatie is noodzakelijk om afstoting van het donororgaan tegen te 
gaan, echter zijn ernstige bijwerkingen een keerzijde.  Minimaliseren van de doses van 
deze medicatie zou de kwaliteit van leven bij levertransplantatie patiënten verbeteren 
door vermindering van de bijwerkingen wat tot verlaging van de co-morbiditeit tot 
gevolg heeft.  Onderzoek naar het afbouwen of minimaliseren van immunosuppressiva 
zou in de transplantatieveld meer prioriteit moeten hebben. In ongeveer 20% van de 
levertransplantatie patiënten zouden de afweerdonderdrukkende medicatie volledig 
afgebouwd kunnen worden [6,7]. Echter, een recente prospectieve studie toonde aan 
dat in 40% van alle volwassen levertransplantatie patiënten, de immunosuppressiva vol-
ledig afgebouwd kon worden [8]. Deze patiënten behielden een stabiele orgaanfunctie 
zonder tekenen van afstoting en zijn operationeel tolerant voor hun donor orgaan. 
Deze studie maakte gebruik van transcriptie profielen om tolerante patiënten (trans-
plantatie patiënten waarin veilig immunosuppressiva afgebouwd kunnen worden) en 
niet-tolerante (transplantatie patiënten waarin de immunosuppressiva niet afgebouwd 
kunnen worden) levertransplantaat ontvangers te karakteriseren. Tolerante ontvangers 
toonden perifere bloed mRNA expressie profielen welke significant verrijkt waren met 
genen die bij voorkeur tot expressie worden gebracht door gamma-delta T cellen 
(γδT cellen) en Natural Killer cellen (NK cellen) en in genen coderende voor eiwitten 
die betrokken zijn in cel arrest. Tevens verschilden de tolerante patiënten van de niet-
tolerante patiënten in de distributie van circulerende γδT cel subset (Vδ1:Vδ2 γδT cells) 
en in de frequentie van potentiele regulatoire T cellen (Tregs). Als laatste, tolerante en 
niet-tolerante patiënten  verschilden in gen expressie in het donororgaan welk betrok-
ken zijn in de regulatie van ijzer hemostase [9-11, 49]. Echter, zijn de resultaten van deze 
studies moeilijk te reproduceren omdat het betrekkelijk kleine aantal patiënten betreft 
en de grote variatie is tussen de patiënten die geïncludeerd zijn in deze studies. Daarom 
blijft het mechanisme van operationele tolerantie in LT patiënten onduidelijk en is de 
predictie van patiënten, waarbij de immunosuppressiva veilig afgebouwd kunnen 
worden, niet mogelijk. Om deze redenen is het belangrijk om een beter inzicht van de 
immunologische reacties na levertransplantatie te hebben en tevens ook beter inzicht 
in de rol van verschillende genetische factoren die immunologische responsen bepalen. 
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Deze kennis zou tot nieuwe therapeutische en diagnostische ontwikkelingen kunnen 
leiden welke de potentie hebben om de immunosuppressiva te kunnen individualise-
ren, waarbij de dosis per patiënt voldoende is om afstoting van het donororgaan tegen 
te gaan maar zo laag dat het weinig tot geen bijwerkingen heeft zodat de kwaliteit van 
leven per individuele patiënt verbeterd. Daarnaast zou een financiële voordeel voor 
de samenleving behaald kunnen worden, doordat de kosten van de dure immunosup-
pressiva dalen door minder gebruik, maar ook door vermindering van ernstige bijwer-
kingen welke additionele medische kosten met zich meebrengen. Voorbeelden van 
immunosuppressiva afhankelijke morbiditeit zijn nierfalen [12-14], opportunistische 
infecties [15], kanker [16], cardiovasculaire aandoeningen [17,18] en de novo diabetes 
[19]. Onderzoek naar prognostische factoren zou verricht kunnen worden op moleculair, 
cellulair, immunologisch en genetische niveau.
In deze thesis hebben we getracht een prognostische genetische marker te vinden 
welke gerelateerd is met acute afstoting en we hebben onderzocht of we calcineurin in-
hibitor (CNI) gerelateerde nierfalen na levertransplantatie konden voorspellen middels 
een genetische marker. Tevens hebben we meer inzicht gekregen in  de longitudinale 
kinetiek van circulerende T cellen die volgens de directe route allo-antigenen herken-
nen door gebruik van nieuwe benaderingen. Ook hebben we de invloed van CMV 
infectie op donor specifieke T-cel responsen en acute afstoting na levertransplantatie 
onderzocht. Tenslotte beschrijven we een nieuwe benadering voor de ontwikkeling van 
een diagnostische test om T-cellen met indirecte allospecificiteit te kwantificeren; welke 
uiteindelijk gebruikt zou kunnen worden als hulpmiddel om immunosuppressiva veilig 
te indivudualiseren. 
Acute afstoting komt in 27% tot 58% van de levertransplantatie patiënten voor, afhan-
kelijk van bepaalde factoren als type donororgaan (levende of post mortem donor) en 
de sterkte van de immunosuppressie [20,21]. Prognostische factoren voor het ontwik-
kelen van acute afstoting zouden behulpzaam zijn in het individueel doseren van de 
immunosuppressiva. Hoofdstuk 2 beschrijft de invloed van twee functionele SNPs in 
het CTLA-4 gen op de proportie acute afstoting na levertransplantatie. Volledig intacte 
CTLA-4 moleculen gecodeerd door het +49 allel, worden onvolledig geglycosyleerd dat 
leidt tot retrograde transport van een deel van de moleculen naar het cytoplasma voor 
degradatie, resulterende in verminderde expressie van CTLA-4 op het T-cel membraan 
en verminderde inhibitoire functie van CTLA-4 op T-cel activatie.  Dit gebeurt in patiën-
ten die homozygoot zijn voor het +49 G allel. Het +6230G/A SNP heeft invloed op de 
productie van de oplosbare alternatieve vorm van CTLA-4 (sCTLA-4) waarin het +6230G 
allel sCTLA-4 in lagere snelheid produceert dan het +6230A allel. Omdat sCTLA-4 allo-
gene T-cel activatie remt is het aannemelijk dat dragers van het +6230G allel een hogere 
risico lopen voor het krijgen van afstoting na levertransplantatie. In dit hoofdstuk tonen 
wij een relatie tussen +6230 SNP en acute afstoting waarbij in de groep levertrans-
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plantatie patiënten die homozygoot voor CTLA-4 +6230A zijn en waarbij het G-allel 
ontbreekt, minder acute afstoting voorkomt dan de groep levertransplantatie patiënten 
die drager zijn van het  G allel. Echter, haplotype analyse toonde dat enkel dragerschap 
van het +6230G allel geen risicofactor is voor het ontwikkelen van acute afstoting. Het 
+6230G allel is enkel geassocieerd met acute afstoting als het gecombineerd voorkwam 
als haplotype met het +49A allel. Dus, de genetische predispositie voor het risico al-
lel voor acute afstoting na levertransplantatie (+49A/+6230G) is een  combinatie van 
verminderde capaciteit van sCTLA-4 productie (+6230G) met een normale capaciteit 
van  intact CTLA-4 expressie (+49A) op het T-cel membraan. De invloed van deze ha-
plotype op acute afstoting is dosis afhankelijk, betekenende dat ieder extra gedragen 
allel resulteert in een hoger risico op acute afstoting. Dit wordt verder onderbouwd 
door de observatie dan dragers van één +49A/+6230A allel en één +49G/+6230G allel 
een proportie acute afstoting hebben dat tussen het risico +49A/+6230G haplotype en 
homozygote dragers van +49A/+6230A en +49G/+6230G haplotypen in ligt. Hoewel 
het relatieve risico van +49A/+6230G zowel dosis afhankelijk als significant is, is een 
relatieve risico van 1.34 voor ieder additionele risico haplotype te laag om dit haplotype 
te gebruiken als hulpmiddel om immunosuppressiva af te bouwen. Een bescheiden 2% 
van de patiënten waren homozygoot voor het risico allel. Niettemin, toont deze studie 
aan dat zelfs tijdens het gebruik van immunosuppressiva, het CTLA-4 gen betrokken 
is bij de regulatie van anti-donor immuun respons na levertransplantatie. Voor het 
verkrijgen van een robuuste prognostische genetische marker zouden alle functionele 
SNPs in overige immuun regulatoire genen bepaald moeten worden voor een volledige 
haplotype analyse. 
Een ander veelvoorkomend probleem in levertransplantatie patiënten is chronische 
nierziekten (CKD) waarvan de prevalentie varieert tussen de 20-70% [12-13], welke is 
gerelateerd aan verhoogde morbiditeit en mortaliteit [14,22-26]. Polymorfismen in het 
ABCB1 en CYP3A5 gen die een rol spelen in de metabolisering van CNIs zouden de ont-
wikkeling van CKD na transplantatie kunnen beïnvloeden. In hoofdstuk 3 hebben we de 
relatie tussen SNP ABCB1 3435C>T en CYP3A5 6986A>G met de incidentie van CKD na 
levertransplantatie geëvalueerd. Achtendertig procent van de LT patiënten ontwikkel-
den CKD, een percentage dat overeenkomt met voorgaande studies (20-70%). De allel 
frequenties van de onderzochte SNPs waren vergelijkbaar met eerder gepubliceerde 
studies. Onze data laten zien dat zowel het CYP3A5 6989A>G als het ABCB1 3435C>T 
genotype van zowel donor als patiënt geen associatie hebben met het ontstaan van 
CKD na levertransplantatie. Alhoewel, kunnen we niet uitsluiten dat we geen associatie 
hebben kunnen tonen door de  relatief lage aantallen patiënten die in deze studie zijn 
geïncludeerd. Niettemin, presenteert onze studie wel het grootste volwassen non-renaal 
orgaan transplantatie cohort, waarin is gekeken naar de associatie tussen zowel donor 
als ontvanger CYP3A5 en/of ABCB1 SNP en het risico op CKD na transplantatie. Echter, 
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de resultaten van voorgaande studies waarin wel associaties tussen CYP3A5 6989A>G 
en  ABCB1 3435C>T SNPs met CKD werden getoond [27-29], worden in dit hoofdstuk 
niet bevestigd. Verschillen in studie populatie (etniciteit, leeftijd), type CNI dat gebruikt 
is en primaire definities van eindpunten waarnaar gekeken is zijn mogelijke oorzaken 
voor onze resultaat. De meeste studies naar de relatie tussen CNI en ontstaan van CKD 
na orgaan transplantatie zijn verricht in cohorten met niertransplantatie patiënten [30-
36], waarin confounding factoren  als recidief van primaire nierziekte, ischemie-perfusie 
schade tijdens transplantatie, orgaan afstoting en de kwaliteit van het niertransplantaat 
de associatie met CKD mogelijk hebben beïnvloedt.
T-cellen die allo-antigenen via de directe route herkennen, worden geactiveerd door 
donor afgeleide APC, die van het donororgaan naar de secundaire lymfoide organen 
in de ontvanger migreren [37-40]. Dit is een tijdelijk proces, welke zowel in dieren als 
humane studies is aangetoond [37,39,41]. In dierenexperimenten is aangetoond dat de 
respons van T-cellen met directe allospecificiteit gedurende de vroege post-transplanta-
tie periode domineert waarna het uitdooft [42]. Maar in humane transplantatie setting 
zijn er enkel aanwijzingen voor dit effect uit crossectionele studies [43-48]. Er was geen 
beschrijvende studie naar de kinetiek van de allogene T-cel responsen in mensen. De 
kinetiek van de directe-route in levertransplantatie ontvangers wordt beschreven in 
hoofdstuk 4, door gebruik te maken van een nieuwe technische benadering. Onze data 
laat voor de eerste keer zien dat er een stijging is van donorspecifieke T-cel frequenties 
kort na levertransplantatie. Aanvullend tonen wij in dit hoofdstuk dat T-cellen met di-
recte allospecificiteit tenminste 1 jaar na transplantatie nog aanwezig zijn in frequenties 
vergelijkbaar met die van vooraf aan transplantatie (pre-transplantatie niveaus). Eerdere 
studies beschrijven een snelle daling van de T-cellen met directe allospecificiteit, waarin 
de frequenties binnen een maand dalen naar onder het pre-transplantatie niveau [48]. 
Onze studie toont aan dat de directe route langer actief blijft en dat het mogelijk een 
rol speelt in afstoting episodes die tot een jaar na levertransplantatie ontstaan. Om 
deze hypothese te bewijzen, zouden bloedmonsters bij levertransplantatie patiënten 
genomen moeten worden ten tijde van afstotingsreacties, welke vervolgens onder-
zocht dienen te worden naar de frequentie van T-cellen met directe allospecificiteit. 
Het verschil tussen onze observatie en voorgaande observaties zou verklaard kunnen 
worden door de krachtigere donor-afgeleide stimulator cellen die zijn gebruikt, welke 
hebben geresulteerd in een gevoeligere test vergeleken met eerder beschreven testen. 
Om deze vorm van technische benadering te gebruiken als diagnostische  leidraad ter 
individualisering van immunosuppressiva, zou eerst de relatie tussen de circulerende 
T-cellen met directe allospecificiteit en episoden van late acute afstoting onderzocht 
moeten worden.
De exacte mechanisme en de cellen die een rol spelen in immunologische tolerantie 
voor allogene (lever) transplaten is nog steeds onduidelijk. Studies hebben laten zien 
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dat tolerante LT patiënten een expansie van de Vδ1+ γδT cellen vertonen met daaraan 
gerelateerde transcriptionele profielen in perifeer bloed [9,10,49]. Expansie van Vδ1+ 
γδT cellen wordt ook gezien na een CMV infectie [50-52], wat zou kunnen betekenen 
dat er mogelijk een relatie bestaat tussen CMV infectie en levertransplantaat tolerantie. 
TEMRA  accumulatie is een typisch kenmerk van  CMV geïnduceerd ouder en zwakker 
wordende immuunsysteem[53-54].Tevens is accumulatie van CD8+ TEMRA  gerelateerd 
aan verhoogde risico op infecties bij ouderen en een zwakke respons op vaccinaties, 
wat een zwak immuun systeem suggereert [55-56].  Aan de andere kant CMV specifieke 
memory T cellen kunnen schadelijk zijn voor het donororgaan indien zij kruisreactiviteit 
vertonen tegen allogene HLA moleculen [57]. Ondanks de vele studies die zijn verricht is 
het tot op heden nog steeds onduidelijk  hoe CMV infectie de T-cel alloreactiviteit beïn-
vloed. In hoofdstuk 5 laten we zien dat CMV infectie na LT geassocieerd is met accumu-
latie van gedifferentieerde effector memory  (TEM) CD4+ en CD8+ T-cellen en met CD8+ 
terminaal gedifferentieerde effector memory cellen (TEMRA) in perifeer bloed in het eerste 
half jaar na levertransplantatie. Meest belangrijke observatie is dat 6 maanden post-LT, 
hyporesponsiviteit van circulerende CD8+ T cellen tegen donor allo-antigenen die via 
de directe route gepresenteerd worden, in patiënten met een primaire CMV infectie. 
Deze observatie suggereert dat deze patiënten wellicht een soort van immunologische 
tolerantie voor hun donororgaan hebben ontwikkeld. Dit wordt ondersteund door de 
observatie dat LT patiënten met primaire CMV infectie een hogere ratio circulerende 
Vδ1:Vδ2 γδT-cellen hebben vergeleken met patiënten die geen CMV infectie hebben 
en patiënten die reeds CMV IgG positief vooraf aan de levertransplantatie waren. Ook 
tonen we in dit hoofdstuk dat patiënten met een primaire CMV infectie minder kans op 
late episodes van acute afstoting hebben. Directe pathway donorspecifieke respons in 
patiënten met primaire CMV infectie was bij observatie in alle CD8+ subsets, behalve 
in te TEMRA hoog. Blijkbaar zijn TEMRA niet  erg schadelijk voor lever transplantaten, welk 
mogelijk verklaard kan worden door de observatie dat zij niet goed het transplantaat 
kunnen infiltreren.  Onze data laat een onverwachte rol zien van primaire CMV infectie 
op de ontwikkeling van hyporesponsiviteit van CD8+ T-cellen tegen allo-antigenen die 
via de directe pathway gepresenteerd worden. Welk mechanisme ervoor zorgt dat CMV 
infectie  invloed heeft op de  deze donorspecifieke hyporesponsiviteit van de CD8+ T-
cellen is niet duidelijk. CMV staat bekend om zijn gebruik van diverse strategieën voor 
invasie van het immuunsysteem, om aan te zetten tot latentie, in het bijzonder door het 
moduleren van antigeen presentatie [58].  Terwijl de dendritische cellen in levertrans-
plantaten  voornamelijk de aanstichters zijn van T-cel immuniteit tegen het transplantaat 
[40,59], zijn CMV geïnfecteerde dendritische cellen niet in staat om allogene lymfocyten 
respons te stimuleren [60,61]. Alhoewel, het myelosuppressieve effect van ganciclovir 
behandeling mag niet genegeerd worden. Het exacte mechanisme dat resulteert in dit 
fenomeen zou verder opgehelderd moeten worden door verder onderzoek. 
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Hoofdstuk 6 is een methodologische beschrijving over de ontwikkeling van een 
robuuste test om T-cellen met indirecte allospecificiteit te bepalen. Indirecte pathway 
allopeptide herkenning is respons van ontvanger T-cellen op donor antigenen, die 
bewerkt zijn en als peptiden in eigen MHC moleculen  gepresenteerd worden. Bewijs 
voor deze pathway van afstoting werd geleverd door de observatie dat transplantaat 
afstoting nog steeds kon plaatsvinden in experimentele diertransplantatie modellen, 
waarbij de immunogene donorgeleide cellen in het transplantaat afwezig waren. 
[62,63]. Allo-antigenen die worden afgeworpen van het transplantaat worden geïnter-
naliseerd en  verwerkt op dezelfde manier als exogene antigenen. Vervolgens worden 
zij door ontvanger APC als peptiden in eigen MHC klasse II moleculen aan T-helper 
cellen gepresenteerd. Ontvanger APCs migreren continue naar het donor transplantaat 
alwaar donor afgeleide peptiden worden aangetroffen, vervolgens geïnternaliseerd, 
verwerkt en gepresenteerd aan ontvanger T-cellen in perifere lymfeklieren en in de milt. 
Experimentele diertransplantaat modellen laten zien dat de frequentie van T-cellen met 
indirecte allospecificiteit lager is dan T-cellen met directe allospecificiteit en dat de T-
cellen met indirecte respons later pieken dan T-cellen met directe respons [64]. Hoewel 
de omvang van de indirecte T-cel respons lager is, is het wel voldoende om afstoting te 
induceren [63]. Huidige testen om T-cellen met indirecte allospecificiteit te kwantificeren 
zijn relatief ongevoelig en staat de accuraatheid ter discussie [65]. Door de complexheid 
van de indirecte pathway, is het lastig om deze in vitro na te bootsen.  Daarom is er 
weinig bekend met betrekking tot de contributie van T –cellen, die antigeen herkennen 
via de indirecte pathway, op transplantaat afstoting en in de ontwikkeling van tolerantie 
voor transplantaten. Verschillende technieken voor detectie van T-cellen met indirecte 
allospecificiteit zijn beschreven. Sommige studies gebruiken donor cel fragmenten om 
ontvanger APC te laden met allo-antigenen. Een voordeel is dat donor cel fragmenten 
theoretisch het gehele HLA-repertoire omvatten. Maar de HLA-specificiteit van de 
responderende T-cel is onbekend en er is bewijs dat  intacte donor HLA-moleculen 
nog kunnen voorkomen in gefragmenteerde donor cel suspensies, welke tot gevolg 
kunnen hebben dat zij via de directe pathway gepresenteerd kunnen worden waardoor 
er T-cellen met directe allospecificiteit geïnduceerd kunnen worden bij dit soort in 
vitro stimulaties [66]. Andere studies gebruiken synthetische donor HLA peptiden om 
ontvanger APC te laden. Een nadeel van deze benadering is dat het onmogelijk is om 
voldoende verschillende peptiden toe te voegen welke het totale aantal gemismatchte 
donor HLA-moleculen bevatten. Omdat we ook niet weten welke donor HLA peptiden 
er in vitro gepresenteerd worden, zou het kunnen zijn dat gesynthetiseerde peptiden 
neo-epitopen bevatten welke in vivo niet voorkomen. Om deze redenen hebben wij 
een nieuwe benadering bestudeerd om T-cellen met indirecte allospecificiteit te me-
ten, waarbij  we ontvanger APC door middel van gen overdracht geladen hebben met 
donor HLA. Hiervoor hebben we een DNA construct gemaakt welke geschikt is voor in 
145
Chapter 8 : Nederlandse samenvatting
vitro transcriptie en welke codeert voor het gehele HLA-A*0201 sequentie, behalve het 
transmembraan domein, waardoor er wordt voorkomen dat er intacte HLA-A*0201 tot 
expressie wordt gebracht. Electroporatie is gekozen als de techniek voor gen transfectie 
vanwege de hoge efficiëntie vergeleken met overige transfectie methoden. CD40 geac-
tiveerde B-cellen werden gekozen als ontvanger APC, omdat deze cellen vanuit kleine 
aantallen PBMCs  kunnen worden opgekweekt tot grote hoeveelheden. In dit hoofdstuk 
laten we zien dat in het beginsel deze benadering van antigeen laden veelbelovend is; 
drie verschillende CD4+ T cel klonen, waarbij ieder een HLA-A*0201 peptide herkent 
in de context van een HLA-DR*0101 molecuul, reageerden ieder afzonderlijk op HLA-
A*0201-HLA-DR*0101+ CD40 B-cellen die met HLA-A*0201 mRNA geelectroporeerd 
waren. Door toevoeging van anti-MHC klasse II antilichaam aan deze reactie laat zien 
dat de  CD4+ respons compleet teniet wordt gedaan, wat aantoont dat de activatie 
van deze T-cel klonen MHC-klasse II afhankelijk is. Tevens, na electroporatie van HLA-
A*0201-CD40 B-cellen met HLA-A*0201 coderende mRNA waarvan het transmembraan 
gedeelte van het α3 domein ontbreekt, observeerden we dat HLA-A*0201 intracellulair 
gemeten kon worden en niet op het cel oppervlak. Dit toont aan dat directe presenta-
tie van intacte HLA moleculen hiermee voorkomen wordt. Een accurate test voor het 
detecteren van indirecte T cel alloresponsen is essentieel ter bepaling van de kinetiek 
en klinische relevantie van deze T-cellen in transplantaat afstoting. Als deze T-cellen 
met indirecte allospecificiteit significant bijdragen aan afstoting, dan zou een robuuste 
test kunnen helpen bij het identificeren van patienten waarin immunosuppressie veilig 
afgebouwd kan worden. Verder onderzoek zou aan moeten tonen dat de benadering 
die wij beschrijven accuraat genoeg is om CD4+ T-cel responsen met indirecte allospe-
cifciteit te kwantificeren.
De voornaamste resultaten van dit onderzoek zijn:
1. CTLA-4 +49A/+6230G haplotype is een co-dominant risico allel voor acute afstoting 
na levertransplantatie. Dit impliceert dat zelfs onder immunosuppressiva, CTLA-4 
invloed heeft op de regulatie van humane immuun respons tegen allogene trans-
plantaten.
2. Genetische variaties in CYP3A5 en ABCB1 genen, zijn geen significante risicofactoren 
voor de ontwikkeling van CKD na LT. Het genotyperen van LT ontvangers of diens 
donoren voor SNPs in deze genen zullen geen inzicht leveren ter preventie van CKD.
3. Door een nieuwe technische benadering hebben we voor de eerste keer aangetoond 
dat er kort na levertransplantatie een stijging van donorspecifieke T-cel frequenties 
ontstaat. Daarnaast hebben we laten zien dat met deze nieuwe benadering T-cellen 
met directe allospecificiteit nog na 1 jaar na transplantatie detecteerbaar zijn in 
bloed. 
4. Patiënten met primaire CMV infectie ontwikkelen een donorspecifieke T-cel hypo-
responsiviteit waardoor deze patiënten beschermd zijn voor het ontwikkelen van 
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late acute afstoting. Dit zou een teken kunnen zijn dat CMV infectie tolerantie voor 
allogene levertransplantaten in mensen kan bevorderen.
5. We beschrijven nieuwe methode om T-cellen met indirecte allospecificiteit te meten 
waarbij CD40 B-cellen worden geelectroporeerd met mRNA van gemismatchte 
donor HLA-genen wat resulteert in succesvolle specifieke respons van deze T-cellen.
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